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A chemical genetic approach that uses small organic molecules to modulate 
protein function has the potential to overcome the limitations of classical genetic 
techniques for the study of biological processes. However, acquiring the features of 
broad applicability and specificity that are inherent to traditional genetics is still a 
challenge in chemical genetics. The impact that chemical genetics will have on our 
understanding of biological systems depends on a steady supply of biologically active 
small molecules with novel targets or improved specificity for known targets.  
Diversity-oriented synthesis (DOS) of small molecule libraries is an emerging 
method to identify new probes for biological studies and potential therapeutic lead 
compounds. We have explored the use of an approach that employs structural features 
commonly found in natural products as starting points for library design. Our library 
incorporates spiroketal motifs, but is otherwise stereochemically and structurally 
diverse to address a wide range of biological targets. Although many efforts have been 
made to synthesize members of the spiroketal class of natural products, traditional 
methods are not suitable for generating stereochemical diversity in DOS. Therefore, 
we have developed a strategy to create stereochemical diversity by using novel 
stereocontrolled spiroketalization reactions that provide access to both spiroketal 
stereoisomers from a common C1-substituted glycal epoxide precursor. Our route has 
allowed the synthesis of a library of diastereomeric spiroketals in which we control the 
stereochemical configuration not only at the quaternary spiroketal carbon, but also at 
multiple ring carbons. The library will ultimately be screened against a number of 
biological targets to evaluate the effectiveness of the design strategy, and potentially 
identify new biological probes or lead compounds for drug development. 
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CHAPTER 1 
INTRODUCTION TO SPIROKETALS 
 
1.1. Genetic and Chemical Genetic Approaches to Studying Biological Processes 
 Developing an understanding of biological processes is a monumental task, 
requiring the functions of multiple participating components with complex regulation 
and interactions to be unraveled. Historically, genetic approaches have proven to be 
extremely useful for dissecting biological systems. Forward genetic techniques 
involve mutating the genome of a particular organism, followed by identification of 
the gene mutation that produces a desired phenotype. Conversely, reverse genetic 
techniques help to elucidate the function of a protein through analysis of the resulting 
phenotype when the corresponding gene is mutated. Although these complementary 
genetic approaches have had a powerful impact on the progress of molecular biology, 
there are inherent limitations. One problem is that it is difficult to perform forward 
genetic analyses in mammalian systems because of the complexity of mammalian 
genomes and the slow rate of mammalian reproduction. In addition, genetic mutations 
are usually constitutive, so the activity of the protein cannot be easily turned on and 
off. Constitutive mutations may result in embryonic lethality or the effects may be 
obscured by compensatory changes in related genes and proteins. Although techniques 
for conditional activation have been developed (e.g. temperature-sensitive mutations 
or control by inducible promoters), the time required for initiation limits the potential 
for studying dynamic processes.  
RNA interference (RNAi) has recently become a valuable tool for modulating 
protein function. When a small interfering RNA (siRNA) is introduced into a cell, it 
can knock down a cognate mRNA by targeting it for degradation. In this way, siRNA 
may be used to suppress the expression of specific genes of interest, but it does not 
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provide the possibility of direct functional activation. RNAi offers improved temporal 
control over protein function relative to most genetic approaches, but the timescale is 
still significantly slower than many dynamic biological processes. In contrast to the 
specificity that can be obtained using genetic mutations, off-target effects are common 
with the use of RNAi techniques.  
 A chemical genetic approach that uses small organic molecules to modulate 
protein function has the potential to overcome the limitations of classical genetic and 
RNAi techniques. In chemical genetics, small molecules are used to directly alter 
protein function by binding to a target and either inhibiting or activating its function. 
In analogy to traditional genetics, both forward and reverse chemical genetic 
techniques are used. In forward chemical genetics, a biological system is treated with 
various small molecules, and then the target of a molecule that causes a particular 
phenotype is identified. In reverse chemical genetics, small molecules are identified 
that modulate the function of a particular protein; the effect of the small molecule in a 
biological system is then analyzed. There are several advantages of chemical genetics 
compared to traditional genetics. The compounds can be added in variable amounts or 
removed at any time, so the effects are conditional, potentially reversible, and often 
tunable based on dosage. Furthermore, the rapid action of small molecules makes 
them useful for dissecting dynamic cellular processes. Small molecules can also be 
used to modulate individual functions of multifunctional proteins, which is not 
possible with either genetic or RNAi techniques. Additionally, small molecules that 
are found to modulate a target of therapeutic interest can then serve as leads for drug 
development. However, while traditional genetic approaches to modulating protein 
function are broadly applicable and completely specific, attaining these features in 
chemical genetics is still a challenge.   
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1.2. Sources of Small Molecules for Chemical Genetics 
The effectiveness of chemical genetics in understanding biological systems and 
identifying therapeutic leads depends on a steady supply of biologically active small 
molecules with novel targets or improved specificity for known targets. Traditionally, 
natural products have been a valuable source of chemical probes for biological studies, 
in addition to playing an important role in drug discovery. Natural products are 
extremely diverse and their biological activities are often highly specific. However, 
isolation of natural products is frequently problematic, and useful amounts cannot 
always be obtained from natural sources. Although many efficient synthetic routes to 
natural products have been developed in response to this problem, difficulties with 
scale-up are still common. Therefore, alternative sources that provide molecules for 
biological screening in an efficient and practical way are needed. 
The development of combinatorial chemistry has led to the production of a 
large number of small molecules available for high-throughput screening. The initial 
expectation was that the synthesis and screening of millions of compounds would lead 
to large numbers of biological hits. However, these early efforts have mainly resulted 
in disappointment. The underlying problem in this approach is that the number of 
small molecules that could potentially be synthesized is essentially infinite, and most 
of those molecules are not biologically relevant. More recently, the focus of library 
synthesis has shifted from quantity to quality; the present goal is to design smaller 
libraries that permit hit or lead compounds to be found with increased probability. One 
common approach has been to synthesize libraries of molecules with properties typical 
of known drugs. Although commercial libraries of “drug-like” molecules are now 
readily accessible for biological screening, these libraries consist of molecules 
comprising a focused region of chemical structure space. As a result, the range of 
biological targets that they are able to address may be limited. The finding that drug-
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like molecules have significantly different structural properties from those of natural 
products lends credibility to this concern. Natural products are comparatively rigid, 
and they tend to have higher molecular weights, more stereogenic centers, fewer 
rotatable bonds, more complex ring systems, fewer nitrogen and sulfur atoms, and 
more hydrogen bond donors and acceptors than drug-like molecules.1 
An alternate approach to designing biologically relevant libraries uses nature 
as inspiration. Natural products are selected by evolution to bind to specific protein 
domains; accordingly, they are a logical starting point for library design. Basing a 
library on natural products increases the likelihood that the molecules will be 
biologically compatible and therefore useful for applications in chemical genetics. In 
addition, creation of libraries with properties distinct from drug-like molecules allows 
relatively untapped regions of chemical structure space to be explored, and potentially, 
novel biological targets to be identified. A common strategy is to build a library 
around the core scaffold of a natural product; the goal is normally to improve the 
properties of the natural compound in relation to its original biological target. 
However, the minimal diversity of this type of library is not likely to lead to the 
identification of novel targets. Importantly, it has been found that substructures or 
fragments of natural products sometimes maintain biological activity, and this activity 
is often distinct from that of the parent natural product. Additionally, there are a 
number of structural motifs commonly found in natural products that are capable of 
interacting with multiple unrelated biological targets, referred to as privileged 
structures.2,3 Therefore, there has been an increasing interest in the synthesis of small-
molecule libraries based on natural product motifs for use in discovery screening. We 
wanted to explore the effectiveness of this approach, and we chose the spiroketal motif 
for our studies. 
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1.3. Bioactive Spiroketals in Nature 
 The spiroketal substructure is found in a wide variety of biologically active 
natural products with diverse biological activities (Figure 1.1).4  
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Figure 1.1. Structures of various natural products containing a spiroketal substructure 
 
The steroidal sapogenins, originally discovered in the 1930s and 1940s, are the 
first known spiroketal-containing molecules that were isolated from natural sources. 
This class of compounds consists of a steroidal nucleus possessing a spiroketal fused 
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to the D-ring (e.g. sarsasapogenin), and is often glycosylated on the A-ring (referred to 
as a saponin). Over 200 saponins have been isolated, although variation in the 
spiroketal portion is rare. Saponins have shown hypocholesterolemic, 
immunostimulant, antiviral, antifungal, and anticancer properties. The biological 
activity of these molecules is likely due to their interaction with membrane sterols, 
which disrupts membrane function.5,6 
Insect pheromones constitute another major class of spiroketals, and are some 
of the most structurally simple spiroketal natural products. Because they lack 
additional functionality, insect pheromones demonstrate that the spiroketal itself is 
capable of binding to biological receptors.7 Although the structural variation and 
complexity found in these compounds is limited, stereochemical diversity is often 
displayed. In fact, stereoisomers are often found in the same organism and exhibit 
stereospecific biological activities. For example, both enantiomers of olean are 
produced by the female olive fly, but the (R)-enantiomer only attracts males, while the 
(S)-enantiomer is only active on females. Similarly, the European spruce bark beetle 
produces both (2S,5R)- and (2S,5S)-chalcogran, but only the (2S,5R)-epimer is active. 
This phenomenon illustrates the importance of stereochemistry for recognition of 
biological targets. 
Other natural products also demonstrate the ability of the spiroketal to bind 
directly to biological targets. Talaromycin, a potent mycotoxin, is one example.8 Other 
examples include the milbemycin and related avermectin antibiotics (e.g. avermectin 
A2a), which are spiroketal-containing 16-membered macrolides that have potent anti-
parasitic activity and low mammalian toxicity. They are widely used in human and 
veterinary medicine to combat infections, as well as in agriculture for the control of 
pests.9 The spiroketal portion in the avermectins exhibits a narrow structure–activity 
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profile, suggesting that it is directly involved in binding to the target.10 Molecules in 
this class are thought to target glutamate-gated chloride channels.11  
There are many other larger, more complex natural products that also contain 
the spiroketal motif. However, the main role of the spiroketal in these cases is likely to 
act as a rigid scaffold to present sidechains in orientations that allow binding to 
specific sites on the biological targets.12 Examples include the polyketide polyether 
antibiotics (e.g. endusamycin), which have ionophoric properties,13 the spongistatins, 
which inhibit tubulin protein–protein interactions, and tautomycin, calyculin A, and 
okadaic acid, which are serine/threonine phosphatase inhibitors. Interestingly, some 
simple spiroketal analogs of these complex natural products have been shown to 
exhibit biological activity of their own.14-16 
Spiroketals are an attractive starting point for library design because of their 
proven ability to bind directly to multiple classes of biological targets, along with their 
capability of serving as rigid scaffolds to present functional groups in three 
dimensions. Since the appropriate stereochemistry is often crucial for recognition of a 
particular biological target, incorporating stereochemical diversity in a compound 
library should improve the probability of identifying biologically active molecules. 
Importantly, spiroketal-based libraries can exploit stereochemical diversity at the 
spiroketal carbon, in addition to the more typically-used sidechain stereodiversity. 
1.4. Synthetic Approaches to Spiroketals 
The wealth of biological activity displayed by spiroketals in nature has inspired 
the development of numerous strategies for spiroketal synthesis. Although these 
syntheses have traditionally focused on natural product targets with known biological 
activity, a number of unnatural spiroketals have been synthesized and found to be 
biologically active.14–16  The most frequently used strategy is acid-catalyzed 
spiroketalization of a dihydroxyketone precursor or an equivalent. Under equilibrating 
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conditions, the more thermodynamically stable isomer will be generated as the major 
product. For example, Merifield showed that acid-catalyzed spirocyclization of 
dithiane 1 yielded the spiroketal isomer 2, which is found in the natural product 
milbemycin.17  
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Figure 1.2. Thermodynamically controlled acid-catalyzed spiroketalization 
 
Since many spirocyclizations in target-oriented syntheses are carried out under 
equilibrating conditions, the ability to predict thermodynamic stability is important. 
Thermodynamic stability of spiroketals is influenced by steric interactions, anomeric 
effects,18 chelation effects, and intramolecular hydrogen bonding. The typical 
preference for substituents to occupy an equatorial orientation must be considered in 
addition to the stabilization provided by the anomeric effect. The anomeric effect has 
been estimated to lower the total energy of the molecule by 1.4–2.4 kcal/mol per 
interaction;19 accordingly, it plays a major role in determining the relative stabilities of 
spiroketal structures. When the two factors are reinforcing (i.e. the contribution of 
anomeric stabilizations is maximized and unfavorable steric interactions are 
minimized), the preferred structure can be predicted. 
For example, each of the 6,5-spiroketal isomers 3 and 4 can exist in an 
anomeric conformation (3a or 4b, Figure 1.3). However, unfavorable steric 
interactions in 4b will cause 3a to predominate in an equilibrating mixture of 3 and 4. 
Similarly, each of the two 6,6-spiroketal isomers 5 and 6 can exist as four chair–chair 
conformers (Figure 1.3). While spiroketals 5 and 6 can both exist as conformers 
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having two anomeric stabilizations (5a or 6a), 5a will predominate due to steric strain 
in 6a. Therefore, 5 would be the major isomer in an equilibrating mixture of 5 and 6.  
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 Although spiroketals are most commonly synthesized using internal 
ketalization strategies, other methods have also been developed. One conceptually 
unique approach developed by Paul utilizes a hetero-Diels–Alder cycloaddition.20 The 
effectiveness of this strategy was demonstrated by Ireland in the synthesis of racemic 
chalcogran (Figure 1.4).21 The condensation between vinyl ether 7 and 
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α,β-unsaturated ketone 8 proceeded in the presence of hydroquinone to yield 
spiroketal 9 in high yield.  
 
O
O
+
hydroquinone
rt, 4 days
82%7
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9
O
O O
O
chalcogran
 
Figure 1.4. Hetero-Diels–Alder approach to spiroketals 
 
Another unconventional approach to spiroketals made use of ketal-tethered 
ring-closing metathesis to construct a range of spiroketal structures.22 In one case, the 
insect pheromone 12 was synthesized via a Grubbs’ I-catalyzed RCM, followed by 
hydrogenation. The RCM precursor 11 was formed via addition of the lithiated analog 
of 10 to crotyl bromide, followed by stereoelectronically favored axial addition of allyl 
alcohol.  
  
O
O
O
O
O1) t-BuLi, THF    crotyl bromide
2) allyl alcohol
    PPTS, CH2Cl2
11 (4:1 dr)10
1) 10 mol % Grubbs' I
    CH2Cl2
12
2) H2, Pd-C
    EtOAc
 
Figure 1.5. Ketal-tethered ring-closing metathesis 
 
1.5. Synthetic Approaches to Nonanomeric Spiroketals: Thermodynamic Control 
Although most known spiroketal natural products have two anomeric 
stabilizations, there are a number of naturally occurring compounds that do not.23 
These “nonanomeric” spiroketals may be favored due to steric effects or macrocyclic 
constraints, or may be stabilized by intramolecular hydrogen bonding. Alternatively, 
they could be formed kinetically and exist as contrathermodynamic spiroketals. 
Chemical synthesis of nonanomeric spiroketals has generally relied on methods that 
stabilize the nonanomeric product under thermodynamic, equilibrating conditions. 
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These methods often use steric constraints, intramolecular hydrogen bonding, or a 
chelating metal to drive the equilibrium in the desired direction. 
 For example, Ireland has taken advantage of steric strain in an acid-catalyzed 
equilibration to generate the spiroketal segment of 3-deoxyaplysiatoxin (Figure 1.6).24 
The enol ether 15 was formed via a hetero-Diels–Alder reaction between 13 and 14, 
then converted to the bis-anomeric spiroketal 16 through hydroboration and benzoate 
protection. The desired spiroketal 17 was formed as a 70:30 equilibrium mixture with 
16 upon treatment with HCl. This equilibrium ratio is likely due to the 1,3-diaxial 
interactions in 16, which counteract the two anomeric stabilizations.  
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Figure 1.6. Thermodynamic equilibration using imposed steric constraints 
  
Another common approach, demonstrated by Evans in the synthesis of the CD 
spiroketal segment of spongistatin, involves equilibration in the presence of a 
chelating metal (Figure 1.7).25 Removal of the protecting groups in 18 resulted in 
spontaneous spirocyclization to yield an 85:15 mixture of the spiroketal 19 and its 
anomer 20. The amount of the desired isomer 20 was increased (80:20 with 19) when 
the mixture was equilibrated with a stoichiometric amount of ZnCl2, presumably due 
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to an internal chelate between the hydroxyl groups, metal cation, and the anomeric 
oxygens (21), which stabilizes this isomer during equilibration.   
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Figure 1.7. Thermodynamic equilibration with chelation by a metal 
 
1.6. Synthetic Approaches to Nonanomeric Spiroketals: Kinetic Control 
 Although the equilibrative strategies described in Section 1.5 are often 
successful in producing nonanomeric spiroketals, in some cases the inherent stability 
of the bis-anomeric isomer is difficult to overcome. The selectivity complications 
arising from thermodynamically controlled reactions have inspired the development of 
several kinetically controlled methods for spirocyclization that allow formation of the 
desired product independent of thermodynamic considerations. While acid-catalyzed 
spiroketalizations are typically under thermodynamic control, Deslongchamps has 
shown that certain acidic conditions can provide access to kinetically controlled 
cyclization products.18 However, more recent approaches toward 
contrathermodynamic products have completely avoided acid-catalyzed cyclization. 
These reactions usually take advantage of stereoelectronically preferred axial attack of 
an oxygen nucleophile at the anomeric position. For example, to construct the CD 
spiroketal subunit of spongistatin, Paterson subjected the alcohol intermediate 22 to a 
base-induced hetero-Michael reaction (Figure 1.8).26,27  Favored axial attack provided 
the desired isomer 23 as the major product, although a significant amount of the 
thermodynamically favored anomer 24 was also formed. Similarly, the CD spiroketal 
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segment of spongistatin was obtained by Roush via activation of glycal 25 with 
N-iodosuccinimide to form the activated oxonium species 26.28 Axial attack by the 
C19 hydroxyl group formed the desired isomer (27) as the major product.  
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Figure 1.8. Kinetically controlled approaches to the CD spiroketal segment of 
spongistatin 
 
One kinetic approach that is not limited by dependence on spirocyclization of 
an oxygen nucleophile along an axial trajectory was developed by Rychnovsky for the 
synthesis of the spiroketal portion of the polyketide antibiotic spirofungin B (Figure 
1.9).29 This method reverses the usual roles of the nucleophile and electrophile in 
spiroketal synthesis, avoiding the preference for formation of an axially-oriented 
oxygen. Lithium di-tert-butylbiphenylide is used to convert the cyanide 30 to the axial 
lithium species 31. The lithiated acetal then displaces the chloride on the sidechain to 
form the desired spiroketal 32 as a single diastereomer.  
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Figure 1.9. Reductive cyclization approach to the spiroketal segment in spirofungin B 
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1.7. Previous Approaches to Spiroketal Libraries 
 As described above, the spiroketal motif is an attractive starting point for 
library design. The syntheses of several spiroketal-based libraries have been described 
recently. The first of these, reported by Porco in 2002,30 consisted of a single 
spiroketal scaffold containing three independently addressable functional groups that 
were used for elaboration of the scaffold (Figure 1.10). The spiroketal scaffold (34), 
which has two anomeric stabilizations, was synthesized by deprotection and 
cyclization of 33 under acidic conditions. After cyclization, diversity was introduced 
at positions R1, R2, and R3 (35) by systematic introduction of sidechains at each 
position using solution-phase parallel synthesis techniques. No biological screening of 
the resulting library has been reported. 
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R2HN
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NHR1
O
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R3HN
O
O
O
HO
TBDPSO O OH
O
O HF
CH3CN, CH2Cl2
33
34
35
Figure 1.10. Porco’s synthesis of a library based on a single spiroketal scaffold 
  
In 2005, a spiroketal library based on a single spiroketal scaffold was reported 
by Waldmann (Figure 1.11).31 A series of immobilized spirocyclization substrates 36 
was synthesized using asymmetric boron enolate aldol reactions. Spontaneous 
spirocyclization of these substrates occurred upon deprotection with DDQ to form 
spiroketals 37, usually providing the isomer with two anomeric stabilizations as the 
major product. In cases where mixtures were produced, only the doubly anomeric 
product was included in the library. Therefore, stereochemical diversity was achieved 
only through decoration of the spiroketal skeleton with stereogenic centers, not 
through variations in spiroketal stereochemistry. The library was found to contain 
several phosphatase inhibitors and modulators of microtubule formation. Importantly, 
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changes in the stereochemistry of the substituents were shown to affect biological 
activity. For example, spiroketal 38 inhibited the phosphatase VHR with an IC50 of     
6 ± 4 µM, while 39 was a less potent inhibitor (IC50 = 31 ± 17 µM). 
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Figure 1.11.  Waldmann’s synthesis of a library based on a single spiroketal scaffold 
  
The synthesis of a library encompassing multiple spiroketal scaffolds was 
reported in 2006 by Ley (Figure 1.12).32 This approach was the first to make use of 
stereochemical diversity at the spiroketal carbon for library synthesis. When treated 
with acid, the β-keto-1,3-dithiane derivatives 40 cyclized to form the 6,6- (41) or 
6,5-spiroketals (42) as mixtures of isomers. In addition to these structural and 
stereochemical skeletal variations, removal of the dithiane and elaboration of R1 and 
R2 provided functional group and sidechain diversity. Biological screening was not 
reported for this library.   
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Figure 1.12. Ley’s synthesis of a library based on multiple spiroketal scaffolds 
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1.8. Synthesis of a Structurally and Stereochemically Diverse Spiroketal Library 
Using Stereoselective Spirocyclizations of C1-Substituted Glycal Epoxides 
While previous approaches to spiroketal libraries have focused primarily on 
structural diversity, we wanted to take advantage of the potential for stereochemical 
diversity presented by spiroketals. However, existing methods for synthesizing 
spiroketals had mainly been developed in the context of target-oriented synthesis, and 
were not suitable for the stereodiversified library that we envisioned. In order to 
synthesize systematically stereodiversified spiroketals, we needed to develop a general 
method allowing control of anomeric stereochemistry independent of thermodynamic 
stabilization or stereoelectronically favored axial attack.  
We envisioned a stereoselective route to spiroketals using C1-substituted 
glycal epoxides (Figure 1.13). This approach would use the C3-substituent as a 
directing element for a stereoselective epoxidation reaction (45 46). The epoxide 
could then be used to invoke stereochemical control in two discrete kinetic 
spirocyclization reactions, providing access to both spiroketal stereoisomers (47 or 48) 
from a common intermediate.  
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Figure 1.13. Stereoselective route to spiroketals (*site of stereochemical diversity) 
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Via this route, we would be able to generate stereochemical and structural 
diversity by: 1) using all four stereoisomers of 4-deoxyglycal substrates 44; 2) 
attaching sidechains of different lengths at the C1-position (45), which would result in 
multiple spiroketal ring sizes; 3) varying the R3 substituent; 4) carrying out 
spirocyclization reactions with either inversion or retention of configuration at C1 (47 
and 48); and 5) derivatizing the spiroketals at the C2- or C7-position (not shown).  
As will be described in Chapters 2–3, we have developed the synthetic 
methodology required to complete this route, providing access to eight spiroketal 
stereoisomers (four pairs of enantiomers) for each combination of R3 and n = 0–1. As 
discussed in Chapter 4, we have used our novel methodology to synthesize a small 
library of stereochemically and structurally diverse spiroketals, which will be 
subjected to a range of biological assays. Comparison of the results of these screens to 
other types of libraries will allow us to evaluate the effectiveness of our library design 
strategy. We have also explored ways to increase the diversity and utility of our first-
generation library, as illustrated in Chapter 5. Chapter 6 describes efforts to adapt our 
spiroketal synthetic methodology to a related problem in intermolecular glycosylation 
reactions. 
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CHAPTER 2 
ENANTIOSELECTIVE SYNTHESIS OF C1-SUBSTITUTED THREO- AND 
ERYTHRO-4-DEOXYGLYCALS 
 
2.1. Introduction 
Our plan for spiroketal library synthesis (Figure 1.13) required access to 
C1-substituted analogs (6) of all four stereoisomeric 4-deoxyglycals 2–5 (Figure 2.1). 
We designed these substrates to maintain the spacing of oxygen functionalities found 
in polyketide natural products. We also envisioned that an orthogonally protected 
C7-hydroxyl (OR1) might provide an attachment point for future application in solid 
phase synthesis. This chapter is based in part on a previous publication.1 
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Figure 2.1. 4 stereoisomeric C1-substituted 4-deoxyglycal scaffolds required for 
spiroketal synthesis 
 
2.2. Synthesis of the threo-4-Deoxyglycals 
A synthesis of the threo-4-deoxyglycals (2 and 3) was developed by Justin 
Potuzak (Figure 2.2). An enantioselective cyclocondensation2 of aldehyde 7 and the 
Danishefsky diene (8) to a dihydropyrone (10) is accomplished using a catalyst 
developed by Jacobsen3 (9). Substrate-controlled stereoselective Luche reduction4 of 
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the dihydropyrone followed by protection of the C3-hydroxyl of 11 produces the 
D-threo-glycal 12. The corresponding L-threo-glycal is synthesized by using the 
enantiomer of the Jacobsen catalyst 9.  
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Figure 2.2. Enantioselective synthesis of the threo-4-deoxyglycals 12 
 
2.3. Synthesis of the erythro-4-Deoxyglycals 
  To expand the stereochemical diversity of the library, a route was needed to 
the erythro-4-deoxyglycals 4 and 5. Attempts to synthesize the erythro-glycal 15 by 
1,2-reduction of the dihydropyrone 13 using sterically demanding hydride reagents 
were based on the expectation that equatorial attack would occur to produce the 
desired product. However, treatment of 13 with a variety of bulky hydride reagents 
(Figure 2.3) resulted in exclusive formation of the threo stereoisomer 14. Although 
these results contrast with stereoselectivity trends observed with bulky hydride 
reductions of cyclohexanones,5 they can be rationalized by the reduced steric conflict 
along the axial trajectory,6 increased torsional strain associated with the transition state 
for equatorial attack,7 stereoelectronic effects involving the ring oxygen,8 or the 
availability of a competing reactive conformation in which the C5-substituent is 
oriented axially. 
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Figure 2.3. Reduction of the dihydropyrone 13 with bulky hydride reagents.  
R = Ph or n-Pr 
 
Subsequent efforts to synthesize the erythro glycals were focused on inversion 
of the C3-hydroxyl group of the threo-glycal 14. Attempts at Mitsunobu inversion 
were unsuccessful due to competing SN2  displacement to form 16 (Figure 2.4). This 
result was not surprising due to the known propensity of glycals to undergo 
nucleophilic attack at the C1 position.9 
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Figure 2.4. Attempted Mitsunobu inversion using the threo-glycal substrate 14.  
R = Me or n-Pr 
 
The susceptibility of glycals to SN2  displacement has been exploited by 
Danishefsky in an indirect approach to C3 inversion. This approach converted the 
glucal substrate 18 to the allal product 22 using a thiophenol Ferrier/sigmatropic 
rearrangement sequence10 (Figure 2.5). Unfortunately, substrate 24 was unstable to the 
reported thiophenol Ferrier conditions (BF3•OEt2) and the use of SnCl4 resulted in 
direct substitution at the C3 position by thiophenol to provide glycal 25. Interestingly, 
treatment with 4-methoxyphenol in the presence of SnCl4 resulted in allylic 
substitution (23). 
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Figure 2.5. Net C3-inversion of 3,4,6-tri-O-acetyl-D-glucal 18 and related reactions of 
threo-4-deoxyglycal 24 
 
This regioselectivity can be rationalized by the hard-soft acid-base principle, in 
which soft nucleophiles tend to attack at the C3 position, and hard nucleophiles favor 
the C1 position.11 With this idea in mind, the harder nucleophile S-trimethylsilyl 
thiophenol was tested since it favors C1 attack on other glycal substrates.12 However, 
attack still occurred at the C3-position (25). This surprising regioselectivity may be 
due to the absence of a C4-substituent in our 4-deoxyglycal substrate, which reduces 
the steric conflict for attack at the C3-position. 
Having explored the classical approaches, an alternative strategy involving 
endo-cycloisomerization of a linear alkynol precursor was evaluated. This class of 
reaction has been explored extensively by McDonald and Trost and is generally driven 
by molybdenum,13 tungsten,14-17 rhodium,18 or ruthenium19 catalysts. McDonald has 
reported a series of reactions catalyzed by W(CO)6 that form glycals with various 
stereochemical configurations17 (27) in high yield (Figure 2.6). The conditions were 
effective regardless of substrate stereochemistry, but no examples using 4-deoxy 
substrates were reported. While our work was in progress, Wipf reported a strong 
influence of stereochemistry, substitution patterns, and protecting groups on the 
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regiochemical outcome of the reaction (29 (endo-glycal) vs 30 (exo-glycal) 
formation).20 Discouragingly, cycloisomerization of substrates with our required 
substitution pattern and stereochemical configuration (28a–e) were reported to lead to 
low yields (3–15%) of the desired erythro-4-deoxyglycal products (29a–e). When a 
coordinating substituent was present at the propargylic position, the low yield was due 
to competing exo-cycloisomerization. Although the endo-glycal was the major product 
when the propargylic substituent was non-coordinating (28e), the yield was still low 
(15% 29e, unreported byproducts). 
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Figure 2.6. Tungsten-catalyzed cycloisomerizations of alkynol substrates 26 and 28 
 
To determine if higher yields of the desired erythro-4-deoxyglycal could be 
achieved by a cycloisomerization route, we synthesized a series of alkynol precursors 
using methodologies that have been developed in the context of polyketide synthesis. 
Enantioselective allylation of aldehyde 7 with Leighton’s allylsilane reagent21 (31) 
provided homoallylic alcohol 32 with high optical purity (96% e.e.) The homoallylic 
alcohol was protected as the triethylsilyl ether then converted to aldehyde 33. At this 
point, several recently developed diastereoselective alkyne addition reactions were 
evaluated. Unfortunately, attempted couplings of 33 with trimethylsilylacetylene using 
Zn(OTf)2/N-methylephedrine
22 led to recovered starting material, consistent with a 
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report involving related substrates.23 Reactions at higher temperatures or with 
Et2Zn/Ti(Oi-Pr)4/BINOL
18,24 led to β-elimination of 33 to the corresponding 
α,β-enone. Direct addition of lithium trimethylsilylacetylide resulted in a mixture of 
propargylic alcohol diastereomers (52:39 34:35), however, the minor diastereomer 35 
was readily separated chromatographically from 34 and carried on to alkynol 36 using 
standard Mitsunobu inversion protocols. Protecting group manipulations of 36 
provided cycloisomerization substrates 37a–g.  
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Figure 2.7. Enantioselective synthesis of protected alkynol substrates 37a–g and 
endo-cycloisomerization reactions to form erythro-4-deoxyglycals 38a–g  
  
We were then in a position to carry out a series of alkynol cycloisomerization 
reactions. Unfortunately, attempted cycloisomerizations of 37a,e–g using conditions 
developed by Trost (catalysis by Rh[P(m-FPh)3]3Cl or Rh(PPh3)3Cl)
18 yielded only 
trace amounts of the corresponding glycals 38a,e–g. Interestingly, W(CO)6-catalyzed
17 
cycloisomerizations of 37b and 37c resulted in the formation of truncated diene 39a as 
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the only product. This diene was a major product for 37d (50:50 with 38d) and 37e 
(45:2:53 with 38e and the corresponding exo-glycal). Similarly, reaction of the doubly 
PMB-protected alkynol 37f yielded the corresponding diene 39b (54:23:23 with 38f 
and the corresponding exo-glycal).  
The appearance of the diene and exo-glycal20 products can be rationalized by 
the mechanisms shown in Figure 2.8. When an alkynol 37 is exposed to the 
W(CO)6/Et3N/hν cycloisomerization conditions, coordination of tungsten to the 
alkyne (40 or 41) can be followed by direct cyclization to the exo-glycal (44). 
However, if hydride transfer is faster than exo-cyclization, endo-cyclization can then 
occur, yielding the endo-glycal (38) after protonation.  
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Figure 2.8. Proposed mechanisms of formation of endo-glycal 38, exo-glycal 44, and 
diene 39 from alkynol 37 
 
Since the C3-substituent of our erythro glycal substrates is in an axial 
orientation, the intermediate following endo-cyclization (42) is stereoelectronically 
predisposed to undergo elimination to 45. Alkene isomerization to 46 followed by 
[4+2] cycloreversion leads to the observed diene (39). Analogous diene products had 
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not been reported previously, however, the proposed diene formation pathway may not 
be relevant for threo stereoisomers (due to the decreased propensity for elimination), 
or substrates having a substituent at the C4 position (due to decreased acidity). 
Furthermore, the low isolated yields reported by Wipf for erythro-4-deoxy substrates20 
could be partially due to volatility of dienes lacking our bulky sidechains. 
After extensive experimentation with alkynol substrates 37a–f, it was found 
that exposure of 37a to W(CO)6/Et3N/hν provided the desired erythro-4-deoxyglycal 
38a in good yield with no evidence of competing exo-cycloisomerization and only 
trace amounts of the diene byproduct (Figure 2.7). Replacement of Et3N with 
DABCO, which is now more commonly used as the base,16,17 resulted in distinctly 
slower reaction rates and incomplete conversion to the desired glycal. This route 
provided access to gram quantities of the critical erythro-4-deoxyglycal 
(approximately 30% overall yield of glycal 38a from aldehyde 7 when carried out on a 
multigram scale) that provided the first basis for stereochemical diversity in our 
library. Importantly, synthesis of the glycal enantiomer (3) was equally successful 
when the enantiomer of the allylation reagent 31 was used, providing even greater 
stereochemical diversity.  
2.4. Reactivity of the erythro-4-Deoxyglycals 
Access to the erythro-4-deoxyglycals also provided the opportunity to explore 
their reactivity, and to determine the feasibility of stereoselective reactions of the 
glycal double bond that are complementary to those available using the corresponding 
threo stereoisomer. Reactions were expected to occur selectively at the β-face of the 
double bond due to a favored reactive conformation in which the C3-OTIPS 
substituent is axially disposed (47, Figure 2.9).  
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Figure 2.9. Half-chair conformations of the erythro-4-deoxyglycal 38a and steric 
influences upon double bond reactivity 
 
As anticipated, epoxidation of 38a with dimethyldioxirane25 afforded the 
β-epoxide 53 (Figure 2.10). Methanolysis of the epoxide proceeded stereoselectively 
to the α-D-arabino-4-deoxyglycoside 49. Similarly, allylation of 53 with 
allylmagnesium chloride provided the corresponding α-allyl C-glycoside 55. 
Hydroboration–oxidation of 38a using BH3 led to a 2:1 ratio of 50 and its α-C2-
epimer while 9-BBN and dicyclohexylborane were unreactive. However, the use of 
thexylborane led to highly stereoselective formation of the β-C2-alcohol 50. 
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Figure 2.10. Stereoselective reactions of the erythro-4-deoxyglycal 38a 
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Interestingly, attempted direct methanolysis of the glycal double bond under 
mild acidic conditions (PPh3•HBr) led to a 41:14:45 mixture of β-methyl erythro-2,4-
dideoxyglycoside 56, its α-anomer (not shown), and the α-glycoside Ferrier 
rearrangement product 57. Notably, exposure of the corresponding threo-4-
deoxyglycal to identical conditions did not result in any Ferrier rearrangement. These 
results are consistent with axial orientation of the C3-OTIPS substituent in the 
erythro-glycal, which would be stereoelectronically predisposed to Ferrier-type 
elimination. Similarly, Sc(OTf)3-catalyzed condensation of 38a with salicylaldehyde
26 
resulted in the formation of tricycle 51 instead of the expected Diels–Alder reaction 
product. Although the isolated yield of the tricycle was low, the reaction proceeded 
with high regio- and stereoselectivity, which can be rationalized by the mechanism 
shown in Figure 2.11.  
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Figure 2.11. Proposed mechanism for formation of tricycle 51 through Sc(OTf)3-
catalyzed condensation of 38a with salicylaldehyde. R = (CH2)2OTBDPS 
 
After exposure of glycal 38a to Sc(OTf)3, a Ferrier-type reaction leads to 60, 
which then undergoes reaction with 61 to form 62. Although this addition reaction is 
probably not stereoselective, facile Ferrier-type elimination of the α-C3-substituent in 
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intermediate 62 would cause the β-C3-substituted 63 to become the major 
stereoisomer. Reversible cyclization then occurs to produce the thermodynamically-
favored 64, which is then quenched by MeOH. The observed stereochemistry at the 
anomeric position may be due to positioning of the incoming MeOH by Sc(OTf)3 
through coordination with the α-OMe-substituent. 
The erythro-4-deoxyglycal 38a was also converted to C1-substituted glycals 
54a,b via Suzuki27 or Stille28 coupling, respectively (Figure 2.10). Hydroboration–
oxidation with thexylborane proceeded from the β-face of the glycal double bond with 
complete stereoselectivity to provide the corresponding α-D-arabino-4-deoxy-C-
glycosides 52a,b. Interestingly, acid-catalyzed alcoholysis of the C1-substituted 
glycals 54a,b provided α-methyl ketoglycosides 59a,b, corresponding to a double 
substitution at both the C1 and C3 positions. It is likely that steric factors in these 
C1-substituted glycals cause MeOH to attack at the C3 position following an initial 
Ferrier-type elimination, leading to the 3-methoxyglycal intermediates 58a,b. In the 
C1-phenylglycal series, 58b was observed as a reaction intermediate in equilibrium 
with 59b, supporting the proposed mechanism. 
2.5. Synthesis of C1-Substituted Glycals 
 An efficient and flexible method for attaching sidechains to the C1 position of 
the threo-4-deoxyglycal (12) was developed by Justin Potuzak. The C1-iodoglycal 66 
is prepared via the corresponding glycal stannane 65 according to Friesen’s protocol.29 
The iodide can then be coupled to a range of olefins using an optimized B-alkyl 
Suzuki–Miyaura cross-coupling reaction to yield C1-alkylglycals 67a–r.27 This route 
also allows efficient formation of the analogous erythro-C1-alkylglycals (not shown). 
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Figure 2.12. Synthesis of C1-alkyl glycals 67 
 
2.6. Experimental Section 
Materials and Methods: 
Reagents were obtained from Aldrich Chemical (www.sigma-aldrich.com) or 
Acros Organics (www.fishersci.com) and used without further purification. 
1-Methoxy-3-trimethylsiloxy-1,3-butadiene was obtained from Alfa Aesar. Optima 
grade solvents were obtained from Fisher Scientific (www.fishersci.com), degassed 
with Ar, and purified on a solvent drying system as described in Pangborn, A. B.; 
Giardello, M. A.; Grubbs, R. H.; Rosen, R. K.; Timmers, F. J. Organometallics 1996, 
15, 1518–1520 unless otherwise indicated. Triethylamine was distilled from CaH 
under N2. Reactions were performed in flame-dried glassware under positive Ar 
pressure with magnetic stirring unless otherwise indicated. Cold baths were generated 
as follows: 0 °C, wet ice/water; –78 °C, dry ice/acetone; –63 °C dry ice/chloroform. 
Photolysis reactions were carried out in a Rayonet photoreactor at 300 nm. Flash 
chromatography was performed on E. Merck 60 230–400 mesh silica gel. Chiral 
HPLC analysis was carried out on a Varian analytical HPLC with a Chiracel OD-H 
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column using a flow rate of 0.7 mL/min of 2% isopropanol in hexanes, with UV 
detection at 252 nm. Optical rotations were recorded on a JASCO model DIP-370 
digital polarimeter. TLC was performed on 0.25 mm E. Merck silica gel 60 F254 
plates and visualized under UV light (254 nm) or by using potassium permanganate or 
cerium ammonium molybdenate stains. IR spectra were recorded neat on NaCl plates 
with a Perkin–Elmer model 1600 FTIR spectrometer with peaks reported in cm–1. 
NMR spectra were recorded on Bruker DRX500 or AMX400 instruments at 24 °C in 
CDCl3 unless otherwise indicated. Chemical shifts are expressed in ppm relative to 
TMS (1H, 0 ppm) or solvent signals: CDCl3 (
13C, 77.0 ppm), C6D6 (
1H, 7.16 ppm; 13C, 
128.0 ppm) or acetone-d6 (
13C, 206.2 ppm). Coupling constants are expressed in Hz. 
Mass spectra were obtained at the MSKCC Analytical Core Facility on a PE SCIEX 
API 100 mass spectrometer by electrospray (ESI) ionization. 
Atom numbering in IUPAC compound names herein does not correspond to 
conventional carbohydrate nomenclature and is used for naming purposes only. Atom 
numbering in the text corresponds to conventional carbohydrate nomenclature. 
Compounds not cited in the previous sections of this chapter are numbered herein 
E1−E9. 
 
Synthesis of threo-4-deoxyglycal 12: 
Compounds 10–12 were characterized by Justin Potuzak. 
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(6R)-6-[2-(tert-Butyldiphenylsilyloxy)ethyl]-2,3-dihydropyran-4-one (10). A 
solution of catalyst 93 (310 mg, 0.64 mmol, 0.050 equiv) in anhyd acetone (2.5 mL) 
  34 
was stirred over 4 Å molecular sieves (2.5 g) for 30 min then cooled to 0 ºC. Aldehyde 
7
30,31 (4.0 g, 0.013 mol, 1.0 equiv) was added and the reaction was stirred 10 min. 
1-Methoxy-3-(trimethylsilyloxy)-1,3-butadiene (3.7 mL, 0.019 mol, 1.5 equiv) was 
added slowly then the reaction was warmed to rt. After 3 h, the reaction was cooled to 
0 ºC then CH2Cl2 (25 mL) was added. After 10 min, TFA (1.5 mL, 0.019 mol, 1.5 
equiv) was added slowly then the reaction was warmed to rt. The mixture was filtered 
through Celite/silica and the filtrate was concentrated. The residue was purified by 
flash chromatography (elution with 5:1 hexanes/EtOAc) to yield dihydropyrone 10 as 
a yellow oil (3.4 g, 70%). The e.e. of 10 was determined to be 88% by chiral HPLC 
analysis. TLC: Rf  0.51 (2:1 hexanes/EtOAc). ][
25
Dα = +46º (c 1.0, CDCl3). IR (NaCl, 
film): 3071, 2953, 2930, 2884, 2856, 1679, 1594, 1469, 1429, 1403, 1272, 1212, 1107, 
1031, 739, 703, 613, 503. 1H-NMR (400 MHz): δ 7.65 (m, 4H), 7.46–7.37 (m, 6H), 
7.28 (d, 1H, J = 6.0), 5.40 (dd, 1H, J = 0.7, 5.8), 4.68 (m, 1H), 3.89–3.76 (m, 2H), 
2.57–2.43 (m, 2H), 2.03 (m, 1H), 1.88 (m, 1H), 1.05 (s, 9H). 13C-NMR (125 MHz): 
δ 192.6, 163.1, 135.5, 133.4, 129.8, 127.7, 107.1, 76.4, 59.2, 42.0, 37.2, 26.8, 19.2. 
ESI-MS m/z: pos 403.0 [M+Na]+; neg 379.2 [M–H]–, 415.3 [M+Cl]–. 
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(4S,6R)-6-[2-(tert-Butyldiphenylsilyloxy)ethyl]-3,4-dihydro-2H-pyran-4-ol (11). 
CeCl3•7H2O was added to a solution of dihydropyrone 10 (3.4 g, 9.0 mmol, 1.0 equiv) 
in anhyd MeOH (40 mL) at rt then the mixture was cooled to –78 ºC. NaBH4 (510 mg, 
13 mmol, 1.5 equiv) was added in one portion. After 30 min at –78 ºC, the reaction 
was warmed to rt then quenched by slow addition of sat’d aq NaOAc. The aqueous 
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layer was extracted 3x with EtOAc then the combined organic layers were washed 
with brine, dried (MgSO4), filtered, and concentrated. The residue was purified by 
flash chromatography (elution with 3:1 hexanes/EtOAc) to yield glycal 11 as a clear 
oil (3.1 g, 90%). TLC: Rf  0.38 (2:1 hexanes/EtOAc). ][
25
Dα = –3.4º (c 1.0, CDCl3). IR 
(NaCl, film): 3335, 3066, 2951, 2931, 2880, 2858, 1642, 1469, 1427, 1389, 1234, 
1105, 1059, 1030, 953, 822, 739, 702, 612, 502. 1H-NMR (400 MHz): δ 7.65 (m, 4H), 
7.44–7.36 (m, 6H), 6.33 (d, 1H, J = 6.0), 4.73 (dt, 1H, J = 6.2, 1.8), 4.41 (m, 1H), 4.18 
(m, 1H), 3.86–3.73 (m, 2H), 2.17 (m, 1H), 1.91–1.78 (m, 2H), 1.64–1.55 (m, 1H), 
1.35 (d, 1H, J = 7.1), 1.05 (s, 9H). 13C-NMR (125 MHz): δ 145.2, 135.5, 133.8, 
129.6, 127.7, 105.3, 71.7, 63.1, 59.9, 38.2, 37.8, 26.9, 19.2. ESI-MS m/z: pos 405.2 
[M+Na]+. 
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(4S,6R)-6-[2-(tert-Butyldiphenylsilyloxy)ethyl]-4-(triisopropylsilyloxy)-3,4-
dihydro-2H-pyran (12). Imidazole (1.1 g, 16 mmol, 2.0 equiv) then TIPSCl (2.6 mL, 
12. mmol, 1.5 equiv) was added to a solution of glycal 11 (3.1 g, 8.1 mmol, 1.0 equiv) 
in CH2Cl2 (40 mL) at rt. After stirring at rt 2 h, the reaction was quenched with sat’d 
aq NaHCO3. The aqueous layer was extracted 3x with Et2O then the combined organic 
layers were washed with H2O then brine, dried (MgSO4), filtered and concentrated. 
The residue was purified by flash chromatography (elution with 99:1 hexanes/EtOAc) 
to yield threo-4-deoxyglycal 12 as a clear oil (3.6 g, 82%). TLC: Rf  0.70 (4:1 
hexanes/EtOAc). ][ 25Dα = –19º (c 1.0, CDCl3). IR (NaCl, film): 3067, 2941, 2863, 
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1643, 1465, 1428, 1388, 1237, 1104, 1005, 883, 822, 738, 702, 502. 1H-NMR (400 
MHz): δ 7.65 (m, 4H), 7.44–7.35 (m, 6H), 6.28 (d, 1H, J = 6.27), 4.71 (dt, 1H, J = 6.2, 
1.7), 4.53 (dd, 1H, 8.2, 6.7), 4.18 (m, 1H), 3.85-3.73 (m, 2H), 2.08 (m, 1H), 1.92 (m, 
1H), 1.82–1.69 (m, 2H), 1.05 (m, 30H). 13C-NMR (125 MHz): δ 144.1, 135.5, 133.8, 
129.6, 127.6, 106.2, 71.6, 63.3, 60.1, 38.2, 37.8, 36.9, 19.2, 18.1, 12.3. ESI-MS m/z: 
pos 561.5 [M+Na]+; neg 573.4 [M+Cl]–. 
 
 
Synthesis of erythro-4-deoxyglycal 38a: 
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(3S)-1-(tert-Butyldiphenylsilyloxy)-hex-5-en-3-ol (32). A solution of aldehyde 730,31 
(3.0 g, 9.7 mmol, 1.0 equiv) in anhyd CH2Cl2 (40 mL) was transferred by cannula to a 
cooled (–78 ºC) solution of (3aR,7aR)-2-allyl-1,3-bis-(4-bromobenzyl)-2-
chlorooctahydrobenzo[1,3,2]diazasilole32 (8.1 g, 15 mmol, 1.5 equiv) in anhyd CH2Cl2 
(40 mL). The reaction was transferred to a freezer (–10 ºC) then allowed to stand for 
21 h. The cold reaction mixture was quenched with sat’d aq NaHCO3 then warmed to 
rt and stirred 15 min. The aqueous layer was extracted 2x with EtOAc then the 
combined organic layers were dried (MgSO4), filtered, and concentrated. The residue 
was purified by flash chromatography (elution with 9:1 hexanes/EtOAc) to yield 
alcohol 32 as a clear oil (2.5 g, 71%). The e.e. of 32 was determined to be 96% by 
analysis of its Mosher ester. TLC: Rf  0.13 (9:1 hexanes/EtOAc). IR (NaCl, film): 
3441, 3058, 2926, 2854, 1463, 1428, 1104, 1080, 823, 739, 703, 613, 506. 1H-NMR 
(400 MHz): δ 7.71 (d, 4H, J = 7.1), 7.45 (m, 6H), 5.86 (m, 1H), 5.11 (m, 2H), 3.96 (m, 
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1H), 3.89 (m, 2H), 3.19 (d, 1H, J = 2.6), 2.25 (m, 2H), 1.70 (m, 2H), 1.21 (s, 9H). 
13
C-NMR (125 MHz): δ 135.7, 133.2, 128.8, 127.7, 117.5, 70.9, 63.4, 41.7, 37.9, 
26.6, 19.0. ESI-MS m/z: (pos) 377.1 [M+Na]+; (neg) 389.2 [M+Cl]–. 
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The homoallylic alcohol 32 was converted to aldehyde 33 in two steps as described.33 
For analytical scale synthesis, olefin E1 and aldehyde 33 were purified by flash 
chromatography as usual. For preparative scale synthesis, 14 g of alcohol 32 was 
converted to 19 g of crude aldehyde 33 (84% overall yield based on NMR analysis of 
the crude product) that was carried on to 34 without further purification (see below).  
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(3R,5R)-7-(tert-Butyldiphenylsilyloxy)-5-(triethylsilyloxy)-1-(trimethylsilyl)-hept-
1-yn-3-ol (34) and (3S,5R)-7-(tert-Butyldiphenylsilyloxy)-5-(triethylsilyloxy)-1-
(trimethylsilyl)-hept-1-yn-3-ol (35).  n-BuLi (2.5 M in hexane, 2.0 mmol, 1.3 equiv) 
was added dropwise to a cooled (–78 °C) solution of TMS acetylene (270 µL, 2.0 
mmol, 1.3 equiv) in anhyd THF (4.5 mL). The reaction mixture was stirred at –78 °C 
for 1 h then treated over 5 min with a solution of the aldehyde 33 (720 mg, 1.5 mmol, 
1.0 equiv) in anhyd THF (3.5 mL). After an additional 20 min at –78 °C, the reaction 
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was quenched with H2O. The aqueous layer was extracted 3x with Et2O and the 
combined extracts were washed with brine, dried (MgSO4), filtered, and concentrated 
to afford a 59:41 mixture of 34 and 35. The crude material was purified by flash 
chromatography (elution with 93:7 hexanes/EtOAc) to yield propargylic alcohols 34 
(450 mg, 52%) and 35 (340 mg, 39%) as clear oils. For preparative scale synthesis, 
18.7 g of crude aldehyde 33 (see above) was converted to alcohol 34, which was 
purified by flash chromatography (10 g, 46% overall yield over 3 steps 32 → 34).  
34: TLC: Rf  0.11 (9:1 hexanes/EtOAc). ][
25
Dα = –8.7° (c 0.5, CHCl3). IR (NaCl, film): 
2955, 2871, 1422, 1249, 1111, 1087, 1009, 841, 739, 703, 613, 505. 1H-NMR (400 
MHz): δ 7.63 (m, 4H), 7.39 (m, 6H), 4.52 (m, 1H), 4.14 (m, 1H), 3.69 (m, 2H), 2.80 
(d, 1H, J = 3.9), 1.89-1.70 (m, 4H), 1.04 (s, 9H), 0.95 (t, 9H, J = 7.9), 0.50 (q, 6H, J = 
7.9), 0.16 (s, 9H). 13C-NMR (100 MHz): δ135.8, 135.0, 133.9, 129.9, 127.9, 106.9, 
89.3, 69.2, 62.0, 60.6, 44.2, 40.9, 27.1, 19.3, 7.1, 5.3. ESI-MS m/z: (pos) 569.4 
[M+H]+, 591.3 [M+Na]+; (neg) 567.3 [M–H]–. 
35: TLC: Rf  0.34 (9:1 hexanes/EtOAc). ][
25
Dα = –6.4° (c 1.0, CHCl3). IR (NaCl, film): 
3436, 2955, 2872, 1467, 1420, 1384, 1249, 1096, 1008, 844, 738, 697, 615, 503. 
1
H-NMR (400 MHz): δ 7.64 (m, 4H), 7.40 (m, 6H), 4.59 (m, 1H), 4.37 (m, 1H), 3.68 
(m, 2H), 3.41 (d, 1H, J = 5.5), 1.92-1.63 (m, 4H), 1.06 (s, 9H), 0.95 (t, 9H, J = 7.9), 
0.61 (q, 6H, J = 8.0), 0.15 (s, 9H). 13C-NMR (100 MHz): δ136.3, 135.6, 133.6, 127.8, 
127.5, 127.0, 106.7, 88.8. 60.4, 27.1, 26.8, 26.6, 19.1, 5.0. ESI-MS m/z: (pos) 569.2 
[M+H]+, 591.3 [M+Na]+; (neg) 567.3 [M–H]–, 603.3 [M+Cl]–. 
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(3R,5R)-7-(tert-Butyldiphenylsilyloxy)-5-(triethylsilyloxy)-1-(trimethylsilyl)-hept-
1-yn-3-yl benzoate (E2). Benzoic acid (1.9 g, 0.015 mol, 1.2 equiv) then PPh3 (4.0 g, 
0.015 mol, 1.2 equiv) were added sequentially to a solution of alcohol 35 (7.3 g, 0.013 
mol, 1.0 equiv) in benzene (32 mL). The mixture was stirred until a clear solution was 
obtained, then cooled to 0 °C. DEAD (2.4 mL, 0.015 mol, 1.2 equiv) was added 
dropwise. The mixture was stirred at 0 °C for 15 min then quenched with brine. The 
aqueous layer was extracted 3x with Et2O then the combined extracts were washed 
with brine, dried (MgSO4), filtered and concentrated. The crude material was purified 
by flash chromatography (elution with 95:5 hexanes/EtOAc) to yield benzoate E2 (7.7 
g, 90%) as a clear oil. TLC: Rf  0.30 (9:1 hexanes/EtOAc). 
1
H-NMR (400 MHz): δ 
8.06 (d, 2H, J = 8.1), 7.66 (m, 4H), 7.54 (m, 1H), 7.40 (m, 8H), 5.79 (t, 1H, J = 7.3), 
4.22 (m, 1H), 3.73 (t, 2H, J = 6.1), 2.05 (m, 2H), 1.77 (m, 2H), 1.03 (m, 9H), 0.98 (m, 
9H), 0.64 (m, 6H), 0.15 (s, 9H). 
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(3R,5R)-7-(tert-Butyldiphenylsilyloxy)-5-(triethylsilyloxy)-hept-1-yn-3-ol (36). 
Method A: A cooled (0 °C) solution of 34 (10 g, 18 mmol) in MeOH (180 mL, 
Optima grade) was treated with H2O (9.8 mL) and K2CO3 (5.0 g, 36 mmol). The 
mixture was stirred at 0 °C for 10.5 h then the MeOH was evaporated to afford a white 
solid. The solid was dissolved in Et2O, washed 3x with H2O, washed with brine, dried 
(MgSO4), filtered, and concentrated to yield propargylic alcohol 36 as a white solid 
(9.4 g, 91% based on NMR analysis of the crude product) that was carried on without 
further purification. The reaction was also carried out on analytical scale with 
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purification by flash chromatography to provide 110 mg of 36. 
Method B: H2O (6 mL) was added to a solution of benzoate E2 (7.7 g, 0.011 mol, 1.0 
equiv) in MeOH (120 mL) then the solution was cooled to 0 °C. K2CO3 (4.7 g, 0.034 
mol, 3.0 equiv) was added then the mixture was stirred at 0 °C for 7h. The majority of 
the solvent was removed by rotary evaporation then the mixture was diluted with 
ether. The organic layer was washed 2x with H2O, dried (MgSO4), filtered and 
concentrated. The crude material was purified by flash chromatography (elution with 
9:1 hexanes/EtOAc) to yield propargylic alcohol 36 (4.9 g, 86%) as a white solid. 
TLC: Rf: 0.24 (4:1 hexanes/EtOAc). IR (NaCl, film): 3307, 2950, 2881, 1461, 1427, 
1104, 1006, 816, 735, 695, 505. 1H-NMR (400 MHz): δ 7.66 (m, 4H), 7.40 (m, 6H), 
4.52 (m, 1H), 4.20 (m, 1H), 3.70 (m, 2H), 2.81 (d, 1H, J = 4.0), 2.44 (d, 1H, J = 2.1), 
1.91-1.68 (m, 4H), 1.03 (s, 9H), 0.92 (t, 9H, J = 7.9), 0.60 (q, 6H, J = 7.9). 13C-NMR 
(100 MHz): δ135.8, 135.0, 133.8, 129.9, 127.9, 85.0, 73.1, 69.0, 61.3, 60.6, 44.2, 40.8, 
27.1, 19.4, 7.1, 5.3. ESI-MS m/z: (pos) 497.3 [M+H]+, 519.3 [M+Na]+; (neg) 495.3 
[M–H]–, 531.0 [M+Cl]–. 
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(3R,5R)-7-(tert-Butyldiphenylsilyloxy)-5-(triethylsilyloxy)-3-(triisopropylsilyloxy)-
hept-1-yne (E3). Triisopropylsilyl chloride (73 µL, 0.34 mmol, 1.5 equiv) was added 
dropwise to a solution of the propargylic alcohol 36 (110 mg, 0.23 mmol, 1.0 equiv) 
and imidazole (31 mg, 0.46 mmol, 2.0 equiv) in anhyd DMF (2.3 mL, sureseal bottle). 
After 22 h at rt the reaction mixture was quenched with sat’d aq NaHCO3. The 
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aqueous layer was extracted 3x with Et2O and the combined extracts were washed 
with H2O and brine, dried (MgSO4), filtered, and concentrated. The residue was 
purified by flash chromatography (elution with 98:2 hexanes/EtOAc) to yield alkyne 
E3 a clear oil (130 mg, 84%). For preparative scale synthesis, 9.4 g of crude alcohol 
36 was converted to 14 g of crude alkyne E3 that was carried on without further 
purification (see below). TLC: Rf  0.59 (9:1 hexanes/EtOAc). IR (NaCl, film): 3296, 
2950, 2869, 1461, 1427, 1237, 1104, 1058, 1006, 885, 822, 735, 695. 1H-NMR (400 
MHz): δ 7.67 (d, 4H, J = 6.9), 7.40 (m, 6H), 4.61 (m, 1H), 4.19 (m, 1H), 3.70 (m, 2H), 
2.40 (d, 1H, J = 1.8), 1.91-1.69 (m, 4H), 1.13-1.02 (m, 30H), 0.92 (t, 9H, J = 7.9), 
0.59 (q, 6H, J = 7.9). 13C-NMR (100 MHz): δ135.8, 134.1, 129.7, 127.8, 85.7, 73.2, 
67.1, 61.3, 60.6, 46.5, 41.1, 27.0, 19.3, 18.2, 12.4, 7.2, 5.3. ESI-MS m/z: (pos) 653.6 
[M+H]+, 675.3 [M+Na]+; (neg) 687.4 [M+Cl]–. 
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(3R,5R)-1-(tert-Butyldiphenylsilyloxy)-5-(triisopropylsilyloxy)-hept-6-yn-3-ol 
(37a). Acetic acid (1.1 mL) was added to a solution of alkyne E3 (120 mg, 0.19 
mmol) in THF (0.4 mL, Optima grade) and water (0.4 mL). After 1.5 h at rt the 
mixture was quenched with sat’d aq NaHCO3. The aqueous layer was extracted 3x 
with Et2O and the combined organic layers were dried (MgSO4), filtered, and 
concentrated. The crude material was purified by flash chromatography (elution with 
95:5 hexanes:EtOAc) to yield alcohol 37a as a clear oil (80 mg, 79%). For preparative 
scale synthesis, 14 g of crude alkyne E3 (see above) was converted to alcohol 37a, 
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which was purified by flash chromatography (8.0 g, 81% overall yield over 3 steps; 34 
→ 37a). TLC: Rf  0.35 (9:1 hexanes/EtOAc). ][
25
Dα = +4.2º (c 1.0, CHCl3).  IR (NaCl, 
film): 2934, 2862, 1462, 1426, 1105, 881, 820, 736, 699, 506. 1H-NMR (400 MHz): δ 
7.66 (m, 4H), 7.41 (m, 6H), 4.72 (m, 1H), 4.18 (m, 1H), 3.85 (m, 2H), 3.27 (d, 1H, J = 
2.7), 2.45 (d, 1H, J = 2.0), 1.97 (m, 1H), 1.82 (m, 1H), 1.72 (m, 2H), 1.20-1.13 (m, 
30H). 13C-NMR (100 MHz): δ 135.8, 133.5, 130.0, 128.0, 85.4, 73.2, 68.7, 62.6, 61.8, 
46.1, 39.3, 27.0, 19.3, 18.2, 12.5. ESI-MS m/z: (pos) 561.4 [M+Na]+; (neg) 537.3 [M–
H]–. 
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(2R,4R)-2-[2-(tert-Butyldiphenylsilyloxy)-ethyl]-4-(triisopropylsilyloxy)-3,4-
dihydro-2H-pyran (38a). A solution of the alkynol 37a (120 mg, 0.22 mmol, 1.0 
equiv) in anhyd THF (0.6 mL) was added to W(CO)6 (19 mg, 0.054 mmol, 0.25 equiv) 
and the mixture was treated with distilled Et3N (140 µL, 0.97 mmol, 4.5 equiv). The 
mixture was irradiated without cooling for 8 h. The solvent was evaporated to give a 
yellow mixture of oil and solid. The crude material was purified by flash 
chromatography (elution with 99:1 hexanes:EtOAc) to yield erythro-4-deoxyglycal 
38a as a clear oil (95 mg, 81%). For preparative scale synthesis, the reaction was 
carried out in three parallel batches of alkynol 37a (160, 200, and 250 mg), which 
were then combined and purified to afford 480 mg of glycal 38a (79%). TLC: Rf  0.33 
(9:1 hexanes/EtOAc). ][ 25Dα = +70º (c 1.0, CHCl3). IR (NaCl, film): 2941, 2864, 2360, 
1636, 1241, 1111, 1088, 997, 882, 735, 701, 614, 504. 1H-NMR (400 MHz): δ 7.64 
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(d, 4H, J = 6.8), 7.39 (m, 6H), 6.39 (d, 1H, J = 6.1), 4.88 (t, 1H, J = 4.9), 4.28–4.17 
(m, 2H), 3.81 (m, 2H), 1.81 (m, 3H), 1.60 (m, 1H), 1.03 (m, 30H). 13C-NMR (100 
MHz): δ145.9, 135.8, 134.3, 134.1, 129.8, 127.8, 104.1, 68.4, 60.6, 60.3, 38.7, 38.5, 
27.1, 19.4, 18.4, 12.6. ESI-MS m/z: (pos) 539.3 [M+H]+, 561.4 [M+Na]+; (neg) 573.5 
[M+Cl]–. 
 
Reactions of erythro-4-deoxyglycal 38a: 
The following reactions were carried out with (±)-38a. Treatment of aldehyde 7 with 
allylmagnesium chloride provided (±)-32, which was converted to (±)-38a as 
described above. Yields of the following reactions are unoptimized. 
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(2R*,4R*,5S*,6S*)-2[2-(tert-Butyldiphenylsilyloxy)ethyl]-4-(triisopropylsilyloxy)-
3,4-dihydro-2H-pyran-5,6-oxide (53). A solution of dimethyldioxirane (0.030 M in 
acetone, 1.9 mL, 0.056 mmol, 1.5 equiv) was added dropwise to a cooled (–78 ºC) 
solution of glycal 38a (20 mg, 0.037 mmol, 1.0 equiv) in anhyd CH2Cl2 (1.9 mL). 
After 15 min the reaction was allowed to warm to rt and the solvent was removed with 
a stream of Ar. The crude glycal epoxide 53 was carried on without further 
purification, but was stable enough to characterize by NMR, which indicated a single 
diastereomer. The stereochemical configuration was assigned by multidimensional 
NMR analysis (COSY, NOESY). Diagnostic NOEs are shown below. 
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1
H-NMR (500 MHz, C6D6): δ 7.80 (m, 4H), 7.27 (m, 6H), 4.74 (d, 1H, J = 2.4), 4.41 
(m, 2H), 3.98 (m, 1H), 3.78 (m, 1H), 2.95 (bs, 1H), 1.96 (m, 1H), 1.68-1.53 (m, 2H), 
1.45 (d, 1H, J = 13.6), 1.16 (s, 9H), 1.02-0.95 (m, 21H).  13C-NMR (125 MHz, C6D6): 
δ136.0, 134.3, 134.2, 129.9, 77.8, 66.2, 64.9, 60.2, 54.6, 39.1, 36.7, 30.1, 27.1, 19.5, 
18.2, 12.4.  
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(2S*,3R*,4R*,6R*)-6-[2-(tert-Butyldiphenylsilyloxy)ethyl]-2-methoxy-4-
(triisopropylsilyloxy)-tetrahydropyran-3-ol (49). Epoxide 53 formed from glycal 
38a (10 mg, 0.019 mmol, 1.0 equiv) was dissolved in anhyd MeOH (1.0 mL, 
Sureseal™ bottle). After 10 min at rt the solvent was evaporated to yield 
methylglycoside 49 as a clear oil (11 mg, 100%). NMR analysis indicated a single 
diastereomer. The stereochemical configuration was assigned by multidimensional 
NMR analysis (COSY, NOESY). Diagnostic NOEs are shown below. 
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TLC: Rf: 0.61 (2:1 hexanes/EtOAc). IR (NaCl, film): 2943, 2864, 2345, 1462, 1428, 
1101, 881, 700. 1H-NMR (400 MHz): δ 7.67 (m, 4H), 7.40 (m, 6H), 4.50 (d, 1H, J = 
3.4), 4.39 (m, 1H), 4.00 (m, 1H), 3.82 (m, 1H), 3.71 (m, 1H), 3.50 (m, 1H),3.31 (s, 
3H),2.00 (d, 1H, J = 5.7), 1.82-1.53 (m, 4H), 1.02 (m, 30H). 13C-NMR (125 MHz): 
δ135.5, 133.9, 129.5, 127.6, 101.5, 72.1, 69.0, 62.6, 60.2, 55.3, 3.7, 35.9, 26.8, 19.2, 
18.0, 12.3. ESI-MS m/z: (pos) 609.3 [M+Na]+; (neg) 585.3 [M–H]–, 621.3 [M+Cl]–. 
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(2R*,3R*,4R*,6R*)-2-Allyl-6-[2-(tert-butyldiphenylsilyloxy)ethyl]-4-
triisopropylsilyloxy)-tetrahydropyran-3-ol (55). Epoxide 53 formed from glycal 
38a (10 mg, 0.019 mmol, 1.0 equiv) was dissolved in anhyd THF (0.2 mL) and cooled 
to –78 ºC. Allylmagnesium chloride (2.0 M in THF, 19 µL, 0.037 mmol, 2.0 equiv) 
was added and the reaction mixture was stirred at –78 ºC for 20 min then warmed to 
0 ºC. After 45 min at 0 ºC the reaction was quenched with sat’d aq NH4Cl. The 
aqueous layer was extracted 3x with Et2O and the combined organic layers were 
washed with H2O and brine, dried (MgSO4), filtered, and concentrated. The residue 
was purified by flash chromatography (elution with 9:1 hexanes/EtOAc) to yield 55 as 
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a clear oil (8.9 mg, 80%). NMR analysis of the crude product indicated a single 
diastereomer. The stereochemical configuration was assigned by multidimensional 
NMR analysis (COSY, NOESY). Diagnostic NOEs are shown below. 
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TLC: Rf 0.67 (2:1 hexanes/EtOAc). IR (NaCl, film): 3448, 2931, 2861, 2355, 1467, 
1425, 1108, 873, 820, 738, 697, 509. 1H-NMR (400 MHz): δ 7.65 (t, 4H, J = 7.8), 
7.40 (m, 6H), 5.79 (m, 1H), 5.10-4.93 (m, 2H), 4.22 (m, 1H), 3.92 (m, 1H), 3.78 (m, 
1H), 3.65 (m, 1H), 3.41 (td, 1H, J = 7.8, 3.6), 3.23 (td, 1H, J = 7.4, 3.4), 2.51 (m, 1H), 
2.40 (m, 1H), 2.29 (d, 1H, J = 3.4), 1.99 (m, 1H), 1.80 (m, 2H), 1.61 (m, 1H), 1.05 (m, 
30H). 13C-NMR (125 MHz): δ135.9, 135.6, 134.3, 130.0, 128.0, 117.0, 75.6, 73.8, 
71.5, 66.2, 60.9, 37.2, 36.3, 35.2, 27.2, 19.6, 18.5, 15.7, 12.9. ESI-MS m/z: (pos) 
619.4 [M+Na]+; (neg) 595.4 [M–H]–, 631.3 [M+Cl]–. 
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(3R*,4R*,6R*)-6-[2-(tert-Butyldiphenylsilyloxy)ethyl]-4-(triisopropylsilyloxy)-
tetrahydropyran-3-ol (50). Thexylborane34 (0.50 M in THF, 94 µL, 0.047 mmol, 2.0 
equiv) was added dropwise to a cooled (0 ºC) solution of glycal 38a (13 mg, 0.023 
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mmol, 1.0 equiv) in anhyd THF (0.3 mL). After 2 h at 0 ºC, aq NaOH (1.0 M, 0.15 
mL, 0.15 mmol, 6.6 equiv) was added slowly, followed by H2O2 (30 wt % in H2O, 18 
µL, 0.15 mmol, 6.6 equiv). The reaction mixture was warmed to rt, stirred 1 h, then 
diluted with Et2O. The aqueous layer was extracted 3x with Et2O then the combined 
organic layers were washed with brine, dried (MgSO4), filtered, and concentrated. The 
residue was purified by flash chromatography (elution with 9:1 hexanes/EtOAc) to 
yield alcohol 50 as a clear oil (9.6 mg, 74%). NMR analysis of the crude product 
indicated an 11.7:1.0 diastereomeric ratio. The stereochemical configuration was 
assigned by multidimensional NMR analysis (COSY, NOESY). Diagnostic NOEs are 
shown below. 
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TLC: Rf 0.38 (4:1 hexanes/EtOAc). IR (NaCl, film): 3401, 2943, 2861, 2355, 1467, 
1096, 885, 738, 703, 679, 503. 1H-NMR (400 MHz): δ 7.68 (m, 4H), 7.40 (m, 6H), 
4.00 (m, 3H), 3.81 (m, 1H), 3.70 (m, 2H), 3.48 (m, 1H), 2.20 (d, 1H, J = 8.8), 1.75 (m, 
1H), 1.62 (m, 3H), 1.05 (m, 30H). 13C-NMR (125 MHz): δ135.6, 129.5, 127.6,  68.8, 
67.99, 67.6, 59.9, 39.0, 35.4, 26.8, 18.1, 12.2. ESI-MS m/z: (pos) 579.2 [M+Na]+; 
(neg) 555.3 [M–H]–, 591.5 [M+Cl]–. 
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(1S*,3R*,5S*,6S*,10S*)-1,10-Dimethoxy-3-[2-(tert-butyldiphenylsilyloxy)ethyl]-
4,4a,10,10a-tetrahydro-1H,3H-pyrano[4,3-b]chromene (51) and (2R*,4R*,6R*)-
2,4-Dimethoxy-6-[2-(tert-butyldiphenylsilyloxy)-ethyl]-tetrahydropyran (E4). A 
mixture of salicylaldehyde (23 µL, 0.22 mmol, 1.2 equiv), TMOF (24 µL, 0.22 mmol, 
1.2 equiv), and Sc(OTf)3 (2.7 mg, 5.6 µmol, 0.030 equiv) in anhyd CH2Cl2 (1.7 mL) 
was stirred at rt for 20 min. The reaction mixture was cooled to 0 ºC then treated with 
a solution of glycal 38a (100 mg, 0.19 mmol, 1.0 equiv) in anhyd CH2Cl2 (1.0 mL). 
The reaction mixture was warmed to rt, stirred for 30 min, then quenched with H2O. 
The aqueous layer was extracted 3x with CH2Cl2, dried (MgSO4), filtered, and 
concentrated. NMR analysis of the crude product indicated a 1.0:3.5:1.3 ratio of 51, 
E4, and Ferrier rearrangement product 57. The crude material was purified by flash 
chromatography (4:1 hexanes/EtOAc) to yield a 2.5:1.0 mixture of 51 and E4 (4.7 mg, 
3.6% yield of 51) as a clear oil. The stereochemical configurations were assigned by 
multidimensional NMR analysis (COSY, NOESY). Diagnostic NOEs are shown 
below. 
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TLC: Rf: 0.11 (9:1 hexanes/EtOAc). 
1
H-NMR (400 MHz): 51: δ 7.72-7.61 (m, 4H), 
7.51 (d, 1H, J = 7.6), 7.40 (m, 6H), 7.18 (t, 1H, J = 7.6), 6.96 (t, 1H, J = 7.3), 6.78 (d, 
1H, J = 7.3), 5.59 (d, 1H, J = 3.2), 4.71 (d, 1H, J = 4.7), 4.27 (m, 1H), 3.85 (m, 1H), 
3.75 (m, 1H), 3.59 (s, 3H), 3.30 (m, 1H), 3.21 (s, 3H), 2.50 (m, 1H), 2.08 (ddd, 1H, J 
= 14.2. 5.0, 2.1), 1.82-1.70 (m, 2H), 1.25 (m, 1H), 1.07 (s, 9H). E4: 7.65 (m, 4H), 7.38 
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(m, 6H), 4.56 (dd, 1H, J = 9.8, 2.1), 3.99 (m, 1H), 3.89-3.70 (m, 2H), 3.69 (m, 1H), 
3.40 (s, 3H), 3.31 (s, 3H), 2.01 (m, 1H), 1.84-1.68 (m, 3H), 1.44 (m, 1H), 1.34 (m, 
1H), 1.04 (s, 9H). ESI-MS m/z: 51: (pos) 555.2 [M+Na]+; (neg) 531.2 [M–H]–, 567.3 
[M+Cl]–. E4: 451.1 [M+Na]+. 
 
 
O
O
O
Si
Si
O
OO
Si
O
56 57
 
(2R*,4R*,6R*)-2-[2-(tert-Butyldiphenylsilyloxy)ethyl]-6-methoxy-4-
(triisopropylsilyloxy)-tetrahydropyran (56) and (2R*,6S*)-6-Methoxy-2-[2-(tert-
butyldiphenylsilyloxy)-ethyl]-3,6-dihydro-2H-pyran (57). Anhyd methanol (2.3 µL, 
0.057 mmol, 3.0 equiv, sureseal bottle) then Ph3P•HBr (0.30 mg, 0.95 µmol, 0.050 
equiv) was added to a solution of 38a (10 mg, 0.019 mmol, 1.0 equiv) in anhyd 
CH2Cl2 (0.2 mL). After 20 min at rt the reaction mixture was diluted with CH2Cl2, 
washed 2x with sat’d aq NaHCO3, once with brine, dried (MgSO4), filtered, and 
concentrated. NMR analysis of the crude product indicated a 3.0:1.0:3.3 ratio of 56, its 
α-anomer, and 57. Purification by flash chromatography (elution with 95:5 
hexanes/EtOAc) yielded a 1.0:1.1 mixture of 56 and 57 (4.5 mg, 24% yield of 56, 27% 
yield of 57) as a clear oil. The stereochemical configurations were assigned by 
multidimensional NMR analysis (COSY, NOESY). Diagnostic NOEs for 56 are 
shown below. The stereochemical configuration of 57 was tentatively assigned based 
on the absence of an NOE between the anomeric C1-H and C5-H. 
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TLC: Rf 0.31 (9:1 hexanes/EtOAc). 
1
H-NMR (400 MHz): 56: δ 7.66 (m, 4H), 7.40 
(m, 6H), 4.71 (dd, 1H, J = 1.9, 9.6), 4.38 (m, 1H), 4.22 (m, 1H), 3.93-3.69 (m, 2H), 
3.42 (s, 3H), 1.90 (m, 1H), 1.76 (m, 2H), 1.63 (m, 1H), 1.54-1.39 (m, 2H). 57: 7.65 
(m, 4H), 7.38 (m, 6H), 6.00 (m, 1H), 5.72 (m, 1H), 4.80 (s, 1H), 4.11 (m, 1H), 3.92-
3.72 (m, 2H), 3.32 (s, 3H), 1.96 (m, 2H), 1.78 (m, 2H), 1.02 (s, 9H). ESI-MS m/z: 56: 
(pos) 593.4 [M+Na]+; (neg) 605.2 [M+Cl]–. 57: (pos) 419.1 [M+Na]+. 
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(2R*,4R*)-2-[2-(tert-Butyldiphenylsilyloxy)ethyl]-6-(tributylstannanyl)-4-
(triisopropylsilyloxy)-3,4-dihydro-2H-pyran (E5). t-BuLi (1.5 M in pentane, 2.1 
mL, 3.2 mmol, 4.0 equiv) was added slowly to a cooled (–78 ºC) solution of glycal 
38a (430 mg, 0.80 mmol, 1.0 equiv) in anhyd THF (4.0 mL). After 15 min at –78 ºC, 
the reaction was warmed to 0 ºC, maintained at that temperature 1 h, then cooled to    
–78 ºC. Tributyltin chloride (540 µL, 2.0 mmol, 2.5 equiv) was added, the reaction 
was stirred at –78 ºC 30 min, then quenched with sat’d aq NaHCO3. The aqueous layer 
was extracted 3x with Et2O then the combined organic layers were washed with H2O 
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and brine, dried (MgSO4), filtered, and concentrated. The crude material was purified 
by flash chromatography (elution with 7:1 hexanes/CH2Cl2+ 0.5% Et3N) to yield 
glycal stannane E5 as a clear oil (490 mg, 74 %). TLC: Rf 0.67 (9:1 hexanes/EtOAc). 
IR (NaCl, film): 2959, 2923, 2864, 1590, 1460, 1087, 1063, 998, 879, 737, 695, 506. 
1
H-NMR (400 MHz): δ 7.63 (dt, 4H, J = 1.8, 7.7), 7.39 (m, 6H), 4.90 (d, 1H, J = 4.2), 
4.09 (m, 2H), 3.81 (m, 2H), 1.82-1.71 (m, 3H), 1.60-1.40 (m, 7H), 1.23 (m, 6H), 1.02 
(m, 30H), 0.82 (m, 15H). 13C-NMR (125 MHz): δ135.6, 134.1, 129.5, 127.6, 114.9, 
68.2, 60.7, 60.6, 38.7, 38.6, 29.0, 27.2, 26.9, 19.2, 18.2, 13.7, 12.5, 9.6. ESI-MS m/z: 
(pos) 851.3 [M+Na]+; (neg) 863.4 [M+Cl]–. 
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(2R*,4R*)-2-[2-(tert-Butyldiphenylsilyloxy)ethyl]-6-iodo-4-(triisopropylsilyloxy)-
3,4-dihydro-2H-pyran (E6). A solution of iodine (0.20 M in CH2Cl2, 620 µL, 0.12 
mmol, 1.0 equiv) was added dropwise to a solution of glycal stannane E5 (100 mg, 
0.12 mmol, 1.0 equiv) in anhyd CH2Cl2 (2.4 mL) in the dark. As soon as a purple 
color persisted in the reaction mixture, the reaction was quenched with 10% aq 
Na2S2O3. The aqueous layer was extracted 3x with CH2Cl2, then the combined organic 
layers were washed with brine, dried (MgSO4), filtered, and concentrated. The crude 
material was purified by flash chromatography (elution with 4:1 hexanes/CH2Cl2 + 
0.5% Et3N) to yield glycal iodide E6 as a clear oil (80 mg, 98%). TLC: Rf 0.70 (4:1 
hexanes/EtOAc). 1H-NMR (400 MHz, C6D6): δ 7.77 (m, 4H), 7.40-7.22 (m, 6H), 5.58 
  52 
(d, 1H, J = 4.0), 4.75 (m, 1H), 3.91 (m, 1H), 3.85 (m, 1H), 3.65 (m, 1H), 1.79-1.52 (m, 
3H), 1.40 (m, 1H), 1.14 (s, 9H), 1.08-0.92 (m, 21H). 
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(2R*,4R*)-2-[2-(tert-Butyldiphenylsilyloxy)ethyl]-6-(3-acetoxypropyl)-4-
(triisopropylsilyloxy)-3,4-dihydro-2H-pyran (54a). 9-BBN (0.50 M in THF, 1.4 
mL, 0.72 mmol, 3.0 equiv) was added dropwise to a cooled (0 ºC) solution of allyl 
acetate (39 µL, 0.36 mmol, 1.5 equiv) in anhyd THF (3.6 mL). The mixture was 
stirred at 0 ºC for 5 min then warmed to rt. After 4 h, aq NaOH (1.0 N, 730 µL, 0.72 
mmol, 3.0 equiv) was added and the mixture was stirred an additional 30 min. The 
hydroboration reaction was then added to a mixture of glycal iodide E6 (160 mg, 0.24 
mmol, 1.0 equiv), PdCl2(dppf) (20 mg, 0.024 mmol, 0.10 equiv), and H2O (0.7 mL) in 
THF (2.4 mL, Optima grade). After 20 min at rt the reaction mixture was diluted with 
pentane and the solid was filtered off. The filtrate was washed with 1 N NaOH, H2O, 
and brine, dried (MgSO4), filtered, and concentrated. The crude material was purified 
by flash chromatography (elution with 95:5 hexanes/EtOAc) to yield 1-alkylglycal 
54a as a clear oil (110 mg, 68%). TLC: Rf 0.32 (4:1 hexanes/EtOAc). IR (NaCl, film): 
2935, 2864, 1739, 1661, 1460, 1241, 1093, 695, 506. 1H-NMR (500 MHz): δ 7.68 (d, 
4H, J = 7.3), 7.40 (m, 6H), 4.69 (d, 1H, J = 5.0), 4.29-4.19 (m, 2H), 4.02 (t, 2H, J = 
6.6), 3.90-3.70 (m, 2H), 2.05 (t, 2H, J = 7.3), 2.02 (s, 3H), 1.82-1.71 (m, 5H), 1.51 (m, 
1H), 1.03 (m, 30H). 13C NMR (125 MHz): δ155.3, 135.6, 133.9, 129.5, 127.6, 99.5, 
  53 
68.4, 63.9, 61.2, 60.1, 38.2, 38.1, 30.6, 26.8, 25.9, 21.0, 19.2, 18.2, 12.4. ESI-MS m/z: 
(pos) 661.3 [M+Na]+. 
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(2R*,4R*)-2-[2-(tert-Butyldiphenylsilyloxy)ethyl]-6-phenyl-4-
(triisopropylsilyloxy)-3,4-dihydro-2H-pyran (54b). A mixture of glycal stannane E5 
(80 mg, 0.097 mmol, 1.0 equiv), bromobenzene (15 µL, 0.15 mmol, 1.5 equiv), and 
Pd(PPh3)4 (5.6 mg, 4.9 µmol, 0.050 equiv) in anhyd THF (1.9 mL) was refluxed 7 h. 
The solvent was evaporated and the residue was purified by flash chromatography 
(elution with 98:2 hexanes/EtOAc) to yield 1-phenylglycal 54b as a clear oil (58 mg, 
96%). TLC: Rf 0.54 (9:1 hexanes/EtOAc). IR (NaCl, film): 2935, 2864, 1644, 1466, 
1424, 1282, 1093, 1004, 873, 737, 701. 1H-NMR (400 MHz): δ 7.69 (m, 4H), 7.51 
(m, 2H), 7.42-7.27 (m, 9H), 5.49 (d, 1H, J = 4.8), 4.45 (m, 2H), 4.02 (m, 1H), 3.90 (m, 
1H), 2.00-1.86 (m, 3H), 1.69 (m, 1H), 1.06 (m, 30H). 13C-NMR (125 MHz): δ135.6, 
129.5, 128.3, 128.1, 127.6, 125.1, 99.7, 68.7, 61.6, 60.2, 38.4, 38.2, 26.8, 19.2, 18.2, 
12.4. ESI-MS m/z: (pos) 615.5 [M+H]+, 637.2 [M+Na]+; (neg) 649.2 [M+Cl]–. 
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(2R*,3R*,4R*,6R*)-2-(3-Acetoxypropyl)-6-[2-(tert-butyldiphenylsilyloxy)ethyl]-4-
(triisopropylsilyloxy)tetrahydropyran-3-ol (52a). Thexylborane34 (0.50 M in THF, 
65 µL, 0.033 mmol, 2.0 equiv) was added dropwise to a cooled (0 ºC) solution of 
1-alkylglycal 54a (10 mg, 0.016 mmol, 1.0 equiv) in anhyd THF (0.2 mL). The 
reaction mixture was stirred for 1.5 h at 0 ºC then warmed to rt. After 1.5 h at rt, aq 
NaOH (1.0 M, 0.11 mL, 0.11 mmol, 6.6 equiv) was added slowly, followed by H2O2 
(30 wt % in H2O, 12 µL, 0.11 mmol, 6.6 equiv). The reaction mixture was stirred for 
1 h then diluted with Et2O. The organic layer was washed with sat’d aq NH4Cl, H2O, 
and brine, dried (MgSO4), filtered, and concentrated. The residue was purified by flash 
chromatography (elution with 4:1 hexanes/EtOAc) to yield alcohol 52a as a clear oil 
(8.1 mg, 76%). NMR analysis of the crude product indicated a single diastereomer. 
The stereochemical configuration was assigned by multidimensional NMR analysis 
(COSY, NOESY). Diagnostic NOEs are shown below. 
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TLC: Rf 0.40 (9:1 CH2Cl2/Et2O). IR (NaCl, film): 3460, 2943, 2861, 1731, 1425, 
1361, 1243, 1108, 703. 1H-NMR (400 MHz): δ 7.64 (m, 4H), 7.39 (m, 6H), 4.22 (m, 
1H), 4.01 (m, 2H), 3.90 (m, 1H), 3.75 (m, 1H), 3.65 (m, 1H), 3.32 (m, 1H), 3.19 (td, 
1H, J = 3.3, 7.3), 2.29 (d, 1H, J = 3.3), 2.01 (s, 3H), 1.95 (m, 1H), 1.81-1.48 (m, 7H), 
1.03 (m, 30H). 13C NMR (125 MHz): δ135.5, 129.6, 127.6, 73.2, 71.1, 64.6, 41.0, 
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36.8, 34.8, 26.8, 24.9, 18.1, 12.4. ESI-MS m/z: (pos) 679.5 [M+Na]+; (neg) 655.4 
[M+H]–, 691.3 [M+Cl]–. 
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(2R*,3R*,4R*,6R*)-2-Phenyl-6-[2-(tert-butyldiphenylsilyloxy)ethyl]-4-
(triisopropylsilyloxy)tetrahydropyran-3-ol (52b). Thexylborane34 (0.50 M in THF, 
140 µL, 68 µmol, 10 equiv) was added dropwise to a cooled (0 ºC) solution of 
1-phenylglycal 54b (4.2 mg, 6.8 µmol, 1.0 equiv) in anhyd THF (0.2 mL). The 
reaction mixture was stirred for 1 h at 0 ºC then warmed to rt and stirred for 20 h. At 
this time, the reaction was approximately 50% complete (TLC). Additional freshly 
prepared thexylborane (0.50 M in THF, 140 µL, 68 µmol, 10 equiv) was added and 
the reaction mixture was stirred an additional 4 h at rt. Aq NaOH (1.0 N, 0.45 mL, 
0.45 mmol, 66 equiv) was added slowly, followed by H2O2 (30 wt % in H2O, 51 µL, 
0.45 mmol, 66 equiv). The reaction mixture was stirred 2 h then diluted with Et2O. 
The organic layer was washed with sat aq NH4Cl, brine, dried (MgSO4), filtered, and 
concentrated. The residue was purified by flash chromatography (elution with 9:1 
hexanes/EtOAc) to yield alcohol 52b as a clear oil (3.1 mg, 72%). NMR analysis of 
the crude product indicated a single diastereomer. The stereochemical configuration 
was assigned by multidimensional NMR analysis (COSY, NOESY). Diagnostic NOEs 
are shown below. 
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TLC: Rf 0.21 (9:1 hexanes/EtOAc). IR (NaCl, film): 2931, 2861, 1462, 1428, 1111, 
882, 738, 700. 1H-NMR (400 MHz): δ 7.62 (m, 4H), 7.40-7.21 (m, 11H), 4.40 (m, 
1H), 4.22 (d, 1H, J = 9.2), 4.05 (m, 1H), 3.80 (m, 1H), 3.69 (m, 1H), 3.49 (m, 1H), 
2.18 (m, 2H), 1.98 (m, 2H), 1.75 (m, 1H), 1.02 (m, 30H). 13C-NMR (125 MHz): 
δ139.5, 135.5, 129.6, 129.5, 128.3, 128.0, 127.6, 127.5, 77.7, 75.3, 71.2, 70.0, 60.7, 
37.3, 33.8, 26.8, 19.2, 18.1, 18.0, 12.5, 12.3. ESI-MS m/z: (pos) 655.4 [M+Na]+; (neg) 
631.4 [M–H]–, 667.4 [M+Cl]–. 
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(2R*,3R*,4R*,6R*)-2-(3-Acetoxypropyl)-6-[2-(tert-butyldiphenylsilyloxy)ethyl]-
2,4-dimethoxytetrahydropyran (59a). Anhyd MeOH (2.3 µL, 0.058 mmol, 3.0 
equiv, sureseal bottle) then Ph3P•HBr (0.30 mg, 0.96 µmol, 0.050 equiv) were added 
to a solution of 1-alkylglycal 54a (12 mg, 0.019 mmol, 1.0 equiv) in anhyd CH2Cl2 
(0.2 mL). The reaction was stirred at rt for 1 h then diluted with CH2Cl2, washed with 
sat’d aq NaHCO3, brine, dried (MgSO4), filtered, and concentrated. The residue was 
purified by flash chromatography (elution with 4:1 hexanes/EtOAc) to yield methyl 
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glycoside 59a as a clear oil (5.1 mg, 50%). The stereochemical configuration was 
assigned by multidimensional NMR analysis (COSY, NOESY). Diagnostic NOEs are 
shown below. 
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TLC: Rf 0.14 (4:1 hexanes/EtOAc). IR (NaCl, film): 2935, 2864, 1739, 1466, 1424, 
1359, 1235, 1093, 701, 506. 1H-NMR (500 MHz): δ 7.65 (m, 4H), 7.42 (m, 6H), 4.06 
(t, 2H, J = 6.4), 3.87-3.79 (m, 2H), 3.75 (m, 1H), 3.60 (m, 1H), 3.32 (s, 3H), 3.08 (s, 
3H), 2.15 (dd, 1H, J = 3.5, 12.1), 2.04 (s, 3H), 1.98 (dt, 1H, J = 12.3, 2.1), 1.77-1.53 
(m, 6H), 1.17 (t, 1H, J = 12.1), 1.05 (s, 10H). 13C NMR (125 MHz): δ135.5, 129.6, 
127.6, 100.7, 73.5, 65.6, 64.4, 60.2, 55.5, 47.2, 38.8, 37.2, 32.5, 26.9, 22.9, 21.0. ESI-
MS m/z: (pos) 551.2 [M+Na]+; (neg) 563.3 [M+Cl]–. 
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(2R*,4R*)-2-[2-(tert-Butyldiphenylsilyloxy)ethyl]-4-methoxy-6-phenyl-3,4-
dihydro-2H-pyran (58b) and (2R*,3R*,4R*,6R*)-2-Phenyl-6-[2-(tert-
butyldiphenylsilyloxy)ethyl]-2,4-dimethoxytetrahydropyran (59b). Anhyd MeOH 
(3.4 µL, 0.084 mmol, 3.0 equiv, Sureseal™ bottle) then Ph3P•HBr (0.50 mg, 1.4 µmol, 
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0.050 equiv) were added to a solution of 1-phenylglycal 54b (15 mg, 0.028 mmol, 1.0 
equiv) in anhyd CH2Cl2 (0.3 mL). The reaction was stirred at rt for 1 h then diluted 
with CH2Cl2, washed 2x with sat aq NaHCO3, once with brine, dried (MgSO4), 
filtered, and concentrated to afford a 3.4:1 mixture of 58b and 59b. The residue was 
purified by flash chromatography (elution with 98:2 hexanes/EtOAc then 9:1 
hexanes/EtOAc) to yield methyl ether 58b (2.8 mg, 24%) and methyl glycoside 59b 
(1.0 mg, 8.1%) as clear oils. The stereochemical configuration of 58b was tentatively 
assigned based on comparison of chemical shifts with other C1-substituted glycals. 
The stereochemical configuration of 59b was assigned by multidimensional NMR 
analysis (COSY, NOESY). Formation of the axially oriented C3-OMe (in contrast to 
the equatorial orientation in 59a) may result from stereoelectronic effects of the C1-
phenyl substituent. Diagnostic NOEs are shown below.  
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58b: TLC: Rf 0.18 (9:1 hexanes/EtOAc). 
1
H-NMR (400 MHz): δ 7.68 (m, 4H), 7.52 
(m, 2H), 7.41-7.22 (m, 9H), 5.59 (dd, 1H, J = 1.2, 5.2), 4.28 (m, 1H), 3.94 (m, 2H), 
3.82 (m, 1H), 3.40 (s, 3H), 2.04-1.89 (m, 3H), 1.61 (m, 1H), 1.02 (s, 9H). ESI-MS 
m/z: (pos) 495.3 [M+Na]+; (neg) 507.2 [M+Cl–]. 
59b: TLC: Rf 0.17 (9:1 hexanes/EtOAc). IR (NaCl, film): 2926, 2863, 1427, 1109, 
1087, 742, 700. 1H-NMR (500 MHz): δ 7.68 (m, 4H), 7.46-7.26 (m, 11H), 4.30 (m, 
1H), 3.90 (m, 2H), 3.57 (m, 1H), 3.38 (s, 3H), 2.92.(s, 3H), 2.28 (dt, 1H, J = 2.1, 
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14.9), 1.93-1.74 (m, 3H), 1.58 (obs, 1H), 1.45 (m, 1H), 1.05 (s, 9H).  ESI-MS m/z: 
(pos) 527.2 [M+Na]+. 
 
Synthesis of C1-substituted glycals: 
Compounds E9a–g and 67a–g were synthesized and characterized by Justin Potuzak. 
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(–)-(2R,4S)-2-[2-(tert-Butyldiphenylsilyloxy)ethyl]-6-(tributylstannyl)-4-
(triisopropylsilyloxy)-3,4-dihydro-2H-pyran (65).  To a 50 mL roundbottom flask 
was added threo-glycal 12 (2.3 g, 4.2 mmol, 1.0 equiv) and anhyd THF (21 mL). The 
mixture was cooled to –78 °C, and t-BuLi (1.5 M in pentane, 11 mL, 17 mmol, 4.0 
equiv) was added slowly via syringe. The reaction was stirred at –78 °C for 15 min, 
then warmed to 0 °C, stirred for 1 h, then recooled to –78 °C. Tributyltin chloride 
(2.8 mL, 10 mmol, 2.5 equiv) was added slowly via syringe, and the reaction was 
stirred for 30 min, warmed to rt, quenched with sat’d aq NaHCO3, and extracted with 
Et2O (3 × 50 mL). The combined organic extracts were washed with H2O and brine, 
then dried (MgSO4), filtered, and concentrated by rotary evaporation. Silica flash 
chromatography (elution with 7:1 hexanes/CH2Cl2 + 0.5% Et3N) afforded stannane 65 
as a clear oil (2.7 g, 77%). TLC: Rf 0.26 (4:1 hexanes/CH2Cl2). [α ]D
25 : –9.0° (c 1.0, 
CDCl3). IR (NaCl, film): 2951, 2926, 2862, 1598, 1463, 1103, 1067, 1008, 882, 737, 
700. 1H-NMR (400 MHz): δ 7.65 (m, 4H), 7.43–7.34 (m, 6H), 4.75 (m, 1H), 4.47 (m, 
1H), 4.05 (m, 1H), 3.78 (m, 2H), 2.00 (m, 1H), 1.89 (m, 1H), 1.71 (m, 2H), 1.47 (m, 
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6H), 1.28 (m, 6H), 1.05 (m, 30H), 0.86 (m, 15 H). 13C-NMR (125 MHz): δ 162.9, 
135.5, 134.0, 129.5, 127.6, 117.2, 71.7, 64.0, 60.6, 38.4, 38.3, 28.9, 27.2, 26.9, 19.2, 
18.1, 13.7, 12.3, 9.6.  ESI-MS m/z (rel int): (pos) 851.5 ([M+Na]+, 100); (neg) 863.7 
([M+Cl]–, 100). 
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(2R,4S)-2-[2-(tert-Butyldiphenylsilyloxy)ethyl]-6-iodo-4-(triisopropylsilyloxy)-3,4-
dihydro-2H-pyran (66). To a 100 mL roundbottom flask was added threo-glycal 
stannane 65 (2.5 g, 3.0 mmol, 1.0 equiv) and CH2Cl2 (30 mL). In a separate 100 mL 
flask, iodine (1.5 g, 6.0 mmol, 2.0 equiv) was dissolved in CH2Cl2 (60 mL). The 
iodine solution was then added via syringe to the glycal until a purple color persisted. 
The reaction was immediately quenched with the addition of 10 mL 10% aq Na2S2O3 
with vigorous stirring. The mixture was then poured into 20 mL 10% aq Na2S2O3, and 
extracted with CH2Cl2 (2 × 20 mL). The combined organic extracts were dried 
(MgSO4), filtered, and concentrated by rotary evaporation.  Silica flash 
chromatography (elution with 4:1 hexanes/CH2Cl2 + 0.5% Et3N) afforded iodide 66 as 
a clear oil (2.0 g, 100%), which was used immediately in subsequent cross coupling 
reactions.  TLC: Rf 0.19 (4:1 hexanes/CH2Cl2).  IR (NaCl, film): 2942, 2863, 1622, 
1465, 1427, 1321, 1106, 1038, 882, 737, 701.  1H-NMR (400 MHz): δ 7.66 (m, 4H), 
7.44–7.36 (m, 6H), 5.32 (d, 1H, J  = 1.9), 4.49 (m, 2H), 3.82 (m, 1H), 3.72 (m, 1H), 
2.19 (m, 1H), 2.00 (m, 1H), 1.86–1.76 (m, 2H), 1.05 (m, 30H).  13C-NMR (100 MHz): 
δ 135.5, 133.7, 129.6, 127.7, 116.8, 107.1, 76.5, 65.3, 59.8, 37.3, 37.1, 26.9, 19.2, 
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18.0, 12.2.  ESI-MS m/z (rel int): (pos) 687.3 ([M+Na]+, 100); (neg) 699.4 ([M+Cl]–, 
100). 
 
Synthesis of sidechain precursors: 
Allyl acetate was obtained commercially. But-3-enyl acetate and pent-4-enyl acetate 
were prepared as previously described.35 (R)- and (S)-But-3-en-2-yl acetate, (R)- and 
(S)-1-chlorobut-3-en-2-yl acetate, and (R)- and (S)-1-chloropent-4-en-2-yl acetate 
were prepared by Justin Potuzak as previously described. 36,37 
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(–)-(S)-Pent-4-en-2-yl acetate (E7). To a 10 mL roundbottom flask was added 
(S)-pent-4-en-2-ol (1.0 g, 12 mmol, 1.0 equiv), acetic anhydride (2.2 mL, 23 mmol, 
2.0 equiv), and pyridine (25 L). The reaction was heated to 100 ºC, and stirred for 
16 h. The solution was cooled to rt, then quenched with H2O, and extracted with 
pentane. The combined organic extracts were washed with sat’d aq NaHCO3, 1 M aq 
CuSO4, and brine, then dried (MgSO4) and filtered. Evaporation of the solvent 
provided E7 (650 mg, 44%) as a clear liquid. ][ 25Dα  –23° (c 1.0, CDCl3). IR (NaCl, 
film): 3080, 2980, 1737, 1643, 1435, 1373, 1244, 1126, 1062, 1024, 995, 959, 919. 
1
H-NMR (500 MHz):  5.75 (m, 1H), 5.08 (m, 2H), 4.96 (m, 1H), 2.36–2.25 (m, 2H), 
2.03 (s, 3H), 1.22 (d, 3H, J = 6.3). 13C-NMR (125 MHz):  170.6, 117.7, 70.0, 54.9, 
40.3, 21.3, 19.5. 
 
O
O
 
(+)-(R)-Pent-4-en-2-yl acetate (E8). Prepared from (R)-pent-4-en-2-ol as above. 
Clear liquid (660 mg, 44%). ][ 25Dα  +26° (c 1.0, CDCl3). IR (NaCl, film): 3080, 2980, 
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1737, 1643, 1435, 1373, 1244, 1126, 1062, 1024, 995, 959, 919. 1H-NMR (500 
MHz):  5.75 (m, 1H), 5.08 (m, 2H), 4.96 (m, 1H), 2.36–2.25 (m, 2H), 2.03 (s, 3H), 
1.22 (d, 3H, J = 6.3). 13C-NMR (125 MHz):  170.6, 117.7, 70.0, 54.9, 40.3, 21.3, 
19.5. 
 
General procedure for sidechain coupling: 
The appropriate sidechain precursor (1.5 equiv) was dissolved in anhyd THF (0.1 M).  
A freshly prepared solution of 9-BBN (0.50 M in THF, 3.0 equiv) was added dropwise 
at rt. After 3 h, aq NaOH (1.0 N, 3.0 equiv) was added, and the reaction was stirred for 
an additional 30 min at rt. In a separate flask, the C1-iodoglycal (threo-66 or erythro-
E5, 1.0 equiv) was dissolved in THF and water (3:1, 0.10 M). Solid Pd(dppf)Cl2 (0.20 
equiv) was then added. The hydroboration reaction mixture was then added to the 
mixture via syringe. The reaction was stirred for 1 h at rt, then diluted with pentane, 
filtered through Celite/silica (1:1), washed with 1 N aq NaOH, H2O, and brine, then 
dried (MgSO4), filtered, and concentrated by rotary evaporation. Silica flash 
chromatography yielded the C1-alkylated glycals E9a–r. 
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(–)-(2R,4S)-6-(4-Acetoxybutyl)-2-[2-(tert-butyldiphenylsilyloxy)ethyl]-4-
(triisopropylsilyloxy)-3,4-dihydro-2H-pyran (E9a).  Clear oil (130 mg, 85%).  
TLC: Rf 0.59 (4:1 hexanes/EtOAc). [α ]D
25 : –7.5° (c 1.0, CDCl3).  IR (NaCl, film): 
2943, 2863, 1741, 1668, 1465, 1428, 1385, 1364, 1239, 1087, 1010, 884, 820, 738, 
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702.  1H-NMR (400 MHz): δ 7.66 (m, 4H), 7.44–7.35 (m, 6H), 4.50 (m, 2H), 4.16 (m, 
1H), 4.03 (t, 2H, J = 6.6), 3.86–3.73 (m, 2H), 2.07–1.92 (m, 7H), 1.81 (m, 1H), 1.68–
1.58 (m, 3H), 1.49 (m, 2H), 1.05 (m, 30H).  13C-NMR (100 MHz): δ 171.2, 154.5, 
135.5, 133.9, 129.6, 127.6, 101.2, 71.4, 64.4, 63.9, 60.2, 37.8 (br, 2C), 33.5, 28.1, 
26.8, 23.2, 21.0, 19.2, 18.1, 12.3.  ESI-MS m/z (rel int): (pos) 675.5 ([M+Na]+, 100); 
(neg) 687.5 ([M+Cl]–, 100). 
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(–)-(2R,4S,4′R)-6-(4′-Acetoxypentyl)-2-[2-(tert-butyldiphenylsilyloxy)ethyl]-4-
(triisopropylsilyloxy)-3,4-dihydro-2H-pyran (E9b).  Clear oil (170 mg, 86%).  
TLC: Rf 0.63 (4:1 hexanes/EtOAc). [α ]D
25 : –5.9° (c 1.0, CDCl3).  IR (NaCl, film): 
2940, 2863, 1736, 1668, 1464, 1428, 1371, 1244, 1087, 1014, 959, 884, 821, 738, 702.  
1
H-NMR (400 MHz): δ 7.66 (m, 4H), 7.44–7.35 (m, 6H), 4.87 (m, 1H), 4.50 (m, 2H), 
4.15 (m, 1H), 3.85–3.73 (m, 2H), 2.05–1.92 (m, 7H), 1.79 (m, 1H), 1.64 (m 1H), 
1.60–1.40 (m, 4H), 1.17 (d, 3H, J = 6.2), 1.05 (m, 30H).  13C-NMR (100 MHz): 
δ 170.7, 154.6, 135.5, 133.9, 129.6, 127.6, 101.1, 71.4, 70.8, 63.9, 60.3, 37.7 (br, 2C), 
35.3, 33.7, 26.8, 22.6, 21.4, 19.9, 19.2, 18.1, 12.3.  ESI-MS m/z (rel int): (pos) 689.5 
([M+Na]+, 100); (neg) 701.4 ([M+Cl]–, 100). 
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(–)-(2R,4S,4′S)-6-(4′-Acetoxypentyl)-2-[2-(tert-butyldiphenylsilyloxy)ethyl]-4-
(triisopropylsilyloxy)-3,4-dihydro-2H-pyran (E9c).  Clear oil (180 mg, 90%).  
TLC: Rf 0.63 (4:1 hexanes/EtOAc). [α ]D
25 : –8.5° (c 1.0, CDCl3).  IR (NaCl, film): 
2941, 2863, 1736, 1668, 1464, 1428, 1371, 1244, 1088, 1014, 959, 884, 821, 738, 702.  
1
H-NMR (400 MHz): δ 7.66 (m, 4H), 7.44–7.35 (m, 6H), 4.86 (m, 1H), 4.49 (m, 2H), 
4.16 (m, 1H), 3.85–3.73 (m, 2H), 2.06–1.92 (m, 7H), 1.80 (m, 1H), 1.64 (m 1H), 
1.57–1.40 (m, 4H), 1.17 (d, 3H, J = 6.3), 1.05 (m, 30H).  13C-NMR (100 MHz): 
δ 170.7, 154.5, 135.5, 133.8, 129.6, 127.6, 101.1, 71.3, 70.8, 63.9, 60.3, 37.7 (br, 2C), 
35.3, 33.7, 26.9, 22.6, 21.4, 19.9, 19.2, 18.1, 12.3.  ESI-MS m/z (rel int): (pos) 689.5 
([M+Na]+, 100); (neg) 701.4 ([M+Cl]–, 100). 
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(–)-(2R,4S)-6-(3-Acetoxypropyl)-2-[2-(tert-Butyldiphenylsilyloxy)ethyl]-4-
(triisopropylsilyloxy)-3,4-dihydro-2H-pyran (E9d).  Clear oil (160 mg, 85%).  
TLC: Rf 0.58 (4:1 hexanes/EtOAc).  [α ]D
25 : –6.7° (c 1.0, CDCl3).  IR (NaCl, film): 
2942, 2864, 1742, 1670, 1468, 1428, 1388, 1364, 1240, 1110, 1086, 1011, 998, 961, 
918, 882, 822, 737, 702.  1H-NMR (400 MHz): δ 7.66 (m, 4H), 7.44–7.35 (m, 6H), 
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4.51 (m, 2H), 4.16 (m, 1H), 4.04 (t, 2H, J = 6.6), 3.86–3.73 (m, 2H), 2.06–1.90 (m, 
7H), 1.82–1.73 (m, 3H), 1.65 (m, 1H), 1.05 (m, 30H).  13C-NMR (125 MHz): δ 171.1, 
153.9, 135.5, 133.9, 129.6, 127.6, 101.5, 71.5, 64.0, 63.9, 60.2, 37.8, 37.7, 30.5, 26.9, 
25.8, 21.0, 19.2, 18.1, 12.3.  ESI-MS m/z (rel int): (pos) 661.5 ([M+Na]+, 100); (neg) 
637.4 ([M–H]–, 90), 673.7 ([M+Cl]–, 100). 
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(–)-(2R,4S,3′R)-6-(3′-Acetoxybutyl)-2-[2-(tert-butyldiphenylsilyloxy)ethyl]-4-
(triisopropylsilyloxy)-3,4-dihydro-2H-pyran (E9e).  Clear oil (170 mg, 86%).  
TLC: Rf 0.65 (4:1 hexanes/EtOAc). [α ]D
25 : –3.7° (c 1.0, CDCl3).  IR (NaCl, film): 
2942, 2864, 1738, 1669, 1463, 1428, 1371, 1241, 1110, 1088, 1066, 1012, 961, 882, 
822, 737, 702.  1H-NMR (400 MHz): δ 7.66 (m, 4H), 7.44–7.35 (m, 6H), 4.86 (m, 
1H), 4.50 (m, 2H), 4.15 (m, 1H), 3.86–3.73 (m, 2H), 2.05–1.92 (m, 6H), 1.85–1.60 
(m, 4H), 1.18 (d, 3H, J = 6.2), 1.05 (m, 30H).  13C-NMR (125 MHz): δ 170.7, 154.2, 
135.5, 133.9, 129.6, 127.6, 101.2, 71.5, 70.5, 64.0, 60.2, 37.8, 37.7, 32.9, 30.0, 26.9, 
21.4, 20.0, 19.2, 18.1, 12.3.  ESI-MS m/z (rel int): (pos) 675.6 ([M+Na]+, 100); (neg) 
651.5 ([M–H]–, 100), 687.4 ([M+Cl]–, 10).   
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(–)-(2R,4S,3′S)-6-(3′-Acetoxybutyl)-2-[2-(tert-butyldiphenylsilyloxy)ethyl]-4-
(triisopropylsilyloxy)-3,4-dihydro-2H-pyran (E9f).  Clear oil (160 mg, 84%).  TLC: 
Rf 0.65 (4:1 hexanes/EtOAc). [α ]D
25 : –7.2° (c 1.0, CDCl3).  IR (NaCl, film): 2941, 
2864, 1738, 1669, 1462, 1428, 1370, 1241, 1110, 1087, 1066, 1012, 961, 882, 822, 
737, 702.  1H-NMR (400 MHz): δ 7.66 (m, 4H), 7.44–7.35 (m, 6H), 4.87 (m, 1H), 
4.50 (m, 2H), 4.16 (m, 1H), 3.86–3.73 (m, 2H), 2.05–1.91 (m, 6H), 1.85–1.60 (m, 
4H), 1.19 (d, 3H, J = 6.2), 1.05 (m, 30H).  13C-NMR (125 MHz): δ 170.6, 154.3, 
135.5, 133.9, 129.6, 127.6, 101.0, 71.5, 70.7, 64.0, 60.2, 37.8, 37.7, 33.0, 30.1, 26.9, 
21.4, 19.9, 19.2, 18.1, 12.3.  ESI-MS m/z (rel int): (pos) 675.6 ([M+Na]+, 100); (neg) 
651.5 ([M–H]–, 40), 687.4 ([M+Cl]–, 100). 
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(–)-(2R,4S)-6-(5-Acetoxypentyl)-2-[2-(tert-butyldiphenylsilyloxy)ethyl]-4-
(triisopropylsilyloxy)-3,4-dihydro-2H-pyran (E9g).  Clear oil (160 mg, 82%).  
TLC: Rf 0.58 (4:1 hexanes/EtOAc). [α ]D
25 : –6.7° (c 1.0, CDCl3).  IR (NaCl, film): 
2942, 2834, 1741, 1668, 1463, 1428, 1388, 1363, 1237, 1110, 1087, 1012, 961, 882, 
822, 737, 702.  1H-NMR (400 MHz): δ 7.66 (m, 4H), 7.44–7.35 (m, 6H), 4.50 (m, 
2H), 4.15 (m, 1H), 4.03 (t, 2H, J = 6.7), 3.86–3.73 (m, 2H), 2.06–1.92 (m, 7H), 1.80 
(m, 1H), 1.66–1.56 (m, 3H), 1.44 (m, 2H), 1.33 (m, 2H), 1.05 (m, 30H).  13C-NMR 
(125 MHz): δ 171.2, 154.8, 135.5, 133.9, 129.6, 127.6, 100.9, 71.4, 64.6, 64.0, 60.3, 
37.8, 37.7, 33.8, 28.4, 26.9, 26.4, 25.5, 21.0, 19.3, 18.1, 12.3.  ESI-MS m/z (rel int): 
(pos) 689.6 ([M+Na]+, 100); (neg) 665.5 ([M–H]–, 100), 701.6 ([M+Cl]–, 30).   
  67 
O
O
O
Si
Si
O
O
 
(+)-(2R,4R)-6-(4-Acetoxybutyl)-2-[2-(tert-butyldiphenylsilyloxy)ethyl]-4-
(triisopropylsilyloxy)-3,4-dihydro-2H-pyran (E9h).  Clear oil (270 mg, 79%).  
TLC: Rf 0.61 (4:1 hexanes/EtOAc).  [α ]D
25 : +7.0° (c 1.0, CHCl3).  IR (NaCl, film): 
2941, 2859, 1737, 1661, 1462, 1426, 1360, 1238, 1095, 881.  1H-NMR (400 MHz): 
δ 7.66 (d, 4H, J = 7.4), 7.39 (m, 6H), 4.68 (d, 1H, J = 5.1), 4.22 (m, 2H), 4.01 (t, 2H, J 
= 6.6), 3.88 (m, 1H), 3.79 (m, 1H), 2.01 (m, 5H), 1.80 (m, 3H), 1.62–1.42 (m, 5H), 
1.02 (m, 30H).  13C-NMR (125 MHz): δ 171.2, 156.0, 135.6, 134.0 (Ph), 133.9 (Ph′), 
129.5, 127.6, 99.2, 68.3, 64.4, 61.3, 60.1, 38.2, 38.0, 33.6, 28.0, 26.8, 23.2, 21.0, 19.2, 
18.1, 12.2.  ESI-MS m/z (rel int): (pos) 653.7 ([M+H]+, 1), 675.6 ([M+Na]+, 100); 
(neg) 651.6 ([M–H]-, 100), 687.6 ([M+Cl]–, 10). 
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(+)-(2R,4R,4′R)-6-(4′-Acetoxypentyl)-2-[2-(tert-butyldiphenylsilyloxy)ethyl]-4-
(triisopropylsilyloxy)-3,4-dihydro-2H-pyran (E9i).  Clear oil (86 mg, 65%).  TLC: 
Rf 0.60 (4:1 hexanes/EtOAc).  [α ]D
25 : +59° (c 0.84, CHCl3).  IR (NaCl, film): 2941, 
2864, 1737, 1659, 1462, 1427, 1370, 1245, 1092, 1010, 882, 822, 736, 702.  1H-NMR 
(400 MHz): δ 7.68 (dd, 4H, J = 6.5, 1.3), 7.40 (m, 6H), 4.86 (m, 1H), 4.68 (d, 1H, J = 
5.1), 4.23 (m, 2H), 3.90–3.72 (m, 2H), 1.99 (m, 5H), 1.83–1.72 (m, 3H), 1.53–1.38 
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(m, 5H), 1.16 (d, 3H, J = 6.3), 1.08–1.02 (m, 30H).  13C-NMR (125 MHz): δ 170.8, 
156.0, 135.5, 134.0, 129.5, 127.6, 99.2, 70.8, 68.3, 61.3, 60.2, 38.3, 38.0, 35.2, 33.8, 
26.8, 22.6, 21.4, 19.9, 19.2, 18.2, 12.4.  ESI-MS m/z (rel int): (pos) 689.4 ([M+Na]+, 
100); (neg) 665.4 ([M–H]–, 40), 701.5 ([M+Cl]–, 100). 
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(+)-(2R,4R,4′S)-6-(4′-Acetoxypentyl)-2-[2-(tert-butyldiphenylsilyloxy)ethyl]-4-
(triisopropylsilyloxy)-3,4-dihydro-2H-pyran (E9j).  Clear oil (50 mg, 61%).  TLC: 
Rf 0.59 (4:1 hexanes/EtOAc). [α ]D
25 : +56° (c 0.53, CHCl3).  IR (NaCl, film): 2954, 
2862, 1737, 1588, 1468, 1442, 1427, 1370, 1244, 1111, 823, 737, 702.  1H-NMR (400 
MHz): δ 7.66 (m, 4H), 7.39 (m, 6H), 4.87 (m, 1H), 4.67 (d, 1H, J = 5.0), 4.28–4.17 
(m, 2H), 3.90–3.72 (m, 2H), 2.00 (m, 5H) 1.89–1.73 (m, 3H), 1.57–1.43 (m, 5H) 1.17 
(d, 3H, J = 6.3), 1.08–1.01 (m, 30H).  13C-NMR (100 MHz): δ 170.8, 156.0, 135.5, 
134.0, 129.5, 127.6, 96.7, 70.9, 68.3, 61.3. 60.6, 38.4, 38.0, 35.3, 33.8, 27.2, 26.8, 
21.4, 19.9, 19.2, 18.2, 12.4.  ESI-MS m/z (rel int): (pos) 689.4 ([M+Na]+, 100); (neg) 
665.3 ([M–H]–, 50), 701.3 ([M+Cl]–, 100). 
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(+)-(2R,4R)-6-(3-Acetoxypropyl)-2-[2-(tert-Butyldiphenylsilyloxy)ethyl]-4-
(triisopropylsilyloxy)-3,4-dihydro-2H-pyran (E9k).  Clear oil (100 mg, 68%).  
TLC: Rf 0.32 (4:1 hexanes/EtOAc). [α ]D
25 : +7.6° (c 1.0, CHCl3).  IR (NaCl, film): 
2935, 2864, 1739, 1661, 1460, 1241, 1093.  1H-NMR (500 MHz): δ 7.68 (d, J = 7.3), 
7.40 (m, 6H), 4.69 (d, 1H, J = 5.0), 4.29–4.19 (m, 2H), 4.02 (t, 2H, J = 6.6), 3.90–3.70 
(m, 2H), 2.05 (t, 2H, J = 7.3), 2.02 (s, 3H), 1.82–1.71 (m, 5H), 1.51 (m, 1H), 1.03 (m, 
30H).  13C-NMR (125 MHz): δ 171.1, 155.3, 135.6, 133.9, 129.5, 127.6, 99.5, 68.4, 
63.9, 61.2, 60.1, 38.2, 38.1, 30.6, 26.8, 25.9, 21.0, 19.2, 18.2, 12.4.  ESI-MS m/z (rel 
int): (pos) 661.3 ([M+Na]+, 100). 
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(+)-(2R,4R,3′R)-6-(3′-Acetoxybutyl)-2-[2-(tert-butyldiphenylsilyloxy)ethyl]-4-
(triisopropylsilyloxy)-3,4-dihydro-2H-pyran (E9l).  Clear oil (82 mg, 67%).  TLC: 
Rf 0.54 (4:1 hexanes/EtOAc).  [α ]D
25 : +63° (c 1.0, CHCl3).  IR (NaCl, film): 2361, 
1736, 1696, 1646, 1556, 1538, 1511, 1241, 1102, 701.  1H-NMR (500 MHz): δ 7.67 
(d, 4H, J = 7.7), 7.39 (m, 6H), 4.36 (m, 1H), 4.69 (d, 1H, J = 5.3), 4.28–4.20 (m, 2H), 
3.89 (m, 1H), 3.79 (m, 1H), 2.09–1.95 (m, 5H), 1.86–1.76 (m, 3H), 1.73–1.62 (m, 
2H), 1.52 (m, 1H), 1.20 (d, 3H, J = 6.3), 1.01 (m, 30H).  13C-NMR (125 MHz): 
δ 170.6, 155.8, 135.5, 134.0 (Ph), 133.9 (Ph′), 129.5, 127.6, 99.0, 70.7, 68.3, 61.2, 
60.1, 38.2, 38.0, 33.2, 30.2, 26.8, 21.3, 19.9, 19.2, 18.2, 12.4.  ESI-MS m/z (rel int): 
(pos) 675.6 ([M+Na]+, 100). 
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(+)-(2R,4R,3′S)-6-(3′-Acetoxybutyl)-2-[2-(tert-butyldiphenylsilyloxy)ethyl]-4-
(triisopropylsilyloxy)-3,4-dihydro-2H-pyran (E9m).  Clear oil (62 mg, 46%).  TLC: 
Rf 0.54 (4:1 hexanes/EtOAc). [α ]D
25 : +58° (c 1.6, CHCl3).  IR (NaCl, film): 2940, 
2862, 1733, 1460, 1368, 1241, 1094, 738.  1H-NMR (400 MHz): δ 7.65 (d, 4H, J = 
7.1), 7.37 (m, 6H), 4.85 (m, 1H), 4.66 (d, 1H, J = 5.3), 4.28–4.19 (m, 2H), 3.85 (m, 
1H), 3.78 (m, 1H), 2.07–1.97 (m, 5H), 1.87–1.59 (m, 5H), 1.52 (m, 1H), 1.18 (d, 3H, J 
= 6.2), 1.01 (m, 30H).  13C-NMR (100 MHz): δ 170.5, 155.7, 135.6, 134.0 (Ph), 133.9 
(Ph′), 129.5, 127.6, 99.1, 70.5, 68.4, 61.2, 60.1, 38.2, 38.0, 33.0, 30.2, 26.8, 21.4, 19.9, 
19.2, 18.1, 12.4. 
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(+)-(2R,4R)-6-(5-Acetoxypentyl)-2-[2-(tert-butyldiphenylsilyloxy)ethyl]-4-
(triisopropylsilyloxy)-3,4-dihydro-2H-pyran (E9n).  Clear oil (79 mg, 79%).  TLC: 
Rf 0.58 (4:1 hexanes/EtOAc). [α ]D
25 : +58° (c 1.6, CHCl3).  IR (NaCl, film): 2930, 
2852, 1738, 1363, 1236, 1099, 738.  1H-NMR (400 MHz): δ 7.65 (m, 4H), 7.36 (m, 
6H), 4.67 (d, 1H, J = 5.0), 4.28–4.19 (m, 2H), 4.03 (t, 2H, J = 6.7), 3.88 (m, 1H), 3.77 
(m, 1H), 2.01 (m, 5H), 1.86–1.73 (m, 3H), 1.63–1.53 (m, 2H), 1.52–1.41 (m, 3H), 
1.38–1.31 (m, 2H), 1.10–0.97 (m, 30H).  13C-NMR (100 MHz): δ 171.1, 156.3, 135.5, 
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134.0 (Ph), 133.9 (Ph′), 129.5, 127.5, 99.0, 68.2, 64.5, 61.3, 60.1, 38.2, 38.1, 33.9, 
28.4, 26.8 26.4, 25.4, 21.0, 19.2, 18.1, 12.4.  ESI-MS m/z (rel int): (pos) 689.5 
([M+Na]+, 100); (neg) 665.3 ([M–H]–, 1), 701.4 ([M+Cl]–, 100). 
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(+)-(2R,4S,4′R)-2-[2-(tert-Butyldiphenylsilyloxy)ethyl]-6-(4′-acetoxy-5-
chloropentyl)-4-(triisopropylsilyloxy)-3,4-dihydro-2H-pyran (E9o). Clear oil 
(330 mg, 74%). TLC: Rf 0.53 (4:1 hexanes/EtOAc). [α ]D
25 : +16° (c 0.99, CDCl3). 
1
H-NMR (400 MHz): δ 7.66 (m, 4H), 7.44-7.35 (m, 6H), 5.00 (m, 1H), 4.49 (m, 2H), 
4.15 (m, 1H), 3.85–3.73 (m, 2H), 3.59 (dd, 1H, J = 11.7, 4.4), 3.50 (dd, 1H, J = 11.7, 
5.4), 2.09–1.92 (m, 7H), 1.80 (m, 1H), 1.65 (m, 3H), 1.46 (m, 2H), 1.05 (m, 30H). 
13
C-NMR (125 MHz): δ 170.5, 154.1, 135.5, 133.9, 129.6, 127.6, 101.4, 72.6, 71.5, 
63.9, 60.3, 45.6, 37.7, 33.6, 30.8, 26.9, 22.2, 21.0, 19.2, 18.1, 12.3. ESI-MS m/z (rel 
int): pos 723.6 ([M+Na]+, 100); neg 735.6 ([M+Cl]–, 100). 
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(–)-(2R,4S,4′S)-2-[2-(tert-Butyldiphenylsilyloxy)ethyl]-6-(4′-acetoxy-5-
chloropentyl)-4-(triisopropylsilyloxy)-3,4-dihydro-2H-pyran (E9p). Clear oil 
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(480 mg, 91%). TLC: Rf 0.54 (4:1 hexanes/EtOAc). [α ]D
25 : –8.4°  (c 1.0, CDCl3). 
1
H-NMR (400 MHz): δ 7.66 (m, 4H), 7.44-7.35 (m, 6H), 5.00 (m, 1H), 4.49 (m, 2H), 
4.15 (m, 1H), 3.85–3.73 (m, 2H), 3.60–3.49 (m, 2H), 2.09–1.92 (m, 7H), 1.80 (m, 
1H), 1.65 (m, 3H), 1.46 (m, 2H), 1.05 (m, 30H). 13C-NMR (125 MHz): δ 170.5, 
154.2, 135.5, 133.9, 129.6, 127.6, 101.4, 72.7, 71.5, 63.9, 60.3, 45.6, 37.7, 33.6, 30.9, 
26.9, 22.2, 21.0, 19.2, 18.1, 12.3. ESI-MS m/z (rel int): pos 723.5 ([M+Na]+, 100); 
neg 735.4 ([M+Cl]–, 100). 
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(–)-(2R,4S,3′R)-2-[2-(tert-Butyldiphenylsilyloxy)ethyl]-6-(3′-acetoxy-4-
chlorobutyl)-4-(triisopropylsilyloxy)-3,4-dihydro-2H-pyran (E9q). Yellow oil (56 
mg, 45%). [α ]D
25 = –4.1° (c 1.1, CDCl3). IR (NaCl, film): 2928, 2863, 1744, 1464, 
1428, 1374, 1234, 1111, 1091, 882, 823, 737, 702. 1H-NMR (500 MHz): δ 7.66 (m, 
4H), 7.44–7.35 (m, 6H), 4.99 (m, 1H), 4.49 (m, 2H), 4.15 (m, 1H), 3.84–3.73 (m, 2H), 
3.60 (m, 1H), 3.53 (m, 1H), 2.05–1.91 (m, 7H), 1.83–1.76 (m, 3H), 1.63 (m, 1H), 1.05 
(m, 30H). 13C-NMR (125 MHz): δ 170.7, 153.7, 135.7, 134.0, 129.7, 127.8, 101.7, 
72.6, 71.8, 64.0, 60.3, 45.6, 37.9, 37.8, 29.8, 28.8, 27.0, 21.1, 19.3, 18.2, 12.4. ESI-
MS m/z (rel int): pos 709.5 ([M+Na]+, 100); neg 721.7 ([M+Cl]–, 100). 
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(–)-(2R,4S,3′S)-2-[2-(tert-Butyldiphenylsilyloxy)ethyl]-6-(3′-acetoxy-4-
chlorobutyl)-4-(triisopropylsilyloxy)-3,4-dihydro-2H-pyran (E9r). Yellow oil (61 
mg, 49%). [α ]D
25  = –6.7° (c 1.1, CDCl3). IR (NaCl, film): 2928, 2863, 1744, 1464, 
1428, 1374, 1234, 1111, 1091, 882, 823, 737, 702. 1H-NMR (500 MHz): δ 7.66 (m, 
4H), 7.44–7.35 (m, 6H), 4.98 (m, 1H), 4.49 (m, 2H), 4.13 (m, 1H), 3.84–3.73 (m, 2H), 
3.58 (m, 1H), 3.52 (m, 1H), 2.05–1.92 (m, 7H), 1.83–1.76 (m, 3H), 1.63 (m, 1H), 1.05 
(m, 30H). 13C-NMR (125 MHz): δ 170.5, 153.6, 135.7, 134.0, 129.7, 127.7, 101.9, 
72.4, 71.8, 64.0, 60.3, 45.7, 37.9, 37.8, 29.8, 28.7, 27.0, 21.1, 19.3, 18.2, 12.4. ESI-
MS m/z (rel int): pos 709.5 ([M+Na]+, 100); neg 721.7 ([M+Cl]–, 100). 
 
General procedure for acetate deprotection: 
The acetate-protected glycal (E9a–n, 1.0 equiv) was dissolved in THF/MeOH (1:1, 
0.10 M).  K2CO3 (2.0 equiv) was added, and the mixture was stirred vigorously at rt.  
After 3 h, the mixture was filtered through Celite/silica (1:1), and the flask was rinsed 
with Et2O.  The solvent was evaporated, the residue was dissolved in Et2O, washed 
with H2O (3×), dried (MgSO4), and filtered.  Evaporation of the solvent provided the 
alcohol products 67a–n in sufficient purity (>99%, NMR) for direct use in subsequent 
epoxidation reactions.   
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(–)-(2R,4S)-2-[2-(tert-Butyldiphenylsilyloxy)ethyl]-6-(4-hydroxybutyl)-4-
(triisopropylsilyloxy)-3,4-dihydro-2H-pyran (67a).  Clear oil (140 mg, 100%).  
TLC: Rf 0.35 (4:1 hexanes/EtOAc).  [α ]D
25 : –6.7° (c 1.0, CDCl3).  IR (NaCl, film): 
3332, 2940, 2863, 1668, 1465, 1428, 1385, 1242, 1087, 1007, 883, 820, 738, 702.  
1
H-NMR (400 MHz): δ 7.66 (m, 4H), 7.44–7.35 (m, 6H), 4.50 (m, 2H), 4.16 (m, 1H), 
3.86–3.73 (m, 2H), 3.61 (q, 2H, J = 6.0), 2.06–1.92 (m, 4H), 1.80 (m, 1H), 1.64 (m, 
1H), 1.57–1.48 (m, 4H), 1.05 (m, 30H).  13C-NMR (100 MHz): δ 154.7, 135.5, 133.9, 
129.5, 127.6, 101.1, 71.4, 64.0, 62.8, 60.2, 37.8, 37.7, 33.6, 32.2, 26.8, 22.9, 19.2, 
18.1, 12.3.  ESI-MS m/z (rel int): (pos) 633.4 ([M+Na]+, 100); (neg) 645.3 ([M+Cl]–, 
100). 
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(–)-(2R,4S,4′R)-2-[2-(tert-Butyldiphenylsilyloxy)ethyl]-6-(4′-hydroxypentyl)-4-
(triisopropylsilyloxy)-3,4-dihydro-2H-pyran (67b).  Clear oil (140 mg, 98%).  
TLC: Rf 0.35 (4:1 hexanes/EtOAc). [α ]D
25 : –8.2° (c 1.0, CDCl3).  IR (NaCl, film): 
3349, 2940, 2863, 1668, 1464, 1428, 1383, 1243, 1088, 1006, 883, 821, 738, 702.  
1
H-NMR (400 MHz): δ 7.66 (m, 4H), 7.44–7.35 (m, 6H), 4.50 (m, 2H), 4.16 (m, 1H), 
3.86–3.73 (m, 3H), 2.06–1.92 (m, 4H), 1.80 (m, 1H), 1.64 (m, 1H), 1.54–1.40 (m, 
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4H), 1.16 (d, 3H, J = 6.2), 1.05 (m, 30H).  13C-NMR (100 MHz): δ 154.7, 135.5, 
133.9, 129.5, 127.6, 101.1, 71.4, 67.9, 64.0, 60.3, 38.8, 37.8, 37.7, 33.8, 26.8, 23.4, 
22.9, 19.2, 18.1, 12.3.  ESI-MS m/z (rel int): (pos) 647.5 ([M+Na]+, 100); (neg) 659.3 
([M+Cl]–, 100). 
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(–)-(2R,4S,4′S)-2-[2-(tert-Butyldiphenylsilyloxy)ethyl]-6-(4′-hydroxypentyl)-4-
(triisopropylsilyloxy)-3,4-dihydro-2H-pyran (67c).  Clear oil (150 mg, 98%).  TLC: 
Rf 0.35 (4:1 hexanes/EtOAc).  [α ]D
25 : –5.6° (c 1.0, CDCl3).  IR (NaCl, film): 3350, 
2940, 2863, 1668, 1464, 1428, 1383, 1243, 1088, 1007, 884, 821, 738, 702  1H-NMR 
(400 MHz): δ 7.66 (m, 4H), 7.44–7.35 (m, 6H), 4.50 (m, 2H), 4.16 (m, 1H), 3.86–3.73 
(m, 3H), 2.06–1.93 (m, 4H), 1.80 (m, 1H), 1.64 (m, 1H), 1.54–1.40 (m, 4H), 1.17 (d, 
3H, J = 6.2), 1.05 (m, 30H).  13C-NMR (100 MHz): δ 154.8, 135.6, 133.9, 129.6, 
127.6, 101.1, 71.4, 67.9, 64.0, 60.3, 38.8, 37.72, 37.71, 33.9, 26.9, 23.5, 22.9, 19.2, 
18.1, 12.3.  ESI-MS m/z (rel int): (pos) 647.5 ([M+Na]+, 100); (neg) 659.3 ([M+Cl]–, 
100). 
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(–)-(2R,4S)-2-[2-(tert-Butyldiphenylsilyloxy)ethyl]-6-(3-hydroxypropyl)-4-
(triisopropylsilyloxy)-3,4-dihydro-2H-pyran (67d).  Clear oil (130 mg, 95%).  
TLC: Rf 0.25 (4:1 hexanes/EtOAc).  [α ]D
25 : –4.3° (c 1.0, CDCl3).  IR (NaCl, film): 
3326, 2941, 2864, 1668, 1462, 1428, 1388, 1238, 1111, 1087, 1064, 1011, 882, 822, 
737, 701.  1H-NMR (500 MHz): δ 7.66 (m, 4H), 7.44–7.35 (m, 6H), 4.56 (s, 1H), 3.99 
(t, 1H, J = 6.8), 4.17 (m, 1H), 3.81 (m, 1H), 3.76 (m, 1H), 3.62 (dd, 2H, J = 11.9, 5.9), 
2.06 (m, 3H), 1.93 (m, 1H), 1.82 (m, 1H), 1.72–1.63 (m, 3H), 1.41 (t, 1H, J = 5.5), 
1.05 (m, 30H).  13C-NMR (125 MHz): δ 154.5, 135.5, 133.8, 129.6, 127.6, 101.5, 
71.6, 63.9, 62.5, 60.2, 37.8, 37.7, 30.5, 30.1, 26.9, 19.2, 18.3, 12.3.  ESI-MS m/z (rel 
int): (pos) 619.4 ([M+Na]+, 100); (neg) 631.5 ([M+Cl]–, 100).   
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(–)-(2R,4S,3′R)-2-[2-(tert-Butyldiphenylsilyloxy)ethyl]-6-(3′-hydroxybutyl)-4-
(triisopropylsilyloxy)-3,4-dihydro-2H-pyran (67e).  Clear oil (100 mg, 75%).  TLC: 
Rf 0.39 (4:1 hexanes/EtOAc). [α ]D
25 : –9.5° (c 0.50, CDCl3).  IR (NaCl, film): 3339, 
2957, 2941, 2864, 1668, 1462, 1428, 1388, 1110, 1086, 1011, 959, 882, 822, 736, 701.  
1
H-NMR (500 MHz): δ 7.66 (m, 4H), 7.44–7.35 (m, 6H), 4.56 (s, 1H), 4.50 (t, 1H, J = 
6.3), 4.17 (m, 1H), 3.91–3.73 (m, 3H), 2.10–2.03 (m, 3H), 1.94 (m, 1H), 1.80 (m, 1H), 
1.66–1.57 (m, 3H), 1.16 (d, 3H, J = 6.2), 1.05 (m, 30H).  13C-NMR (125 MHz): 
δ 154.7, 135.5, 133.8, 129.6, 127.6, 101.4, 71.6, 67.6, 63.9, 60.2, 37.8, 37.7, 36.4, 
30.5, 26.9, 23.3, 19.2, 18.1, 12.3.  ESI-MS m/z (rel int): (pos) 633.4 ([M+Na]+, 100); 
(neg) 645.4 ([M+Cl]–, 100). 
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(–)-(2R,4S,3′S)-2-[2-(tert-Butyldiphenylsilyloxy)ethyl]-6-(3′-hydroxybutyl)-4-
(triisopropylsilyloxy)-3,4-dihydro-2H-pyran (67f).  Clear oil (100 mg, 71%).  TLC: 
Rf 0.39 (4:1 hexanes/EtOAc). [α ]D
25 : –2.2° (c 0.50, CDCl3).  IR (NaCl, film): 3339, 
2958, 2941, 2864, 1668, 1462, 1428, 1388, 1110, 1086, 1011, 959, 882, 822, 737, 701.  
1
H-NMR (500 MHz): δ 7.66 (m, 4H), 7.44–7.35 (m, 6H), 4.56 (s, 1H), 4.50 (t, 1H, J = 
6.8), 4.17 (m, 1H), 3.91–3.70 (m, 3H), 2.10–2.03 (m, 3H), 1.94 (m, 1H), 1.80 (m, 1H), 
1.66–1.57 (m, 3H), 1.16 (d, 3H, J = 6.2), 1.05 (m, 30H).  13C-NMR (125 MHz): 
δ 154.7, 135.5, 133.8, 129.6, 127.6, 101.4, 71.6, 67.7, 63.9, 60.2, 37.8, 37.7, 36.6, 
30.5, 26.9, 23.3, 19.2, 18.1, 12.3.  ESI-MS m/z (rel int): (pos) 633.4 ([M+Na]+, 100); 
(neg) 645.5 ([M+Cl]–, 100). 
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(–)-(2R,4S)-2-[2-(tert-Butyldiphenylsilyloxy)ethyl]-6-(5-hydroxypentyl)-4-
(triisopropylsilyloxy)-3,4-dihydro-2H-pyran (67g).  Clear oil (140 mg, 100%).  
TLC: Rf 0.33 (4:1 hexanes/EtOAc). [α ]D
25 : –6.2° (c 1.0, CDCl3).  IR (NaCl, film): 
3336, 2940, 2863, 1668, 1462, 1428, 1388, 1238, 1111, 1086, 1011, 961, 882, 822, 
737, 701.  1H-NMR (500 MHz): δ 7.66 (m, 4H), 7.44–7.35 (m, 6H), 4.50 (m, 2H), 
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4.15 (m, 1H), 3.86–3.74 (m, 2H), 3.61 (dd, 1H, J = 12.3, 6.0), 2.02 (m, 1H), 1.97 (m, 
3H), 1.80 (m, 1H), 1.65 (m, 1H), 1.55 (m, 2H), 1.45 (m, 2H), 1.34 (m, 2H), 1.18 (t, 
1H, J = 5.2), 1.05 (m, 30H).  13C-NMR (125 MHz): δ 155.0, 135.5, 133.9, 129.6, 
127.6, 100.9, 71.4, 64.0, 63.0, 60.3, 37.8, 37.7, 33.9, 32.5, 26.9, 26.5, 25.2, 19.2, 18.1, 
12.3.  ESI-MS m/z (rel int): (pos) 647.6 ([M+Na]+, 100); (neg) 659.3 ([M+Cl]–, 100). 
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(+)-(2R,4R)-2-[2-(tert-Butyldiphenylsilyloxy)ethyl]-6-(4-hydroxybutyl)-4-
(triisopropylsilyloxy)-3,4-dihydro-2H-pyran (67h).  Clear oil (250 mg, 100%).  
TLC: Rf 0.22 (4:1 hexanes/EtOAc). [α ]D
25 : +67° (c 0.95, C6H6).  IR (NaCl, film): 
3315, 2943, 2859, 1661, 1463, 1421, 1247, 1097, 1001, 737, 701.  1H-NMR (400 
MHz, C6D6): δ 7.79 (m, 4H), 7.24 (m, 6H), 4.82 (d, 1H, J = 5.0), 4.52 (m, 1H), 4.22 
(m, 1H), 4.01 (m, 1H), 3.85 (m, 1H), 3.32 (t, 2H, J = 6.3), 2.03 (t, 2H, J = 7.4), 1.89–
1.78 (m, 3H), 1.57–1.43 (m, 3H), 1.38 (m, 2H), 1.22–1.01 (m, 30H).  13C-NMR (125 
MHz, C6D6): δ 157.0, 136.0, 134.4, 134.3, 129.9, 99.3, 68.5, 62.4, 61.9, 60.5, 38.7, 
38.5, 34.2, 32.6, 27.1, 23.6, 19.5, 18.4, 12.8.  ESI-MS m/z (rel int): (pos) 633.4 
([M+Na]+, 100); (neg) 609.4 ([M–H]–, 100), 645.4 ([M+Cl]–, 100). 
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(+)-(2R,4R,4′R)-2-[2-(tert-Butyldiphenylsilyloxy)ethyl]-6-(4′-hydroxypentyl)-4-
(triisopropylsilyloxy)-3,4-dihydro-2H-pyran (67i).  Clear oil (81 mg, 100%).  TLC: 
Rf 0.26 (4:1 hexanes/EtOAc). [α ]D
25 : +60° (c 1.1, C6H6).  IR (NaCl, film): 3345, 2941, 
2864, 1663, 1462, 1428, 1247, 1094, 1008, 882, 822, 734, 701.  1H-NMR (500 MHz, 
C6D6): δ 7.79 (m, 4H), 7.26 (m, 6H), 4.85 (d, 1H, J = 5.1), 4.53 (m, 1H), 4.24 (m, 1H), 
4.03 (m, 1H), 3.88 (m, 1H), 3.53 (m, 1H), 2.06 (m, 2H), 1.90–1.78 (m, 3H), 1.64 (m, 
1H), 1.58–1.47 (m, 2H), 1.32–1.25 (m, 2H), 1.19–1.06 (m, 30H), 0.98 (d, 3H, J = 6.2).  
13
C-NMR (125 MHz, C6D6): δ 157.0, 136.0, 134.4 (Ph), 134.3 (Ph′), 129.9, 128.5, 
99.4, 68.5, 67.4, 61.9, 60.5, 39.0, 38.8, 38.5, 34.4, 27.1, 23.8, 23.5, 19.5, 18.5, 12.8.  
ESI-MS m/z (rel int): (pos) 647.5 ([M+Na]+, 100); (neg) 623.1 ([M–H]–, 10), 659.2 
([M+Cl]–, 100). 
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(+)-(2R,4R,4′S)-2-[2-(tert-Butyldiphenylsilyloxy)ethyl]-6-(4′-hydroxypentyl)-4-
(triisopropylsilyloxy)-3,4-dihydro-2H-pyran (67j).  Clear oil (65 mg, 99%).  TLC: 
Rf 0.26 (4:1 hexanes/EtOAc). [α ]D
25 : +62° (c 0.42, C6H6).  IR (NaCl, film): 3344, 
2940, 2863, 1663, 1462, 1427, 1247, 1094, 1007, 882, 823, 736, 701.  1H-NMR (500 
MHz, C6D6): δ 7.81 (m, 4H), 7.25 (m, 6H), 4.85 (d, 1H, J = 5.0), 4.53 (m, 1H), 4.24 
(m, 1H), 4.03 (m, 1H), 3.86 (m, 1H), 3.52 (m, 1H), 2.06 (t, 2H, J = 7.4), 1.90–1.77 (m, 
3H), 1.68–1.45 (m, 3H), 1.32–1.21 (m, 2H), 1.20–1.05 (m, 30H), 0.98 (d, 3H, J = 6.2).  
13
C-NMR (125 MHz, C6D6): δ 157.0, 136.0, 134.4 (Ph), 134.3 (Ph′), 129.9, 128.5, 
99.4, 68.5, 67.5, 62.0, 60.5, 39.1, 38.8, 38.5, 34.5, 27.1, 23.8, 23.6, 19.5, 18.5, 12.8.  
  80 
ESI-MS m/z (rel int): (pos) 647.5 ([M+Na]+, 100); (neg) 623.2 ([M–H]–, 15), 659.2 
([M+Cl]–, 100). 
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(+)-(2R,4R)-2-[2-(tert-Butyldiphenylsilyloxy)ethyl]-6-(3-hydroxypropyl)-4-
(triisopropylsilyloxy)-3,4-dihydro-2H-pyran (67k).  Clear oil (35 mg, 95%).  TLC: 
Rf 0.27 (4:1 hexanes/EtOAc). [α ]D
25 : +67° (c 1.1, C6H6).  IR (NaCl, film): 3339, 2943, 
2859, 1661, 1463, 1427, 1241, 1091, 1001, 881, 737, 701.  1H-NMR (400 MHz): 
δ 7.68 (m, 4H), 7.39 (m, 6H), 4.72 (d, 1H, J = 5.3), 4.30–4.19 (m, 2H), 3.90-3.73 (m, 
2H), 3.61 (q, 2H, J = 6.1), 2.10 (td, 2H, J = 2.8, 7.1), 1.88–1.76 (m, 3H), 1.69 (p, 2H, J 
= 6.6, 6.8), 1.55 (m, 1H), 1.43 (t, 1H, J = 5.8), 1.02 (m, 30H).  13C-NMR (125 MHz, 
C6D6): δ 156.9, 136.0, 134.3, 134.2, 129.9, 99.5, 68.6, 62.2, 61.9, 60.4, 38.7, 38.4, 
31.1, 30.6, 27.1, 19.5, 18.5, 12.8.  ESI-MS m/z (rel int): (pos) 619.5 ([M+Na]+, 100); 
(neg) 595.2 ([M–H]–, 10), 631.4 ([M+Cl]–, 100). 
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(+)-(2R,4R,3′R)-2-[2-(tert-Butyldiphenylsilyloxy)ethyl]-6-(3′-hydroxybutyl)-4-
(triisopropylsilyloxy)-3,4-dihydro-2H-pyran (67l).  Clear oil (44 mg, 95%).  TLC: 
Rf 0.26 (4:1 hexanes/EtOAc). [α ]D
25 : +60° (c 0.47, C6H6).  IR (NaCl, film): 3352, 
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2945, 2862, 1658, 1460, 1423, 1095, 1058, 1001, 881, 734.  1H-NMR (500 MHz, 
C6D6): δ 7.80 (m, 4H), 7.24 (m, 6H), 4.86 (d, 1H, J = 5.2), 4.53 (m, 1H), 4.22 (m, 1H), 
4.01 (m, 1H), 3.83 (m, 1H), 3.60 (m, 1H), 2.21–2.08 (m), 1.88–1.78 (m), 1.59 (m, 
2H), 1.49 (m, 1H), 1.19 (s, 9H), 1.17–1.02 (m), 0.99 (d, 3H, J = 6.2).  13C-NMR (125 
MHz, C6D6): δ 157.5, 136.4, 134.7, 134.6, 130.1, 99.8, 69.0, 67.6, 62.3, 60.8, 39.1, 
38.8, 37.4, 31.5, 27.5, 24.0, 19.8, 18.8, 13.1.  ESI-MS m/z (rel int): (pos) 633.5 
([M+Na]+, 100); (neg) 609.3 ([M–H]–, 10), 645.5 ([M+Cl]–, 100). 
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(+)-(2R,4R,3′S)-2-[2-(tert-Butyldiphenylsilyloxy)ethyl]-6-(3′-hydroxybutyl)-4-
(triisopropylsilyloxy)-3,4-dihydro-2H-pyran (67m).  Clear oil (51 mg, 98%).  TLC: 
Rf 0.26 (4:1 hexanes/EtOAc). [α ]D
25 : +70° (c 0.37, C6H6).  IR (NaCl, film): 3346, 
2940, 2863, 1665, 1462, 1427, 1093, 998, 882, 736, 701.  1H-NMR (500 MHz, C6D6): 
δ 7.81 (m, 4H), 7.25 (m, 6H), 4.86 (d, 1H, J = 5.1), 4.53 (m, 1H), 4.22 (m, 1H), 4.01 
(m, 1H), 3.83 (m, 1H), 3.60 (m, 1H), 2.19–2.11 (m, 2H), 1.87–1.78 (m, 3H), 1.59 (m, 
2H), 1.49 (m, 1H), 1.21 (s, 9H), 1.13–1.05 (m, 22H), 0.99 (d, 3H, J = 3.7).  13C-NMR 
(125 MHz, C6D6): δ 157.5, 136.4, 134.7, 134.6, 130.3, 99.8, 69.0, 67.6, 62.3, 60.8, 
39.1, 38.8, 37.5, 31.5, 27.5, 24.1, 19.8, 18.8, 13.2.  ESI-MS m/z (rel int): (pos) 633.4 
([M+Na]+, 100); (neg) 645.4 ([M+Cl]–, 100). 
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(+)-(2R,4R)-2-[2-(tert-Butyldiphenylsilyloxy)ethyl]-6-(5-hydroxypentyl)-4-
(triisopropylsilyloxy)-3,4-dihydro-2H-pyran (67n).  Clear oil (120 mg, 97%).  
TLC: Rf 0.21 (4:1 hexanes/EtOAc). [α ]D
25 : +38° (c 0.85, C6H6).  IR (NaCl, film): 
3331, 2935, 2851, 1658, 1465, 1423, 1095, 1058, 1001, 881, 734.  1H-NMR (500 
MHz, C6D6): δ 7.79 (m, 4H), 7.23 (m, 6H), 4.84 (d, 1H, J = 5.0), 4.53 (m, 1H), 4.25 
(m, 1H), 4.02 (m, 1H), 3.87 (m, 1H), 3.33 (t, 2H, J = 6.4), 2.05 (t, 2H, J = 7.5), 1.90–
1.79 (m, 3H), 1.52–1.49 (m, 3H), 1.39–1.34 (m, 3H), 1.26 (m, 2H), 1.19–1.03 (m, 
30H).  13C-NMR (125 MHz, C6D6): δ 157.5, 136.4, 134.7, 134.6, 130.3, 128.9, 99.6, 
68.9, 63.0, 62.3, 60.9, 39.1, 38.9, 34.9, 33.3, 27.5, 26.0, 19.8, 18.8, 13.2.  ESI-MS m/z 
(rel int): (pos) 625.6 ([M+H]+, 1), 647.7 ([M+Na]+, 100); (neg) 623.5 ([M–H]–, 15) 
659.5 ([M+Cl]–, 100). 
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CHAPTER 3 
KINETICALLY CONTROLLED STEREOSELECTIVE 
SPIROCYCLIZATIONS OF C1-SUBSTITUTED GLYCAL EPOXIDES WITH 
INVERSION OR RETENTION OF CONFIGURATION 
 
3.1. Introduction 
In order to generate a library of systematically stereodiversified spiroketals, we 
required kinetically controlled access to both of the two possible stereochemical 
configurations at the spiroketal carbon (Figure 3.1). We envisioned an approach in 
which the stereochemical configuration at the anomeric carbon is controlled by an 
initial stereoselective epoxidation of C1-substituted glycals 1a–n. Further 
stereodiversification would then be accomplished using kinetic spirocyclization 
reactions that proceed with either inversion (3) or retention (4) of configuration at the 
anomeric carbon, independent of thermodynamic considerations or cyclization 
trajectory. This chapter is based in part on two previous publications.1,2 
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Figure 3.1. Stereoselective epoxidation of C1-substituted glycals 1a–n and 
stereoselective spirocyclization of the resulting glycal epoxides 2a–n.  
R1 = (CH2)2OTBDPS 
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3.2. Stereoselective Epoxidation of C1-Substituted Glycals 
 Epoxidation of the C1-substituted glycals 1a–n with DMDO at –78 °C results 
in exclusive formation of the anti-epoxides 2a–n. Although epoxidations of glycals 
with DMDO are well-precedented,3-6 we were concerned about the stability of our 
C1-substituted glycal epoxides, since it is possible for the epoxide to open prematurely 
to form an oxonium species. This activated species would then undergo 
spirocyclization and we would not have an opportunity to control the stereochemistry 
of the cyclization. Indeed, following treatment of C1-alkylglycals 1a–n with DMDO, 
we isolated only a mixture of spiroketals (70:30 3a:4a for 2a; 75:25 3h:4h for 2h), 
with no remaining epoxide. Fortunately, our later experimental results suggested that 
the epoxides are stable at low temperature. This was confirmed by variable 
temperature 1H-NMR experiments, which showed that the epoxide 2a is stable below 
–40 °C.  
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Figure 3.2. Stereoselective epoxidation with DMDO and spontaneous spirocyclization 
  
The possibility of carrying out the corresponding syn-epoxidation was also 
investigated. In the absence of any directing effects, diastereoselectivity of DMDO 
epoxidations is normally attributed to steric factors,7,8 which is consistent with the 
anti-epoxidation observed for glycal substrates 1a–n. Although an early study of 
allylic alcohol epoxidations with DMDO concluded that hydrogen bonding of the 
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substrate hydroxyl group to DMDO did not play a significant role in directing 
epoxidation,9 later studies showed that hydrogen bonding effects are highly solvent 
dependent. Danishefsky first reported that decreasing the polarity of the solvent 
mixture increased the proportion of syn-epoxide formed from an allylic alcohol 
substrate, presumably due to greater opportunity for hydrogen bonding of DMDO with 
the substrate rather than the solvent.10 This idea was developed further by Murray, 
who showed a definite correlation between decreased polarity of the solvent mixture 
and a greater syn:anti epoxide ratio.11  
To explore this concept with a substrate more relevant to our planned 
spiroketal synthesis, epoxidations of the C3-unprotected glycal (5) were conducted in 
various solvent systems. The diastereoselectivity was determined by 1H-NMR analysis 
after methanolysis of the epoxides. As expected, the use of less polar solvent mixtures 
resulted in greater amounts of syn-epoxidation (Table 3.1). 
 
 
Table 3.1. Solvent effects on DMDO epoxidation 
 
O
OH
O
OH
OH
OMe O
OH
OH
OMei) DMDO
    acetone/CH2Cl2
    –78 °C to rt
ii) MeOH
+
5 6 (syn) 7 (anti)
TBDPSO TBDPSO TBDPSO
 
acetone:CH2Cl2 syn (6) anti (7) 
80:20 34 66 
50:50 36 64 
30:70 54 46 
10:90 75 25 
 
In order to investigate a similar syn-epoxidation with a substrate appropriate 
for spirocyclization, the C1-substituted glycal 9 was synthesized. To allow 
coordination of DMDO, the C3-OH of glycal 8 was selectively desilylated by 
treatment with TBAF, although the yield was low because of incomplete conversion. 
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Deprotection of the C11-OH afforded a substrate (9) suitable for syn-epoxidation 
followed by spirocyclization. Treatment of 9 with DMDO followed by exposure to 
MeOH resulted in spirocyclization with inversion of configuration instead of the 
expected methyl glycoside (see Section 3.3). Unfortunately, decreased solvent polarity 
for epoxidation of this C1-substituted glycal did not have as great of an effect as with 
the C1-unsubstituted glycal 5. Epoxidation in a 5:95 acetone/CH2Cl2 solvent mixture 
only afforded a 1:1 mixture of syn and anti epoxidation (identified through 1H-NMR 
analysis of the spiroketal mixture). Use of a 10:90 acetone/CCl4 solvent mixture 
improved the ratio slightly (59:41 syn:anti), but a large amount of an unidentified 
byproduct was also produced. 
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Figure 3.3. syn-Epoxidation and spirocyclization of C1-alkylglycal 9 
 
An alternate approach to syn-epoxidation developed by Chiappe involves 
hydroxyl-directed epoxidation via the m-CPBA-KF (Camps) complex.12-14 The 
presence of KF in the reaction mixture causes precipitation of the m-chlorobenzoic 
acid as it is produced. Although other acid-labile epoxides have been shown to be 
stable under these conditions,14 our glycal epoxides were degraded to the 
corresponding benzoate ester. Due to the problems encountered in attempts at syn-
epoxidation, we chose to only include anti-epoxidation in the synthesis of our primary 
library.  
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3.3. Spirocyclization of C1-Substituted Glycal Epoxides with Inversion of 
Configuration 
 With effective anti-epoxidation conditions in hand, we then turned to the 
development of stereoselective spirocyclization reactions. In the threo series, the 
inversion spiroketal is usually less thermodynamically stable than the corresponding 
retention spiroketal, due to double anomeric stabilization in the retention product. 
Therefore, in most cases, spirocyclization of a C1-substituted threo-glycal epoxide 
(2a,b,d–f) with TsOH results in exclusive formation of the retention product (4a,b,d–
f). A procedure for spirocyclization with inversion of configuration regardless of 
thermodynamic stability evolved from an attempt to form the methyl glycoside 12a in 
a control experiment. Justin Potuzak found that addition of a large excess of MeOH to 
glycal epoxide 2a generated inversion spiroketal 3a as the major product, instead of 
the expected methyl glycoside (Figure 3.4).1 
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Figure 3.4. MeOH-induced spirocyclization. Optimized conditions yield 92:0:8 
3a:4a:12a. 
 
After optimization, we showed that the conditions are also effective for our 
other glycal epoxide substrates (Figure 3.5). Although most of the C1-inversion 
spiroketals in the erythro series can be accessed through thermodynamic equilibration 
with TsOH (3h,i,k–m), the process is accompanied by desilylation of the C3-OH. This 
presumably occurs due to a directing effect of the neighboring diaxial ring oxygen. 
However, spirocyclization with MeOH leaves the C3-OH protecting group intact, and 
also provides access to the contrathermodynamic 3j. Attempted spirocyclizations of 
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2g,n to form seven-membered rings produced only the corresponding methyl 
glycosides. 
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Figure 3.5. MeOH- or TsOH-induced spirocyclization. Isolated yields of the 
C1-inversion products are shown in parentheses. Indicated conformations were 
determined by NMR or predicted based on conformational analysis. a Inseparable 
mixture of spiroketals 3 and 4; bC3-desilylated spiroketal 3. R = (CH2)2OTBDPS 
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3.4. Spirocyclization of C1-Substituted Glycal Epoxides with Retention of 
Configuration 
In the erythro series, the retention spiroketal is usually less thermodynamically 
stable than the corresponding inversion spiroketal, due to double anomeric 
stabilization in the inversion product. Therefore, in most cases, spirocyclization of a 
C1-substituted erythro-glycal epoxide (2h,i,k–m) with TsOH results in exclusive 
formation of the inversion product (3h,i,k–m; Figure 3.5).  
Although the erythro-glycal epoxides should be kinetically predisposed to 
spirocyclization with inversion of configuration via favorable trans-diaxial epoxide 
opening, we realized that an appropriate multidentate Lewis acid might serve as a 
tether between the epoxide oxygen and the sidechain hydroxyl of 2h and drive kinetic 
epoxide opening with retention of configuration (Figure 3.6). Specifically, 
coordination of the Lewis acid (13) could promote formation of the oxonium 
intermediate (14), then deliver the sidechain hydroxyl to the -face of the anomeric 
carbon (15). This would lead to the desired end result of epoxide opening with 
retention of configuration (4h), overriding the inherent thermodynamic and kinetic 
preferences of the system. 
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Figure 3.6. Proposed Lewis acid-tethered kinetic spirocyclization of 2h.  
R = (CH2)2OTBDPS 
 
Therefore, Lewis acid-tethered spirocyclizations were investigated as a means 
of providing kinetically controlled retention of configuration (Table 3.2). Since 
isolation of the epoxide formed from erythro-glycal 1h was not possible due to 
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spontaneous spirocyclization, various multidentate Lewis acids were added directly to 
the nascent epoxide at –78 °C. After 1 h, the reactions were warmed to rt then 
quenched immediately to avoid potential equilibration. Although we were concerned 
that the acetone cosolvent used in the epoxidation reaction might interfere with 
substrate coordination by the Lewis acids, all of the reagents tested provided an 
improved ratio of retention (4h) to inversion (3h). Encouragingly, Ti(Oi-Pr)4 provided 
the retention spiroketal 4h as a single stereoisomer, though large amounts of various 
overoxidation and glycoside byproducts were also formed.  
 
 
Table 3.2. Epoxide-opening spirocyclization reactions of 1h with multidentate Lewis 
acids 
O OH
OTIPS
R i)  DMDO
    1:1 CH2Cl2/acetone, –78 °C
ii) Lewis acid, –78 °C to rt
1h
O
O
R
OTIPS
OH
4h (retention)
O
O
R
OTIPS
OH
3h (inversion)
+
 
Lewis acid retention (4h) inversion (3h) 
none 25 75 
Yb(OTf)3 43 57 
ZnCl2 43 57 
MgCl2 60 40 
SnCl4 67 33 
Ti(Oi-Pr)4 100 0 
 
Further investigations revealed that warming the reaction to 0 °C immediately 
after addition of Ti(Oi-Pr)4 drastically improved the yield (81%). Importantly, 
exposure of the inversion spiroketal 3h to the reaction conditions did not result in 
equilibration to 4h, demonstrating that Ti(Oi-Pr)4-mediated spirocyclization is in fact 
kinetically controlled. Stereoselectivity was reduced when sub-stoichiometric amounts 
of Ti(Oi-Pr)4 were used, suggesting that the metal remains coordinated to the product 
(15) until workup. 
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Figure 3.7. Ti(Oi-Pr)4-, ZnCl2-, or TsOH-induced spirocyclization. Isolated yields of 
the C1-retention products are shown in parentheses. Indicated conformations were 
determined by NMR or predicted based on conformational analysis. a Inseparable 
mixture of spiroketals 4 and 3. R = (CH2)2OTBDPS 
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The optimized reaction conditions are also effective with our other glycal 
epoxide substrates, providing five- and six-membered ring retention spiroketals with 
complete stereocontrol (Figure 3.7). Especially notable is spiroketal 4i, which has no 
anomeric stabilizations. These cyclization conditions are also useful for the single 
threo-glycal epoxide substrate (2c) for which the retention product is 
contrathermodynamic. The seven-membered ring retention spiroketals (4g and 4n) can 
also be accessed using Ti(Oi-Pr)4 with complete stereocontrol, but yields are low due 
to competing formation of the isopropyl glycoside 16 (Figure 3.8).  
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Figure 3.8. Ti(Oi-Pr)4-mediated reaction of glycal epoxide 2n and ZnCl2-mediated 
equilibration of spiroketals 3n + 4n. R = (CH2)2OTBDPS 
 
To address this problem, a related reaction using ZnCl2 that provides retention 
spiroketals through thermodynamic rather than kinetic chelation control was 
developed. Although the stabilization provided by chelation of the metal is not enough 
to overcome the inherent thermodynamic stability of all of the inversion spiroketals in 
the erythro series, we have found that the ZnCl2 conditions are particularly useful for 
forming seven-membered rings. Namely, exposure of inversion/retention spiroketal 
mixture 3n/4n to ZnCl2 results in complete equilibration to 4n. Similar results were 
obtained for the analogous threo spiroketals 3g/4g. This result is especially valuable 
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since equilibration of 3g/4g with TsOH results in the formation of spiroketal 20 
instead of the expected retention spiroketal 4g. A potential mechanism for this reaction 
is shown in Figure 3.9. After treatment of 3g/4g with TsOH, the oxonium ion formed 
(17) could be quenched through formation of glycal 18. This glycal could then 
undergo elimination at the C3 position (19), followed by spirocyclization and 
tautomerization to produce the observed product 20. This ketone product was only 
observed in the 6,7-spiroketal series, presumably because, after initial oxonium 
formation, reclosure of the seven-membered ring is slower than the competing 
reaction pathway. An analogous product was obtained from TsOH treatment of the 
erythro-6,7-spiroketals 3n/4n.  
 
O
O
R
OTIPS
OH
O+R
OTIPS
OH
OH
OR
OTIPS
OH
O+R
OH
OH
OR
O
O
TsOH
CH2Cl2
3g/4g 17 18
19 20
OH
 
Figure 3.9. Potential mechanism for formation of 20 from TsOH-promoted reaction of 
6,7-spiroketal mixture 3g/4g 
 
3.5. Experimental Section 
Materials and Methods: 
See Section 2.6.  
 
Spirocyclization with inversion of configuration: 
Spiroketals 3a–3f were synthesized and characterized by Justin Potuzak. 
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General procedure for epoxidation and methanol-induced spirocyclization: 
The glycal alcohol (1a–n, 1.0 equiv) was dissolved in CH2Cl2 (final ratio 1:1 
acetone/CH2Cl2) and cooled to –63 °C. DMDO (0.092 M in acetone, 1.2 equiv) was 
added, and the mixture was stirred at –63 °C. After 20 min, MeOH (5 volumes) was 
added rapidly via syringe, and stirring continued at –63 °C for 1 h. Warming to rt, 
evaporation of the solvent by rotary evaporation, and silica flash chromatography 
provided the “inversion” spiroketals 3a–f,h–m. 
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(+)-(2R,4S,5R,6R)-2-[2-(tert-Butyldiphenylsilyloxy)ethyl]-4-(triisopropylsilyloxy)-
1,7-dioxaspiro[5.5]undecan-5-ol (3a). White solid (8.6 mg, 86%). TLC: Rf 0.37 (4:1 
hexanes/EtOAc). ][ 25Dα = +13º (c 1.0, CDCl3). IR (NaCl, film): 3486, 2942, 2863, 
1465, 1428, 1384, 1361, 1252, 1184, 1093, 999, 883, 821, 738, 702. 1H-NMR (400 
MHz):  7.66 (m, 4H), 7.44–7.35 (m, 6H), 3.97-3.68 (m, 6H), 3.23 (dd, 1H, J = 9.2, 
1.5), 2.35 (d, 1H, J = 1.8), 1.90-1.41 (m, 10H), 1.06 (m, 30H). 13C-NMR (100 MHz): 
 135.5. 133.2, 129.6, 127.6, 99.1, 79.5,70.8, 65.8, 62.1, 60.3, 40.7, 38.7, 26.8, 25.2, 
22.6, 19.2, 18.1, 17.5, 12.5. ESI-MS m/z: (pos) 649.5 [M+Na]+; (neg) 625.4 [M–H]–, 
661.5 [M+Cl]–. 
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(+)-(2R,4S,5R,6R,8R)-2-[2-(tert-Butyldiphenylsilyloxy)ethyl]-8-methyl-4- 
(triisopropylsilyloxy)-1,7-dioxaspiro[5.5]undecan-5-ol (3b). Clear oil (8.7 mg, 
85%). TLC: Rf 0.41 (4:1 hexanes/EtOAc). ][
25
Dα  = +28° (c 1.0, CDCl3). IR (NaCl, 
film): 3460, 2936, 2863, 1464, 1428, 1381, 1250, 1109, 1014, 967, 883, 822, 738, 702. 
1
H-NMR (400 MHz):  7.66 (m, 4H), 7.44–7.35 (m, 6H), 4.12 (m, 1H), 3.88–3.80 (m, 
2H), 3.77–3.70 (m, 2H), 3.29 (dd, 1H, J = 9.1, 1.7), 2.37 (d, 1H, J = 1.8), 1.93-1.43 
(m, 10H), 1.20 (d, 3H, J = 6.5), 1.05 (m, 30H). 13C-NMR (100 MHz):  135.5, 133.9, 
129.6, 127.6, 100.8, 80.1, 71.3, 69.5, 66.1, 60.5, 40.5, 38.7, 29.6, 26.9, 22.4, 21.6, 
19.2, 18.1, 14.2, 12.6. ESI-MS m/z: (pos) 663.5 [M+Na]+; (neg) 639.2 [M–H]–, 675.4 
[M+Cl]–. 
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(+)-(2R,4S,5R,6R,8S)-2-[2-(tert-Butyldiphenylsilyloxy)ethyl]-8-methyl-4- 
(triisopropylsilyloxy)-1,7-dioxaspiro[5.5]undecan-5-ol (3c). Clear oil (9.5 mg, 
93%). TLC: Rf 0.44 (4:1 hexanes/EtOAc). ][
25
Dα = +11° (c 1.0, CDCl3). IR (NaCl, 
film): 3476, 2938, 2864, 1464, 1428, 1383, 1251, 1106, 1090, 1006, 968, 882, 823, 
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738, 702. 1H-NMR (400 MHz):  7.66 (m, 4H), 7.44–7.35 (m, 6H), 4.02 (m, 1H), 
3.86 (m, 2H), 3.75 (m, 1H), 3.68 (m, 1H), 3.24 (dd, 1H, J = 9.2, 1.8), 2.36 (d, 1H, J = 
1.9), 1.89 (m, 1H), 1.80 (m, 1H), 1.74–1.43 (m, 8H), 1.14 (d, 3H, J = 6.3), 1.06 (m, 
30H). 13C-NMR (100 MHz):  135.5, 133.9, 129.6, 127.6, 99.7, 79.5, 70.8, 67.2, 65.8, 
60.3, 40.6, 38.7, 32.8, 30.9, 26.8, 22.1, 19.2, 18.1, 17.7, 12.5. ESI-MS m/z: (pos) 
663.4 [M+Na]+; (neg) 639.3 [M–H]–. 
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(+)-(2R,4S,5R,6R)-2-[2-(tert-Butyldiphenylsilyloxy)ethyl]-4-(triisopropylsilyloxy)-
1,7-dioxaspiro[4.5]decan-5-ol (3d). Clear oil (8.6 mg, 84%). TLC: Rf 0.39 (4:1 
hexanes/EtOAc). ][ 25Dα  +17° (c 0.86, CDCl3). IR (NaCl, film): 3479, 2942, 2864, 
1463, 1428, 1388, 1248, 1111, 1093, 1068, 998, 883, 822, 737, 701. 1H-NMR (400 
MHz):  7.66 (m, 4H), 7.44–7.35 (m, 6H), 3.99–3.68 (m, 6H), 3.49 (dd, 1H, J = 9.3, 
1.9), 2.34 (d, 1H, J = 2.0), 2.08 (m, 1H), 1.96–1.69 (m, 7H), 1.06 (m, 30H). 13C-NMR 
(100 MHz):  135.5, 133.8, 129.6, 127.6, 109.3, 76.8 (obsc), 72.3, 68.3, 66.7, 60.0, 
40.4, 38.4, 27.0, 26.8, 25.0, 19.2, 18.1, 12.5. ESI-MS m/z: (pos) 635.4 [M+Na]+; (neg) 
611.3 [M–H]–, 647.5 [M+Cl]–. 
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(+)-(2R,4S,5R,6R,8R)-2-[2-(tert-Butyldiphenylsilyloxy)ethyl]-8-methyl-4- 
(triisopropylsilyloxy)-1,7-dioxaspiro[4.5]decan-5-ol (3e). Clear oil (10 mg, 100%). 
TLC: Rf  0.47 (4:1 hexanes/EtOAc). ][
25
Dα = +15° (c 1.0, CDCl3). IR (NaCl, film): 
3466, 2942, 2864, 1462, 1428, 1381, 1247, 1112, 1094, 996, 882, 822, 736, 701. 1H-
NMR (400 MHz):  7.66 (m, 4H), 7.44–7.35 (m, 6H), 4.21 (m, 1H), 3.84 (m, 1H), 
3.71 (m, 3H), 3.49 (dd, 1H, J = 9.3, 1.5), 2.37 (d, 1H, J = 1.9), 2.08–1.43 (m, 8H), 
1.28 (d, 3H, J = 6.2), 1.06 (m, 30H). 13C-NMR (125 MHz):  135.5, 133.9, 129.6, 
127.6, 109.3, 77.1 (obsc), 76.9 (obsc), 72.2, 66.9, 60.2, 40.4, 38.3, 31.9, 26.8, 26.7, 
22.4, 19.2, 18.1, 12.5. ESI-MS m/z: (pos) 649.5 [M+Na]+; (neg) 625.3 [M–H]–, 661.4 
([M+Cl]–. 
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(+)-(2R,4S,5R,6R,8S)-2-[2-(tert-Butyldiphenylsilyloxy)ethyl]-4-
(triisopropylsilyloxy)-1,7-dioxaspiro[4.5]decan-5-ol (3f). Clear oil (9.5 mg, 92%). 
][ 25Dα = +19° (c 0.95, CDCl3). TLC: Rf  0.53 (4:1 hexanes/EtOAc). IR (NaCl, film): 
3482, 2942, 2864, 1463, 1428, 1388, 1247, 1111, 1081, 1008, 882, 822, 737, 701. 
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1
H-NMR (400 MHz):  7.66 (m, 4H), 7.44–7.35 (m, 6H), 4.26(m, 1H), 3.85 (m, 1H), 
3.71 (m, 3H), 3.43 (dd, 1H, J = 9.2, 2.0), 2.32 (d, 1H, J = 2.0), 2.18 (m, 1H), 2.02 (m, 
1H), 1.89–1.70 (m, 4H), 1.47 (m, 2H), 1.26 (d, 3H, J = 6.1), 1.06 (m, 30H). 13C-NMR 
(125 MHz):  135.5, 133.8, 129.6, 127.6, 109.4, 76.8 (obsc), 75.2, 72.2, 66.1, 60.0, 
40.5, 38.3, 33.1, 28.4, 26.8, 20.5, 19.2, 18.1, 12.5. ESI-MS m/z: (pos) 649.5 [M+Na]+; 
(neg) 625.3 [M–H]–, 661.5 [M+Cl]–. 
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(+)-(2R,4R,5S,6S)-2-[2-(tert-Butyldiphenylsilyloxy)ethyl]-4-(triisopropylsilyloxy)-
1,7-dioxaspiro[5.5]undecan-5-ol (3h). Clear oil (15 mg, 73%). TLC: Rf  0.27 (4:1 
hexanes/EtOAc). ][ 25Dα = +34 ° (c 1.0, CHCl3). IR (NaCl, film): 3409, 2930, 2859, 
1462, 1426, 1110, 1080, 998, 886, 703. 1H-NMR (400 MHz, C6D6):  7.79 (m, 4H), 
7.22 (m, 6H), 4.51 (m, 1H), 4.09 (m, 2H), 3.90–3.43 (m, 2H), 3.58 (dd, 1H, J = 11.3, 
3.8), 3.49 (dd, 1H, J = 7.8, 3.0), 1.90–1.79 (m, 2H), 1.77–1.62 (m, 3H), 1.55 (m, 1H), 
1.49–1.33 (m, 3H), 1.23–1.03 (m, 31H). 13C-NMR (100 MHz, C6D6):  136.4, 136.3, 
134.8, 134.7, 130.3, 98.2, 73.0, 71.0, 60.9, 60.8, 39.8, 35.8, 32.5, 27.5, 25.9, 19.8, 
19.3, 18.7, 13.0. ESI-MS m/z: (pos) 627.6 [M+H]+, 649.4 [M+Na]+; (neg) 661.3 
[M+Cl]–. 
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(+)-(2R,4R,5S,6S,8R)-2-[2-(tert-Butyldiphenylsilyloxy)ethyl]-8-methyl-4- 
(triisopropylsilyloxy)-1,7-dioxaspiro[5.5]undecan-5-ol (3i). Clear oil (14 mg, 88%). 
TLC: Rf  0.35 (4:1 hexanes/EtOAc). ][
25
Dα = +26° (c 1.0, CHCl3). IR (NaCl, film): 
3448, 2931, 2861, 1467, 1425, 1384, 1190, 1108, 997, 732. 1H-NMR (500 MHz):  
7.67 (m, 4H), 7.40 (m, 6H), 4.32 (m, 1H), 4.03 (m, 1H), 3.92 (m, 1H), 3.78–3.71(m, 
2H), 3.36 (dd, 1H, J = 8.0, 3.3), 1.76–1.66 (m, 5H), 1.64 (d, 1H, J = 8.0), 1.59 (m, 
1H), 1.49 (m, 1H), 1.36 (m, 1H), 1.15 (m, 2H), 1.07–1.02 (m, 33H). 13C-NMR (125 
MHz):  135.6 (Pha), 135.5 (Pha ), 134.1 (Phb), 133.9 (Phb ), 129.5, 127.6, 98.1, 72.6, 
69.9, 65.5, 60.3, 60.1, 39.1, 35.4, 32.6, 31.2, 26.8, 22.1, 19.1, 18.8, 18.1, 12.2. ESI-
MS m/z: (pos) 641.6 [M+H]+, 663.5 [M+Na]+; (neg) 639.5 [M–H]–, 675.5 [M+Cl]–. 
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(+)-(2R,4R,5S,6S,8S)-2-[2-(tert-Butyldiphenylsilyloxy)ethyl]-8-methyl-4- 
(triisopropylsilyloxy)-1,7-dioxaspiro[5.5]undecan-5-ol (3j). Clear oil (7.0 mg, 
65%). TLC: Rf  0.35 (4:1 hexanes/EtOAc). ][
25
Dα = +6.8° (c 0.86, CHCl3). IR (NaCl, 
film): 3462, 2934, 2862, 1465, 1381, 1105, 1003. 1H-NMR (500 MHz):  7.70 (m, 
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4H), 7.40 (m, 6H), 4.71 (m, 1H), 4.11 (m, 1H), 3.86–3.78 (m, 3H), 3.69 (m, 1H), 1.99 
(m, 1H), 1.76–1.60 (m, 8H), 1.32 (m, 2H), 1.15 (d, 3H, J = 6.2), 1.09 (m, 21H), 1.02 
(m, 9H). 13C-NMR (125 MHz):  135.8 (Pha), 135.6 (Pha ), 134.0 (Phb), 133.8 (Phb ), 
129.4, 127.6 (Phc), 127.5 (Phc ), 98.8, 69.9, 69.2, 66.9, 61.6, 59.8, 38.9, 34.9, 32.1, 
31.6, 26.8, 22.0, 18.8, 18.2, 18.1, 12.4. ESI-MS m/z: (pos) 641.8 [M+H]+, 663.5 
[M+Na]+; (neg) 639.4 [M–H]–, 675.4 [M+Cl]–. 
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(+)-(2R,4R,5S,6S)-2-[2-(tert-Butyldiphenylsilyloxy)ethyl]-4-(triisopropylsilyloxy)-
1,7-dioxaspiro[4.5]decan-5-ol (3k). MeOH was added before DMDO addition         
(–78 °C). Clear oil (5.0 mg, 96%, 96:4 3k/4k). TLC: Rf 0.22 (4:1 hexanes/EtOAc). 
][ 25Dα = +27° (c 0.49, CHCl3). IR (NaCl, film): 3451, 2941, 2864, 1463, 1428, 1112, 
1078, 999, 882, 822, 735, 701. 1H-NMR (400 MHz):  7.65 (m, 4H), 7.38 (m, 6H), 
4.43 (m, 1H), 4.06 (m, 1H), 3.85 (m, 2H), 3.79 (m, 1H), 3.69 (m, 1H), 3.45 (dd, 1H, J 
= 8.5, 3.4), 1.91–1.62 (m, 8H), 1.54 (m, 1H), 1.09–1.01 (m, 30H). 13C-NMR (125 
MHz):  135.5, 134.1, 129.5, 127.5, 107.4, 72.3, 69.6, 68.0, 61.9, 60.3, 38.7, 36.2, 
35.1, 27.0, 22.6, 19.2, 18.0, 12.3. ESI-MS m/z: (pos) 613.5 [M+H]+, 635.3 [M+Na]+; 
(neg) 611.2 [M–H]–, 647.2 [M+Cl]–. 
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(2R,4R,5S,6S,8R)-2-[2-(tert-Butyldiphenylsilyloxy)ethyl]-4-(triisopropylsilyloxy)-
1,7-dioxaspiro[4.5]decan-5-ol (3l). MeOH was added before DMDO addition          
(–78 °C). Clear oil (5.0 mg, 100%, 87:13 3l/4l). TLC: Rf 0.24 (4:1 hexanes/EtOAc). 
IR (NaCl, film): 3439, 2941, 2864, 1462, 1428, 1112, 1086, 1006, 882, 822, 731, 701. 
1
H-NMR (500 MHz):  7.67 (m, 4H), 7.39 (m, 6H), 4.48 (m, 1H), 4.20 (m, 1H), 4.06 
(m, 1H), 3.79 (m, 1H), 3.69 (m, 1H), 3.42 (dd, 1H, J = 8.8, 3.4), 2.02–1.89 (m, 2H), 
1.85 (m, 1H), 1.78–1.60 (m, 5H), 1.30 (m, 1H), 1.15 (d, 1H, J = 6.2), 1.09–1.02 (m, 
30H). 13C-NMR (125 MHz):  135.5, 134.1, 129.5, 127.5, 107.4, 75.1, 72.4, 69.6, 
61.6, 60.2, 38.7, 36.1, 35.1, 30.2, 26.8, 21.0, 19.2, 18.1, 12.3. ESI-MS m/z: (pos) 
627.6 [M+H]+, 649.4 [M+Na]+; (neg) 625.3 [M–H]–, 661.3 [M+Cl]–. 
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(2R,4R,5S,6S,8S)-2-[2-(tert-Butyldiphenylsilyloxy)ethyl]-4-(triisopropylsilyloxy)-
1,7-dioxaspiro[4.5]decan-5-ol (3m). MeOH was added before DMDO addition        
(–78 °C). Clear oil (5.0 mg, 76%, 73:14 3m/4m). TLC: Rf 0.26 (4:1 hexanes/EtOAc). 
IR (NaCl, film): 3450, 2941, 2864, 1462, 1427, 1382, 1245, 112, 1085, 998, 882, 822, 
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734, 701. 1H-NMR (500 MHz):  7.68 (m, 4H), 7.39 (m, 6H), 4.46 (m, 1H), 4.20 (m, 
1H), 4.05 (m, 1H), 3.79–3.66 (m, 2H), 3.38 (dd, 1H, J = 8.9, 3.4), 2.02–1.80 (m, 3H), 
1.73–1.56 (m, 5H), 1.54 (m, 1H), 1.18 (d, 3H, J = 5.1), 1.10–1.01 (m, 30H). 13C-NMR 
(125 MHz):  135.6, 134.1, 129.4, 127.5, 107.2, 77.8, 72.5, 69.6, 61.9, 60.6, 39.0, 
37.8, 35.1, 30.9, 26.8, 23.0, 18.1, 18.0, 12.3. ESI-MS m/z: (pos) 649.5 [M+Na]+; (neg) 
625.4 [M–H]–, 661.2 [M+Cl]–. 
 
Spirocyclization with retention of configuration: 
Spiroketals 4a–f were synthesized and characterized by Justin Potuzak. 
 
General procedure for epoxidation and Ti(Oi-Pr)4-induced spirocyclization:  
The glycal alcohol (1a–n, 1.0 equiv) was dissolved in CH2Cl2 (final ratio 1:1 
acetone/CH2Cl2) and cooled to –78 °C. DMDO (0.03 M in acetone, 1.2 equiv) was 
added, and the mixture was stirred at  –78 °C. After 10 min, Ti(OiPr)4 (2.0 equiv) was 
added via syringe. The reaction mixture was then warmed to 0 °C and stirred for 1 h. 
The cold reaction mixture was quenched with sat’d aq NaHCO3. The aqueous layer 
was separated and extracted with Et2O, then the combined organic extracts were 
washed with H2O and brine, dried (MgSO4), filtered and concentrated by rotary 
evaporation. Silica flash chromatography provided the “retention” spiroketals          
4a–f, h–m.  
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(+)-(2R,4S,5R,6S)-2-[2-(tert-Butyldiphenylsilyloxy)ethyl]-4-(triisopropylsilyloxy)-
1,7-dioxaspiro[5.5]undecan-5-ol (4a).  Clear oil (9.9 mg, 74%).  TLC: Rf 0.44 (4:1 
hexanes/EtOAc).  [α ]D
25 : +40° (c 0.99, CDCl3).  IR (NaCl, film): 3568, 2939, 2863, 
1465, 1429, 1385, 1258, 1106, 1067, 997, 934, 883, 823, 738, 702, 613, 503, 463.  
1
H-NMR (400 MHz): δ 7.66 (m, 4H), 7.44–7.35 (m, 6H), 4.02 (m, 1H), 3.89 (m, 2H), 
3.76 (m, 1H), 3.68 (m, 1H), 3.60 (m, 1H), 3.07 (dd, 1H, J = 8.7, 6.3), 2.18 (d, 1H, J = 
6.3), 2.02 (m, 1H), 1.93 (m, 1H), 1.71 (m, 3H), 1.57 (m, 2H), 1.41 (m, 3H), 1.06 (m, 
30H).  13C-NMR (100 MHz): δ 135.5, 133.9, 129.6, 127.6, 97.7, 78.6, 70.9, 63.6, 
60.8, 60.3, 40.8, 38.4, 30.9, 26.9, 24.9, 19.2, 18.3, 18.2, 12.6.  ESI-MS m/z (rel int): 
(pos) 649.5 ([M+Na]+, 100); (neg) 625.5 ([M–H]–, 100).   
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(+)-(2R,4S,5R,6S,8R)-2-[2-(tert-Butyldiphenylsilyloxy)ethyl]-8-methyl-4-
(triisopropylsilyloxy)-1,7-dioxaspiro[5.5]undecan-5-ol (4b).  Clear oil (11 mg, 
60%).  TLC: Rf 0.44 (4:1 hexanes/EtOAc). [α ]D
25 : +40° (c 1.1, CDCl3).  IR (NaCl, 
film): 3568, 2936, 2863, 1464, 1429, 1385, 1257, 1187, 1105, 1080, 1002, 941, 882, 
820, 737, 702, 613, 503.  1H-NMR (400 MHz): δ 7.66 (m, 4H), 7.44–7.35 (m, 6H), 
4.04 (m, 1H), 3.89 (m, 2H), 3.78-3.71 (m, 2H), 3.06 (m, 1H), 2.10 (d, 1H, J = 7.7), 
1.94 (m, 2H), 1.80–1.68 (m, 4H), 1.57–1.37 (m, 4H), 1.06 (m, 33H).  13C-NMR (100 
MHz): δ 135.5, 133.9, 129.6, 127.6, 98.4, 78.3, 70.9, 65.9, 63.5, 60.2, 40.9, 38.5, 32.4, 
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30.2, 26.8, 21.8, 19.2, 18.7, 18.2, 12.6.  ESI-MS m/z (rel int): (pos) 663.5 ([M+Na]+, 
100); (neg) 639.3 ([M–H]–, 100). 
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(+)-(2R,4S,5R,6S,8S)-2-[2-(tert-Butyldiphenylsilyloxy)ethyl]-8-methyl-4-
(triisopropylsilyloxy)-1,7-dioxaspiro[5.5]undecan-5-ol (4c). Clear oil (3.6 mg, 
70%). TLC: Rf 0.44 (4:1 hexanes/EtOAc). [α ]D
25  = +27° (c 0.36, CHCl3). IR (NaCl, 
film): 3568, 2936, 2863, 1464, 1429,1385, 1257, 1187, 1105, 1080, 1002, 941, 882, 
820, 737, 702, 613, 503. 1H-NMR (400 MHz):  7.66 (m, 4H), 7.44–7.35 (m, 6H), 
4.12 (m, 1H), 4.04 (m, 1H), 3.96 (m, 1H), 3.73 (m, 2H), 2.99 (dd, 1H, J = 8.7, 7.5), 
2.11 (d, 1H, J = 7.5), 2.05 (m, 1H), 1.95 (m, 1H), 1.90–1.79 (m, 2H), 1.70–1.62 (m, 
2H), 1.53–1.44 (m, 3H), 1.38–1.34 (m, 1H), 1.25 (d, 3H, J = 6.7), 1.06 (m, 30H). 13C-
NMR (125 MHz):  135.5, 133.9, 129.6, 127.6, 98.8, 79.0, 70.7, 69.4, 64.9, 60.7, 
40.5, 38.4, 30.8, 29.4, 26.8, 21.2, 19.2, 18.2, 14.0, 12.6. ESI-MS m/z (rel int): pos 
663.5 ([M+Na]+, 100); neg 639.3 ([M–H]–, 100). 
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(+)-(2R,4S,5R,6S)-2-[2-(tert-Butyldiphenylsilyloxy)ethyl]-4-(triisopropylsilyloxy)-
1,7-dioxaspiro[4.5]decan-5-ol (4d).  Clear oil (7.6 mg, 84%).  TLC: Rf 0.57 (4:1 
hexanes/EtOAc). [α ]D
25 : +39° (c 0.76, CDCl3).  IR (NaCl, film): 3568, 2942, 2864, 
1463, 1428, 1389, 1258, 1112, 1092, 1013, 882, 823, 737, 701.  1H-NMR (400 MHz): 
δ 7.66 (m, 4H), 7.44–7.35 (m, 6H), 3.99–3.91 (m, 3H), 3.84 (m, 1H), 3.72 (m, 2H), 
3.39 (dd, 1H, J = 8.7, 7.4), 2.21 (m, 1H), 1.99 (d, 1H, J = 7.2), 1.95–1.65 (m, 6H), 
1.42 (m, 1H), 1.06 (m, 30H).  13C-NMR (125 MHz): δ 135.5, 134.0, 129.6, 127.6, 
107.6, 75.6, 72.0, 68.1, 65.0, 60.5, 40.8, 38.3, 34.0, 26.8, 23.8, 19.2, 18.2, 12.6.  
ESI-MS m/z (rel int): (pos) 635.3 ([M+Na]+, 100); (neg) 611.1 ([M–H]–, 20), 647.2 
([M+Cl]–, 100). 
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(+)-(2R,4S,5R,6S,8R)-2-[2-(tert-Butyldiphenylsilyloxy)ethyl]-8-methyl-4-
(triisopropylsilyloxy)-1,7-dioxaspiro[4.5]decan-5-ol (4e).  Clear oil (9.2 mg, 86%).  
TLC: Rf 0.50 (4:1 hexanes/EtOAc). [α ]D
25 : +37° (c 0.92, CDCl3).  IR (NaCl, film): 
3565, 2942, 2864, 1463, 1428, 1388, 1259, 1112, 1095, 1071, 1013, 926, 882, 822, 
737, 701.  1H-NMR (400 MHz): δ 7.66 (m, 4H), 7.44–7.35 (m, 6H), 4.17 (q, 1H, J = 
6.5), 4.00–3.87 (m, 2H), 3.78–3.69 (m, 2H), 3.30 (t, 1H, J = 8.9), 2.27 (m, 1H), 2.05–
1.65 (m, 7H), 1.38 (m, 1H), 1.21 (d, 3H, J = 6.1), 1.06 (m, 30H).  13C-NMR (125 
MHz): δ 135.5, 134.0, 129.5, 127.6, 107.9, 75.7, 75.1, 72.1, 64.9, 60.4, 40.9, 38.3, 
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34.5, 31.7, 26.8, 20.7, 19.2, 18.2, 12.6.  ESI-MS m/z (rel int): (pos) 649.4 ([M+Na]+, 
100); (neg) 625.2 ([M–H]–, 20), 661.3 ([M+Cl]–, 100). 
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(+)-(2R,4S,5R,6S,8S)-2-[2-(tert-Butyldiphenylsilyloxy)ethyl]-8-methyl-4-
(triisopropylsilyloxy)-1,7-dioxaspiro[4.5]decan-5-ol (4f).  Clear oil (9.5 mg, 98%).  
TLC: Rf 0.57 (4:1 hexanes/EtOAc). [α ]D
25 : +40° (c 0.95, CDCl3).  IR (NaCl, film): 
3562, 2942, 2864, 1463, 1428, 1388, 1258, 1112, 1095, 1012, 997, 825, 882, 822, 737, 
701.  1H-NMR (400 MHz): δ 7.66 (m, 4H), 7.44–7.35 (m, 6H), 4.28 (m, 1H), 3.98 (m, 
1H), 3.91 (m, 1H), 3.73 (t, 2H, J = 6.5), 3.31 (dd, 1H, J = 8.6, 7.9), 2.25 (m, 1H), 
1.99–1.90 (m, 3H), 1.83 (m, 1H), 1.74 (m, 1H), 1.63 (m, 2H), 1.39 (m, 1H), 1.21 (d, 
3H, J = 6.2), 1.06 (m, 30H).  13C-NMR (125 MHz): δ 135.5, 134.8, 134.0, 127.6, 
107.7, 78.3, 75.6, 72.1, 64.7, 60.8, 40.7, 38.5, 34.9, 31.5, 26.8, 23.3, 19.2, 18.2, 12.6.  
ESI-MS m/z (rel int): (pos) 649.4 ([M+Na]+, 100); (neg) 625.2 ([M–H]–, 20), 661.2 
([M+Cl]–, 100). 
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(–)-(2R,4R,5S,6R)-2-[2-(tert-Butyldiphenylsilyloxy)ethyl]-4-(triisopropylsilyloxy)-
1,7-dioxaspiro[5.5]undecan-5-ol (4h).  Clear oil (5.0 mg, 81%). TLC: Rf 0.45 (4:1 
hexanes/EtOAc). [α ]D
25 : –3.9° (c 0.60, CHCl3). IR (NaCl, film): 2938, 2859, 1463, 
1220, 1090, 1005, 886, 734, 705.  1H-NMR (400 MHz): δ 7.66 (m, 4H), 7.39 (m, 6H), 
4.21-4.12 (m, 2H), 4.03-3.92 (m, 2H), 3.77 (m, 1H), 3.68 (m, 1H), 3.40 (d, 1H, J = 
2.9), 2.98 (d, 1H, J = 1.3), 2.51 (m, 1H), 1.85 (m, 1H), 1.77-1.63 (m, C6), 1.59 (m, 
1H), 1.52-1.42 (m, 3H), 1.35 (m, 1H), 1.11-1.00 (m, 30H).  13C-NMR (125 MHz): 
δ 135.6, 134.0 (Ph), 133.9 (Ph′), 129.6, 129.5, 127.6, 96.7, 72.6, 69.3, 64.1, 61.9, 60.1, 
38.8, 34.6, 29.2, 26.8, 25.4, 19.2, 18.1, 18.0, 12.1.  ESI-MS m/z (rel int): (pos) 627.5 
([M+H] +, 30), 649.4 ([M+Na]+, 100), 679.7 ([M+NH4]
+, 30); (neg) 661.3 ([M+Cl]–, 
100). 
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(+)-(2R,4R,5S,6R,8R)-2-[2-(tert-Butyldiphenylsilyloxy)ethyl]-8-methyl-4-
(triisopropylsilyloxy)-1,7-dioxaspiro[5.5]undecan-5-ol (4i). Clear oil (8.9 mg, 86%). 
TLC: Rf 0.35 (4:1 hexanes/EtOAc). [α ]D
25  = +11° (c 0.52, CHCl3). IR (NaCl, film): 
2940, 2865, 1462, 1427, 1385, 1227, 1111, 1059, 1047, 1004, 882, 735, 701. 
1
H-NMR (500 MHz):  7.68 (dd, 2H, J = 7.9, 1.4), 7.64 (dd, 2H, J = 7.9, 1.4), 7.40 
(m, 6H), 4.33–4.26 (m, 2H), 3.91 (m, 1H), 3.83–3.74 (m, 2H), 3.71 (m, 1H), 2.85 (d, 
1H, J = 2.0), 2.66 (m, 1H), 1.85 (m, 1H), 1.76 (m, 2H), 1.68–1.56 (m, 2H), 1.51 (m, 
2H), 1.33–1.25 (m, 2H), 1.24 (d, 3H, J = 6.2), 1.15–1.05 (m, 21H), 1.03 (s, 9H). 
13
C-NMR (125 MHz):  135.6, 134.0, 129.5, 127.6, 99.0, 69.6, 69.4, 66.0, 64.2, 59.9, 
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34.0, 31.8, 26.8, 29.8, 22.3, 20.3, 19.2, 18.2, 12.2. ESI-MS m/z (rel int): (pos) 641.6 
([M+H]+, 5), 663.3 ([M+Na]+, 100); (neg) 639.4 ([M–H]–, 15), 675.3 ([M+Cl]–, 100). 
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(–)-(2R,4R,5S,6R,8S)-2-[2-(tert-Butyldiphenylsilyloxy)ethyl]-8-methyl-4-
(triisopropylsilyloxy)-1,7-dioxaspiro[5.5]undecan-5-ol (4j). Clear oil (4.0 mg, 
82%). TLC: Rf 0.51 (4:1 hexanes/EtOAc). [α ]D
25 : –4.7° (c 0.71, CHCl3). IR (NaCl, 
film): 2934, 2862, 1465, 1384, 1227, 1095, 1007, 881, 737. 1H-NMR (500 MHz): 
δ 7.66 (m, 4H), 7.39 (m, 6H), 4.21 (m, 1H), 4.12 (m, 1H), 4.06 (m, 1H), 3.92 (m, 1H), 
3.73 (m, 1H), 3.39 (d, 1H, J = 3.2), 3.11 (s, 1H), 2.56 (m, 1H), 1.85 (m, 1H), 1.75–
1.66 (m, 3H), 1.51–1.43 (m, 2H), 1.24–1.12 (m, 3H), 1.13-1.01 (m, 33H). 13C-NMR 
(125 MHz): δ 135.6, 134.1 (Ph), 133.9 (Ph′), 129.5, 127.6, 97.2, 72.7, 69.3, 67.1, 64.0, 
60.1, 38.7, 34.6, 33.0, 28.5, 26.8, 22.0, 19.2, 18.3, 18.1, 12.1. ESI-MS m/z (rel int): 
(pos) 663.5 ([M+Na]+, 100), 679.7 ([M+K]+, 5); (neg) 639.4 ([M–H]–, 100), 675.4 
([M+Cl]–, 50). 
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(+)-(2R,4R,5S,6R)-2-[2-(tert-Butyldiphenylsilyloxy)ethyl]-4-(triisopropylsilyloxy)-
1,7-dioxaspiro[5.4]decan-5-ol (4k). Clear oil (9.0 mg, 84%). TLC: Rf 0.22 (4:1 
hexanes/EtOAc). [α ]D
25 : +5.6° (c 0.86, CHCl3). IR (NaCl, film): 3566, 2942, 2865, 
1463, 1427, 1388, 1111, 1083, 998, 823, 736, 701. 1H-NMR (400 MHz): δ 7.65 (m, 
4H), 7.38 (m, 6H), 4.20 (m, 2H), 3.99 (m, 1H), 3.89-3.78 (m, 2H), 3.69 (m, 1H), 3.50 
(m, 1H), 2.63 (d, 1H, J = 2.2), 2.32 (m, 1H), 2.03 (m, 1H), 1.90-1.61 (m, 5H), 1.52 (m, 
1H), 0.08-1.04 (m, 30H). 13C-NMR (125 MHz): δ 135.5 (Ph), 133.9 (Ph′), 129.5, 
127.6, 107.0, 73.2, 69.3, 67.5, 65.6, 59.9, 38.6, 34.5, 32.7, 26.8, 25.0, 19.2, 18.1, 12.2. 
ESI-MS m/z (rel int): (pos) 635.7 ([M+Na]+, 100); (neg) 611.6 ([M–H]–, 10), 647.7 
([M+Cl]–, 100). 
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(+)-(2R,4R,5S,6R,8S)-2-[2-(tert-Butyldiphenylsilyloxy)ethyl]-8-methyl-4-
(triisopropylsilyloxy)-1,7-dioxaspiro[5.4]decan-5-ol (4l).  Clear oil (4.0 mg, 80%).  
TLC: Rf 0.39 (4:1 hexanes/EtOAc). [α ]D
25 : +9.2° (c 0.41, CHCl3). IR (NaCl, film): 
2941, 2864, 1463, 1427, 1388, 1111, 1083, 1012, 882, 823, 736, 701. 1H-NMR (500 
MHz): δ 7.68 (m, 4H), 7.39 (m, 6H), 4.29 (m, 1H), 4.20 (m, 2H), 3.89 (m, 1H), 3.69 
(m, 1H), 3.47 (m, 1H), 2.70 (d, 1H, J = 2.0), 2.21 (m, 1H), 2.09 (m, 1H), 1.84 (m, 1H), 
1.76–1.64 (m, 3H), 1.49 (m, 2H), 1.20 (d, 3H, J = 6.2), 1.11–0.98 (m, 30H). 13C-NMR 
(125 MHz): δ 135.5 (Ph), 133.9 (Ph′), 129.5, 127.6, 107.0, 74.7, 73.4, 69.3, 64.9, 59.8, 
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38.5, 34.5, 32.9, 32.6, 26.8, 21.0, 19.1, 18.1, 12.2. ESI-MS m/z (rel int): (pos) 649.7 
([M+Na]+, 100); (neg) 625.6 ([M–H]–, 20), 661.8 ([M+Cl]–, 100). 
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(+)-(2R,4R,5S,6R,8R)-2-[2-(tert-Butyldiphenylsilyloxy)ethyl]-8-methyl-4-
(triisopropylsilyloxy)-1,7-dioxaspiro[5.4]decan-5-ol (4m).  Clear oil (4.0 mg, 86%).  
TLC: Rf 0.39 (4:1 hexanes/EtOAc). [α ]D
25 : +6.8° (c 0.44, CHCl3). IR (NaCl, film): 
2941, 2865, 1472, 1428, 1388, 1111, 1085, 1005, 954, 882, 823, 737, 701. 1H-NMR 
(400 MHz): δ 7.67 (m, 4H), 7.41 (m, 6H), 4.22 (m, 2H), 4.12 (m, 1H), 3.89 (m, 1H), 
3.70 (m, 1H), 3.49 (m, 1H), 2.70 (d, 1H, J = 1.7), 2.44 (m, 1H), 1.99 (m, 1H), 1.85 (m, 
1H), 1.77–1.61 (m, 4H), 1.49 (m, 1H), 1.25 (d, 3H, J = 6.1), 1.10–0.97 (m, 30H). 
13
C-NMR (125 MHz): δ 135.5, 134.0 (Ph), 133.9 (Ph′), 129.5, 127.6, 106.8, 76.3, 
73.3, 69.4, 65.3, 59.9, 38.5, 34.2, 33.3, 32.6, 26.8, 22.5, 19.2, 18.1, 12.2. ESI-MS m/z 
(rel int): (pos) 649.7 ([M+Na]+, 100); (neg) 625.7 ([M–H]–, 25), 661.8 ([M+Cl]–, 100). 
 
General procedure for epoxidation and ZnCl2-induced spirocyclization and 
equilibration: 
The glycal alcohol (1g or 1n, 1.0 equiv) was dissolved in CH2Cl2 (final ratio 1:1 
acetone/CH2Cl2) and cooled to –78 °C. DMDO (0.030 M in acetone, 1.2 equiv) was 
added, and the mixture was stirred at  –78 °C. After 10 min the reaction was warmed 
to rt and the solvent was evaporated with a stream of Ar. The residue was dissolved in 
anhyd CH2Cl2 (0.030 M) then ZnCl2 (1.0 M in Et2O, 1.2 equiv) was added. The 
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reaction was stirred at rt 2h then quenched with NaHCO3. The aqueous layer was 
separated and extracted with Et2O, then the combined organic extracts were washed 
with H2O and brine, dried (MgSO4), filtered and concentrated by rotary evaporation. 
Silica flash chromatography provided the “retention” spiroketals 4g,n.  
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(+)-(2R,4S,5R,6S)-2-[2-(tert-Butyldiphenylsilyloxy)ethyl]-4-(triisopropylsilyloxy)-
1,7-dioxaspiro[5.6]dodecan-5-ol (4g). Clear oil (8.6 mg, 84%).  TLC: Rf 0.40 (4:1 
hexanes/EtOAc). [α ]D
25 : +43° (c 0.86, CDCl3). IR (NaCl, film): 3572, 2940, 2864, 
1463, 1428, 1389, 1257, 1098, 1053, 966, 883, 822, 738, 701. 1H-NMR (400 MHz): 
δ 7.66 (m, 4H), 7.44–7.35 (m, 6H), 3.99–3.66 (m, 5H), 3.55 (m, 1H), 3.19 (dd, 1H, J = 
8.5, 7.6), 2.17 (m, 1H), 2.08 (d, 1H, J = 7.3), 1.91 (m, 1H), 1.80–1.62 (m, 9H), 1.36 
(m, 1H), 1.06 (m, 30H). 13C-NMR (125 MHz): δ 135.5, 133.9, 129.6, 127.6, 101.3, 
81.5, 71.4, 64.5, 62.1, 60.5, 40.7, 40.6, 38.4, 30.3, 29.5, 26.8, 23.4, 19.2, 18.2, 12.6. 
ESI-MS m/z: pos 663.4 [M+Na]+; neg 639.4 [M–H]–, 675.3 [M+Cl]–. 
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(–)-(2R,4R,5S,6R)-2-[2-(tert-Butyldiphenylsilyloxy)ethyl]-4-(triisopropylsilyloxy)-
1,7-dioxaspiro[5.6]dodecan-5-ol (4n).  Clear oil (8.7 mg, 84%).  TLC: Rf 0.38 (4:1 
hexanes/EtOAc). [α ]D
25 : –4.9° (c 0.87, CHCl3). IR (NaCl, film): 2928, 2863, 1472, 
1428, 1112, 1049, 882, 823, 737, 702. 1H-NMR (500 MHz): δ 7.67 (ddd, 2H, J = 
25.1, 8.0, 1.4), 7.42–7.36 (m, 6H), 4.23 (m, 1H), 4.18 (m, 1H), 3.95–3.87 (m, 2H), 
3.71 (m, 2H), 3.48 (m, 1H), 3.07 (d, 1H, J = 0.85), 2.89 (m, 1H), 1.83–1.72 (m, 3H), 
1.71–1.60 (m, 5H), 1.49 (m, 1H), 1.35 (m, 2H), 1.12–1.02 (m, 30H). 13C-NMR (125 
MHz): δ 135.6, 134.0 (Ph), 133.9 (Ph′), 129.5, 127.6, 100.9, 70.4, 69.6, 64.1, 63.3, 
59.7, 38.8, 34.5, 30.6, 29.9, 26.8, 23.0, 19.2, 18.1, 12.1. ESI-MS m/z: (pos) 641.5 
[M+H] +, 663.3 [M+Na]+; (neg) 639.3 [M–H]–, 675.3 [M+Cl]–. 
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CHAPTER 4 
SYNTHESIS AND BIOLOGICAL SCREENING OF A LIBRARY OF 
STRUCTURALLY AND STEREOCHEMICALLY DIVERSE SPIROKETALS 
 
4.1. Introduction 
 We used the methodology we developed for C1-substituted glycal epoxide 
synthesis and stereoselective spirocyclization to synthesize a library of 52 
stereochemically and structurally diverse spiroketals (Figure 4.1; 6a-f,h-m; 7a–n plus 
enantiomers) for evaluation in biological assays. The majority of the spiroketal library 
was synthesized in solution according to the methods described in Chapters 2–3, then 
desilylated (4 6 and 5 7) to confer solubility in aqueous media. The remainder of 
the library was synthesized on solid support, as described in Section 4.2.  
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Figure 4.1. Synthesis of a library of structurally and stereochemically diverse 
spiroketals 
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4.2. Adaptation of Spiroketal Synthesis to Solid Phase 
 Although the majority of our primary library was synthesized in solution, solid 
phase conditions that could allow larger spiroketal libraries to be produced more 
efficiently in the future have been developed (Figure 4.2). 
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Figure 4.2. Stereoselective solid phase synthesis of spiroketals 6a and 7a 
  
The stannane 9 was loaded onto polystyrene resin via the TBDAS linker1 
developed in our lab (8). Selection of the analogous C7-OTBDPS group for solution 
phase studies facilitated translation of the subsequent reactions to solid phase synthesis 
with only minor modifications. Although initial attempts to form the glycal iodide (11) 
on solid support resulted in decomposition, it was found that careful control of 
stoichiometry and reaction time allowed successful formation of the iodide with little 
or no decomposition. The B-alkyl Suzuki coupling conditions developed in solution 
provided traces of product when translated to solid support, but conversion was slow 
and was complicated by decomposition of the iodide starting material. However, use 
of a THF/DMF solvent mixture and extended reaction times resulted in complete 
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conversion to the desired C1-substituted glycal (12). Heating was necessary to drive 
acetate deprotection (13), which was confirmed by acid-promoted cyclization to the 
C2-dehydroxy spiroketal. Treatment with DMDO provided epoxide 14, which was 
confirmed by MS analysis of the spiroketals formed upon spontaneous 
spirocyclization at room temperature. Surprisingly, the solid phase MeOH-induced 
spirocyclization (14 → 6a) proceeded even more effectively than the corresponding 
solution phase reaction, with no methyl glycosides detected.  Moreover, 
thermodynamic equilibration with TsOH was also readily accomplished (14 → 7a). 
This concise 6-step route provided the spiroketal products 6a and 7a in high purity 
(≥80–90% based on NMR analysis) and overall yields suitable for library synthesis. 
4.3. Evaluation of the Spiroketal Library in Multiple Biological Systems 
The ultimate goal of this project is to identify compounds that can be used as 
probes for biological studies, or possibly used as lead compounds for drug 
development. In order to do this, the spiroketal library will be evaluated in a range of 
high-throughput screens through the NIH Small Molecule Repository and 
collaborations with multiple laboratories in the Tri-Institutional Research Program. 
The results of these screens will allow us to begin analyzing the effectiveness of our 
library design strategy. In addition, to acquire a general cytotoxicity profile, the library 
has been screened against HeLa cells and wild-type yeast. None of the compounds 
were found to be cytotoxic in these assays. 
 
4.4. Experimental Section 
Materials and Methods: 
See Section 2.6. The compound not cited in the previous sections of this 
chapter is numbered herein E1. 
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Solid phase synthesis of spiroketals: 
 
O
O
HO Sn
Si
O
O
O Sn
Si
Si
E1 9  
(2R*,4S*)-2-(2-hydroxyethyl)-6-(tributylstannyl)-4-(triisopropylsilyloxy)-3,4-
dihydro-2H-pyran (9).  Stannane E1 (59 mg, 0.071 mmol, 1.0 equiv) was prepared as 
described in Section 2.6, dissolved in THF (0.6 mL) and HMPA (0.6 mL), then cooled 
to 0 °C.  NaH (60% in oil, 5.7 mg, 0.14 mmol, 2.0 equiv) was added, and the mixture 
was stirred at 0 °C for 7 h then allowed to stand at –20 °C for 12 h.  The mixture was 
then quenched with H2O and the aqueous layer was extracted 3x with Et2O.  The 
combined organic extracts were washed with H2O and brine, dried (MgSO4), filtered 
and concentrated by rotary evaporation.  Silica flash chromatography (19:1 
hexanes/EtOAc) provided stannane 9 (26 mg, 63%) as a colorless oil. TLC: Rf 0.44 
(4:1 hexanes/EtOAc).  IR (NaCl, film): 3346, 2955, 2926, 2866, 1601, 1464, 1376, 
1321, 1062, 882, 785.  1H-NMR (400 MHz): δ 4.79 (m, 1H), 4.52 (m, 1H), 4.05 (m, 
1H), 3.79 (m, 2H), 2.10 (t, 1H, J = 5.6), 2.02 (m, 1H), 1.89–1.72 (m, 3H), 1.52 (m, 
6H), 1.29 (m, 6H), 1.09 (21H), 0.90 (15H).  13C-NMR (125 MHz): δ 162.4, 118.0, 
74.5, 63.9, 60.8, 38.5, 37.6, 28.9, 27.2, 18.0, 13.7, 12.3, 9.6.  ESI-MS m/z (rel int): 
(pos) 613.7 ([M+Na]+, 100); (neg) 589.7 ([M–H]–, 10), 625.6 ([M+Cl]–, 100). 
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O
O
O Sn
Si
 
Resin-bound (2R*,4S*)-2-(2-hydroxyethyl)-6-(tributylstannyl)-4-
(triisopropylsilyloxy)-3,4-dihydro-2H-pyran (10). 1,3-Dichloro-5,5-
dimethylhydantoin (1.0 M in CH2Cl2, 300 µL, 12 equiv) was added to 150–300 µM 
polystyrene-TBDAS-H resin1 (0.94 mequiv/g, 35 mg, 1.0 equiv) in a Bio-Rad column 
and the mixture was vortexed 30 min. The solution was drained off, then the resin was 
washed with CH2Cl2 (3 x 500 µL). Imidazole (1.0 M in CH2Cl2, 400 µL, 12 equiv) 
was added, followed by a solution of alcohol 9 (0.25 M in CH2Cl2, 400 µL, 3.0 equiv). 
After vortexing the mixture for 16 h, the solution was drained off and the resin was 
washed 2 x 400 µL each with CH2Cl2, THF, 3:1 THF/i-PrOH, 3:1 THF/H2O, 3:1 
THF/i-PrOH, THF, TMOF, then anhyd THF. Cleavage of a sample of the resin with 
TBAF (0.2 M in THF) in the presence of a biphenylmethanol internal standard 
released the corresponding diol stannane (78%, 1H-NMR). 
 
 
O
O
O
Si
I
 
Resin-bound (2R*,4S*)-2-[2-(tert-Butyldiphenylsilyloxy)ethyl]-6-iodo-4-
(triisopropylsilyloxy)-3,4-dihydro-2H-pyran (11).  ALL STEPS WERE CARRIED OUT IN 
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THE DARK. Anhyd CH2Cl2 (0.2 mL) then a solution of I2 (0.20 M in CH2Cl2, 29 µL, 
5.9 µmol, 1.5 equiv) was added to resin-bound stannane 10 (0.30 mequiv/g, 13 mg, 
1.0 equiv) in a Bio-Rad column. The mixture was vortexed for 3 min then the solution 
was filtered off.  The resin was washed with CH2Cl2 (3 × 500 µL) then DMF (3 × 500 
µL) then used directly in the next reaction. 
 
 
O
O
O
Si
O
O
 
Resin-bound (2R*,4R*)-6-(4-Acetoxybutyl)-2-[2-(tert-
butyldiphenylsilyloxy)ethyl]-4-(triisopropylsilyloxy)-3,4-dihydro-2H-pyran (12).  
Hydroboration: But-3-enyl acetate (30 µL, 0.22 mmol, 1.0 equiv) was dissolved in 
anhyd THF (2.2 mL). A freshly prepared solution of 9-BBN (0.50 M in THF, 
0.86 mL, 0.44 mmol, 2.0 equiv) was added dropwise at rt. After stirring for 3 h, aq 
NaOH (1.0 N, 430 µL, 0.44 mmol, 2.0 equiv) was added, and the reaction was stirred 
for an additional 30 min at rt. Coupling: ALL STEPS WERE CARRIED OUT IN THE DARK. 
DMF (0.2 mL) then H2O (20 µL) were added to resin-bound iodide 11 (3.9 µmol, 
1.0 equiv) in a Bio-Rad column. PdCl2(dppf) (3.2 mg, 3.9 µmol, 1.0 equiv) was then 
added, followed by a portion of the hydroboration reaction mixture (0.50 mL, 
31 µmol, 8.0 equiv). After vortexing at rt 40 h, the solution was filtered off.  The resin 
was washed 3 × 500 µL each with DMF, THF, CH2Cl2, Ph3P in CH2Cl2, CH2Cl2, 
DMF, 3:1 THF/i-PrOH, DMF, THF, then CH2Cl2. Cleavage of a sample of the resin 
with TBAF (0.04 M in THF) in the presence of a biphenylmethanol internal standard 
released the corresponding diol acetate (>90% over 2 steps, 1H-NMR). 
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O
O
O
Si
OH
 
Resin-bound (2R*,4S*)-2-[2-(tert-Butyldiphenylsilyloxy)ethyl]-6-(4-
hydroxybutyl)-4-(triisopropylsilyloxy)-3,4-dihydro-2H-pyran (13). THF (0.8 mL), 
MeOH (0.2 mL), then K2CO3 (5.3 mg, 38 µmol, 5.0 equiv) were added to resin-bound 
glycal 12 (0.32 mequiv/g, 24 mg, 1.0 equiv) in a 5 mL roundbottom flask. The mixture 
was heated to 60 °C and stirred 20 h. The solution was then filtered off and the resin 
was washed with THF (3 × 500 µL), 3:1 THF/H2O (8 × 1 mL), THF (3 × 500 µL), 
TMOF (3 × 500 µL) then anhydrous THF (3 × 500 µL). The beads were dried under 
high vacuum for 1 h then used directly in the next reaction. 
 
 
O
O
OH
HO
OH
 
(2R*,4S*,5R*,6R*)-2-(2-Hydroxyethyl)-1,7-dioxaspiro[5.5]undecane-4,5-diol (6a).  
DMDO (0.030 M in acetone, 340 µL, 10 µmol, 3.0 equiv) was added to a cooled 
(−78 °C) mixture of resin-bound alcohol 13 (0.32 mequiv/g, 11 mg, 1.0 equiv) and 
anhyd CH2Cl2 (340 µL) in a 4 mL Wheaton vial. The mixture was stirred at –78 °C for 
3 h, then warmed to –63 °C. Anhyd MeOH (450 µL) was added slowly. After stirring 
at –63 °C for 5 h, the reaction mixture was warmed to rt. The solution was removed by 
syringe then the resin was washed with CH2Cl2 (5 × 1 mL). The resin was cleaved by 
treatment with TBAF (1.0 M in THF, 34 µL, 10 equiv) in THF (0.4 mL) at rt for 6 h in 
the presence of a biphenylmethanol internal standard. The solution was removed by 
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syringe then the resin was extracted further with THF (3 × 500 µL). The combined 
organic extracts were evaporated, then the residue was dissolved in 0.2 mL MeOH and 
filtered through a 1-inch plug of normal phase over reverse phase silica gel (4 mL 
MeOH wash) then evaporated, redissolved in 0.2 mL THF, and passed over a second 
1-inch plug of normal phase silica gel (4 mL THF wash). Evaporation of the solvents 
afforded inversion spiroketal 6a ( 90% purity, >90% yield over 4 steps, 78% overall 
yield, 1H-NMR).  
 
 
O
O
OH
HO
OH
 
(2R*,4S*,5R*,6S*)-2-(2-Hydroxyethyl)-1,7-dioxaspiro[5.5]undecane-4,5-diol (7a).  
DMDO (0.030 M in acetone, 330 µL, 9.8 µmol, 3.0 equiv) was added to a cooled           
(–78 °C) mixture of resin-bound alcohol 13 (0.32 mequiv/g, 10.2 mg, 1.0 equiv) and 
anhyd CH2Cl2 (330 µL) in a 4 mL Wheaton vial. The mixture was stirred at –78 °C for 
3 h then warmed to rt. The solution was removed by syringe then additional CH2Cl2 
(0.4 mL) was added. The mixture was cooled (–78 °C) then treated with TsOH 
(0.60 mg, 3.3 µmol, 1.0 equiv). After stirring at –78 °C for 30 min, the mixture was 
warmed to rt and stirred 12 h. The solution was removed and the resin was washed 2 × 
1 mL each with CH2Cl2, DMF, 3:1 THF/i-PrOH, DMF, THF, CH2Cl2, then anhyd 
THF. The resin was cleaved by treatment with TBAF (1.0 M in THF, 33 µL, 10 equiv) 
in THF (0.4 mL) at rt for 6 h in the presence of a biphenylmethanol internal standard. 
The solution was removed by syringe then the resin was extracted further with THF (3 
× 500 µL). The combined organic extracts were evaporated, then the residue was 
dissolved in 0.2 mL MeOH and filtered through a 1-inch plug of normal phase over 
reverse phase silica gel (4 mL MeOH wash) then evaporated, redissolved in 0.2 mL 
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THF, and passed over a second 1-inch plug of normal phase silica gel (4 mL THF 
wash). Evaporation of the solvents afforded retention spiroketal 7a ( 80% purity, 74% 
yield over 4 steps, 58% overall yield, 1H-NMR).  
 
Synthesis of the spiroketal library: 
Spiroketals 4a–g and 5a–g were synthesized and characterized by Justin Potuzak. 
 
General procedure for desilylation: 
The spiroketals 4d–f,h–m and 5a,c–n were synthesized in solution according to the 
procedures in Sections 2.6 and 3.5. These compounds were dissolved in THF (0.1 M) 
then treated with TBAF (1.0 M in THF, 2.6 equiv) at rt. After the reaction was 
complete by TLC, the solvent was evaporated by rotary evaporation. The crude 
material was purified by flash chromatography (elution with 95:5 EtOAc/MeOH) to 
provide spiroketals 6d–f,h–m and 7a,c–n.  
 
The spiroketals 6a–c and 7b were synthesized on solid support as described above. 
Solid phase yields are based on 8. 
 
The enantiomers of spiroketals 6a–f, h–m and 7a–n were synthesized in solution or 
solid phase as indicated.  
 
 
O
OH
HO
OH
O
 
(+)-(2R,4S,5R,6R)-2-(2-Hydroxyethyl)-1,7-dioxaspiro[5.5]undecane-4,5-diol (6a). 
Clear oil (13 mg, 24%). [α ]D
25 : +14° (c 1.3, CDCl3). IR: (NaCl, film): 3385, 2945, 
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2883, 1444, 1359, 1217, 1073, 1048, 1008, 986, 958, 918, 897. 1H-NMR (500 MHz): 
δ 3.94 (m, 1H), 3.91–3.74 (m, 5H), 3.25 (d, 1H, J = 9.6), 2.00 (m, 1H), 1.91–1.78 (m, 
4H), 1.63 (m, 3H), 1.55 (m, 2H). 13C-NMR (125 MHz): δ 99.6, 79.3, 69.0, 68.2, 62.4, 
60.6, 38.7, 37.9, 25.1, 22.5, 17.4. ESI-MS m/z (rel int): pos 255.0 ([M+Na]+, 100);  
neg 230.8 ([M–H]–, 10), 266.9 ([M+Cl]–, 100). 
(–)-Enantiomer: Solid phase, 11 mg, 36%. [α ]D
25 : –16° (c 1.1, CDCl3). 
 
 
O
OH
HO
OH
O
 
(+)-(2R,4S,5R,6R,8R)-2-(2-Hydroxyethyl)-8-methyl-1,7-dioxaspiro[5.5]undecane-
4,5-diol (6b). Clear oil (22 mg, 40%). [α ]D
25 : +42° (c 1.3, CDCl3). IR: (NaCl, film): 
3382, 2929, 2873, 1446, 1373, 1224, 1126, 1060, 1018, 1010, 953. 1H-NMR (500 
MHz): δ 4.09 (m, 1H), 3.86–3.70 (m, 4H), 3.38 (d, 1H, J = 9.5), 2.65 (bs, 2H), 2.18 
(bs. 1H), 1.95–1.71 (m, 7H), 1.68–1.52 (m. 3H), 1.27 (d, 3H, J = 6.6). 13C-NMR (125 
MHz): δ 101.3, 79.5, 69.6, 68.6, 68.5, 60.3, 38.5, 37.9, 29.2, 22.3, 20.8, 13.3. ESI-MS 
m/z (rel int): pos 268.9 ([M+Na]+, 100); neg 245.1 ([M–H]–, 10), 280.9 ([M+Cl]–, 
100). 
(–)-Enantiomer: Solution phase, 12 mg, 84%. [α ]D
25 : –49° (c 1.2, CDCl3). 
 
 
O
OH
HO
OH
O
 
(+)-(2R,4S,5R,6R,8S)-2-(2-Hydroxyethyl)-8-methyl-1,7-dioxaspiro[5.5]undecane-
4,5-diol (6c). Clear oil (14 mg, 24%). [α ]D
25 : +15° (c 1.3, CDCl3). IR: (NaCl, film): 
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3390, 2932, 2872, 1446, 1384, 1372, 1231, 1202, 1132, 1079, 1056, 1006, 951. 
1
H-NMR (500 MHz): δ 4.03 (m, 1H), 3.87–3.71 (m, 4H), 3.26 (d, 1H, J = 9.6), 2.85 
(bs, 2H), 2.35 (bs, 1H), 1.97 (m, 1H), 1.85 (m, 1H), 1.83–1.60 (m, 7H), 1.52 (m, 1H), 
1.16 (d, 3H, J = 6.2). 13C-NMR (125 MHz): δ 100.2, 79.3, 69.1, 68.2, 67.8, 60.6, 38.6, 
37.8, 32.6, 22.0, 21.9, 17.6. ESI-MS m/z (rel int): pos 268.8 ([M+Na]+, 100); neg 
245.2 ([M–H]–, 25), 280.9 ([M+Cl]–, 100). 
(–)-Enantiomer: Solution phase, 24 mg, 100%. [α ]D
25 : –8.4° (c 2.4, CDCl3). 
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OH
HO
O
OH
 
(+)-(5S,7S,9S,10R)-7-(2-Hydroxyethyl)-1,6-dioxaspiro[4.5]decane-9,10-diol (6d). 
Clear oil (15 mg, 100%). [α ]D
25 : +29° (c 1.5, CDCl3). IR: (NaCl, film): 3368, 2918, 
2879, 1363, 1316, 1236, 1173, 1084, 1054, 945, 926, 874, 728. 1H-NMR (500 MHz): 
δ 4.02 (m, 1H), 3.93 (m, 1H), 3.81–3.63 (m, 4H), 3.53 (m, 1H), 2.92 (bs, 2H), 2.28 
(bs, 1H), 2.10–2.02 (m, 2H), 1.99–1.91 (m, 3H), 1.83 (m, 1H), 1.76 (m, 1H), 1.52 (m, 
1H). 13C-NMR (125 MHz): δ 109.5, 76.2, 69.9, 69.7, 68.3, 60.5, 38.4, 37.5, 26.8, 
24.8. ESI-MS m/z (rel int): pos 241.0 ([M+Na]+, 100); neg 216.8 ([M–H]–, 10), 252.8 
([M+Cl]–, 100). 
(–)-Enantiomer: Solid phase, 18 mg, 57%. [α ]D
25 : –30° (c 1.4, CDCl3). 
 
 
O
OH
HO
O
OH
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(+)-(2S,5R,7S,9S,10R)-7-(2-Hydroxyethyl)-2-methyl-1,6-dioxaspiro[4.5]decane-
9,10-diol (6e). Clear oil (13 mg, 97%). [α ]D
25 : +29° (c 1.3, CDCl3). IR: (NaCl, film): 
3394, 2966, 2920, 2878, 1442, 1377, 1317, 1212, 1176, 1087, 1060, 888, 955, 944, 
895. 1H-NMR (500 MHz): δ 4.23 (m, 1H), 3.82–3.69 (m, 3H), 3.64 (m, 1H), 3.51 (d, 
1H, J = 9.7), 2.93 (bs, 2H), 2.38 (bs, 1H), 2.09 (m, 2H), 2.02–1.94 (m, 2H), 1.85 (m, 
1H), 1.75 (m, 1H), 1.66 (m, 1H), 1.53 (m, 1H), 1.32 (d, 3H, J = 6.2). 13C-NMR (125 
MHz): δ 109.5, 77.5, 76.3, 70.1, 69.7, 60.7, 38.5, 37.5, 31.8, 26.7, 22.6. ESI-MS m/z 
(rel int): pos 254.7 ([M+Na]+, 100); neg 231.2 ([M–H]–, 20), 266.9 ([M+Cl]–, 100). 
(–)-Enantiomer: Solution phase, 16 mg, 87%. [α ]D
25 : –28° (c 1.6, CDCl3). 
 
 
O
OH
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(+)-(2S,5R,7S,9S,10S)-7-(2-Hydroxyethyl)-2-methyl-1,6-dioxaspiro[4.5]decane-
9,10-diol (6f). Clear oil (18 mg, 100%). [α ]D
25 : +37° (c 1.8, CDCl3). IR: (NaCl, film): 
3390, 2966, 2928, 2878, 1446, 1384, 1305, 1246, 1196, 1069, 1012, 957. 1H-NMR 
(500 MHz): δ 4.32 (m, 1H), 3.75 (m, 2H), 3.65 (m, 2H), 3.45 (d, 1H, J = 9.6), 3.20–
2.90 (bm, 2H), 2.40 (bs, 1H), 2.19 (m, 1H), 2.12 (m, 1H), 1.96 (m, 1H), 1.84 (m, 2H), 
1.75 (m, 1H), 1.52 (m, 2H), 1.26 (d, 3H, J = 6.1). 13C-NMR (125 MHz): δ 109.6, 
76.2, 75.3, 69.8, 69.2, 60.4, 38.4, 37.5, 32.7, 28.0, 20.5. ESI-MS m/z (rel int): pos 
254.7 ([M+Na]+, 100); neg 231.2 ([M–H]–, 20), 266.9 ([M+Cl]–, 100). 
(–)-Enantiomer: Solution phase, 24 mg, 100%. [α ]D
25 : –45° (c 2.4, CDCl3). 
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(+)-(2R,4R,5S,6S)-2-(2-Hydroxyethyl)-1,7-dioxaspiro[5.5]undecane-4,5-diol (6h). 
White solid (14 mg, 74%). TLC: Rf 0.45 (9:1 CH2Cl2/MeOH). [α ]D
25 : +77° (c 0.70, 
CHCl3). IR: (NaCl, film): 3406, 2940, 1441, 1270, 1996, 1085, 1055, 1002, 945, 889, 
732. 1H-NMR (400 MHz): δ 4.14 (m, 1H), 3.99 (d, 1H, J = 10.6), 3.91–3.82 (m, 3H), 
3.72 (m, 2H), 3.45 (dd, 1H, J = 8.3, 2.8), 2.29 (t, 1H, J = 5.3), 1.91–1.71 (m, 5H), 
1.69–1.56 (m, 5H), 1.47 (m, 1H). 13C-NMR (125 MHz): δ 99.0, 69.9, 69.1, 64.6, 61.3, 
61.0, 37.6, 33.3, 31.5, 24.6, 17.9. ESI-MS m/z (rel int): pos 255.2 ([M+Na]+, 100), 
487.2 ([2M+Na]+, 40); neg 230.9 ([M–H]–, 40), 267.1 ([M+Cl]–, 100). 
(–)-Enantiomer: Solution phase, 25 mg, 84%. [α ]D
25 : –78° (c 1.2, CHCl3). 
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(+)-(2R,4R,5S,6S,8R)-2-(2-Hydroxyethyl)-8-methyl-1,7-dioxaspiro[5.5]undecane-
4,5-diol (6i). White solid (31 mg, 88%). TLC: Rf 0.32 (9:1 CH2Cl2/MeOH). [α ]D
25 : 
+67° (c 0.61, CHCl3). IR: (NaCl, film): 3400, 2934, 1438, 1386, 1229, 1195, 1072, 
992, 887, 729. 1H-NMR (500 MHz): δ 4.16 (d, 1H, J = 10.5), 4.12 (m, 1H), 3.92 (m, 
1H), 3.83 (m, 3H), 3.46 (dd, 1H, J = 8.4, 3.1), 2.40 (m, 1H), 1.90–1.80 (m, 4H), 1.78–
1.61 (m, 5H), 1.42 (m, 1H), 1.28 (m, 1H), 1.19 (d, 3H, J = 6.2). 13C-NMR (125 MHz): 
δ 99.8, 69.9, 69.3, 67.2, 64.5, 61.1, 37.5, 33.4, 32.0, 30.9, 21.6, 18.4. ESI-MS m/z (rel 
int): pos 269.2 ([M+Na]+, 100); neg 245.2 ([M–H]–, 100), 280.9 ([M+Cl]–, 90). 
(–)-Enantiomer: Solution phase, 56 mg, 94%. [α ]D
25 : –66° (c 1.1, CHCl3). 
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(+)-(2R,4R,5S,6S,8S)-2-(2-Hydroxyethyl)-8-methyl-1,7-dioxaspiro[5.5]undecane-
4,5-diol (6j). Clear oil (11 mg, 83%). TLC: Rf 0.33 (9:1 CH2Cl2/MeOH). [α ]D
25 : +48° 
(c 0.56, CHCl3). IR: (NaCl, film): 3400, 2934, 1441, 1382, 1205, 1180, 1065, 995, 
880. 1H-NMR (400 MHz): δ 4.45 (m, 1H), 4.02–3.90 (m, 3H), 3.81 (m, 2H), 3.70 (dd, 
1H, J = 8.8, 2.7), 2.41 (m, 1H), 1.89–1.58 (m, 10H), 1.45 (m, 1H), 1.29 (d, 3H, J = 
6.4). 13C-NMR (125 MHz): δ 100.1, 70.5, 69.1, 66.3, 64.9, 60.9, 37.7, 33.1, 31.0, 
30.6, 21.5, 16.3. ESI-MS m/z (rel int): pos 269.2 ([M+Na]+, 100), 515.4 ([2M+Na]+, 
75); neg 245.0 ([M–H]–, 100), 281.1 ([M+Cl]–, 10). 
(–)-Enantiomer: Solution phase, 18 mg, 88%. [α ]D
25 : –48° (c 0.91, CHCl3). 
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(+)-(5S,7R,9R,10S)-7-(2-Hydroxyethyl)-1,6-dioxaspiro[4.5]decane-9,10-diol (6k). 
White solid (19 mg, 75%). TLC: Rf  0.25 (9:1 CH2Cl2/MeOH). [α ]D
25 : +86° (c 0.93, 
CHCl3). IR: (NaCl, film): 3362, 2944, 2888, 1418, 1061, 1000, 862. 
1
H-NMR (500 
MHz): δ 4.27 (m, 1H), 4.05 (m, 2H), 3.94 (m, 1H), 3.78 (m, 3H), 3.51 (dd, 1H, J = 
8.1, 2.8), 2.37 (t, 1H, J = 4.9), 2.16 (d, 1H, J = 8.5), 2.08–1.92 (m, 4H), 1.85–1.81 (m, 
2H), 1.72–1.64 (m, 2H). 13C-NMR (125 MHz): δ 108.0, 70.0, 69.2, 68.9, 65.7, 61.3, 
37.4, 36.2, 33.3, 22.6. ESI-MS m/z (rel int): pos 241.1 ([M+Na]+, 100); neg 217.0 
([M–H]–, 100), 253.0 ([M+Cl]–, 70). 
(–)-Enantiomer: Solution phase, 17 mg, 73%. [α ]D
25 : –86° (c 0.84, CHCl3). 
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(+)-(2R,5S,7R,9R,10S)-7-(2-Hydroxyethyl)-2-methyl-1,6-dioxaspiro[4.5]decane-
9,10-diol (6l). Clear oil (24 mg, 89%). TLC: Rf  0.34 (9:1 CH2Cl2/MeOH). [α ]D
25 : 
+83° (c 1.2, CHCl3). IR: (NaCl, film): 3388, 2928, 1441, 1412, 1384, 1226, 1177, 
1062, 1005, 873. 1H-NMR (500 MHz): δ 4.38 (sx, 1H, J = 6.4), 4.29 (m, 1H), 3.94 
(m, 1H), 3.82 (d, 1H, J = 10.8), 3.78 (m, 2H), 2.52 (dd, 1H, J = 8.9, 3.2), 2.34 (m, 1H), 
2.11 (m, 2H), 1.98 (m, 2H), 1.82 (m, 2H), 1.72–1.61 (m, 2H), 1.51 (m, 1H), 1.27 (d, 
3H, J = 6.2). 13C-NMR (125 MHz): δ 108.1, 76.9, 70.2, 68.9, 65.8, 61.4, 37.4, 35.9, 
33.3, 30.0, 21.1. ESI-MS m/z (rel int): pos 255.1 ([M+Na]+, 100); neg 231.1 ([M–H]–, 
10), 266.9 ([M+Cl]–, 100). 
(–)-Enantiomer: Solution phase, 22 mg, 90%. [α ]D
25 : –84° (c 1.1, CHCl3). 
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(+)-(2S,5S,7R,9R,10S)-7-(2-Hydroxyethyl)-2-methyl-1,6-dioxaspiro[4.5]decane-
9,10-diol (6m). White solid (22 mg, 88%). TLC: Rf  0.21 (9:1 CH2Cl2/MeOH). [α ]D
25 : 
+83° (c 1.1, CHCl3). IR: (NaCl, film): 3470, 3308, 2972, 2949, 2914, 1435, 1411, 
1236, 1098, 1068, 996, 864. 1H-NMR (400 MHz): δ 4.36 (m, 2H), 3.92 (m, 2H), 3.79 
(m, 2H), 3.48 (dd, 1H, J = 8.7, 2.6), 2.46 (m, 1H), 2.21 (d, 1H, J = 8.7), 2.13 (m, 1H), 
2.05 (m, 1H), 1.94 (m, 1H), 1.82 (m, 2H), 1.71–1.58 (m, 3H), 1.36 (d, 3H, J = 6.2). 
13
C-NMR (125 MHz): δ 107.9, 79.5, 70.3, 69.0, 65.6, 61.4, 37.7, 37.5, 33.5, 30.7, 
22.6. ESI-MS m/z (rel int): pos 255.2 ([M+Na]+, 100); neg 231.2 ([M–H]–, 100), 
267.0 ([M+Cl]–, 20). 
(–)-Enantiomer: Solution phase, 9.0 mg, 88%. [α ]D
25 : –83° (c 0.45, CHCl3). 
 
 
  134 
O
OH
HO
OH
O
 
(+)-(2R,4S,5R,6S)-2-(2-Hydroxyethyl)-1,7-dioxaspiro[5.5]undecane-4,5-diol (7a). 
Clear oil (21 mg, 94%). [α ]D
25 : +77° (c 2.1, CDCl3). IR: (NaCl, film): 3363, 2939, 
2871, 1441, 1386, 1222, 1177, 1090, 1049, 988, 956, 920. 1H-NMR (500 MHz): 
δ 3.93 (m, 1H), 3.84 (m, 3H), 3.70 (m, 1H), 3.02 (m, 1H), 2.46 (bs, 1H), 2.05–1.96 (m, 
1H), 1.88–1.65 (m, 5H), 1.61–1.47 (m, 4H). 13C-NMR (125 MHz): δ 98.0, 78.1, 69.3, 
67.7, 61.1, 61.0, 38.4, 37.3, 30.4, 24.7, 18.4. ESI-MS m/z (rel int): pos 255.1 
([M+Na]+, 100); neg 230.9 ([M–H]–, 20), 266.9 ([M+Cl]–, 100). 
(–)-Enantiomer: Solid phase, 20 mg, 64%. [α ]D
25 : –81° (c 1.5, CDCl3). 
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(+)-(2R,4S,5R,6S,8R)-2-(2-Hydroxyethyl)-8-methyl-1,7-dioxaspiro[5.5]undecane-
4,5-diol (7b). Clear oil (38 mg, 69%). [α ]D
25 : +61° (c 4.5, CDCl3). IR: (NaCl, film): 
3352, 2935, 2871, 1444, 1385, 1230, 1134, 1090, 1056, 1002, 964, 919. 1H-NMR 
(500 MHz): δ 3.89 (m, 2H), 3.79 (m, 3H), 3.02 (m, 1H), 2.60 (bs, 1H), 2.50 (bs, 1H), 
2.08–1.90 (m, 3H), 1.82–1.60 (m, 7H), 1.48 (m, 1H), 1.14 (d, 3H, J = 6.2). 13C-NMR 
(125 MHz): δ 98.6, 78.0, 69.5, 67.8, 66.5, 61.1, 38.4, 37.3, 32.2, 29.8, 21.7, 18.7. 
ESI-MS m/z (rel int): pos 269.0 ([M+Na]+, 100); neg 245 ([M–H]–, 10), 281.0 
([M+Cl]–, 100). 
(–)-Enantiomer: Solution phase, 17 mg, 92%. [α ]D
25 : –82° (c 1.7, CDCl3). 
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(+)-(2R,4S,5R,6S,8S)-2-(2-Hydroxyethyl)-8-methyl-1,7-dioxaspiro[5.5]undecane-
4,5-diol (7c). Clear oil (26 mg, 90%). [α ]D
25 : +49° (c 2.6, CDCl3). IR: (NaCl, film): 
3369, 2943, 1444, 1392, 1225, 1132, 1087, 1060, 1006, 968, 923. 1H-NMR (500 
MHz): δ 4.13 (m, 2H), 3.81 (m, 3H), 2.97 (bm, 1H), 2.68 (bs, 1H), 2.49 (bs, 1H), 2.05 
(m, 2H), 1.96 (m, 1H), 1.86 (m, 1H), 1.80–1.71 (m, 3H), 1.62–1.53 (m, 3H), 1.48 (m, 
1H), 1.35 (d, 1H, J = 6.8). 13C-NMR (125 MHz): δ 98.9, 78.4, 69.7, 69.1, 68.0, 60.7, 
38.3, 37.4, 30.1, 29.0, 21.1, 13.5. ESI-MS m/z (rel int): pos 247.0 ([M+H]+, 20), 269.1 
([M+Na]+, 100); neg 245.0 ([M–H]–, 10), 281.1 ([M+Cl]–, 100). 
(–)-Enantiomer: Solution phase, 22 mg, 96%. [α ]D
25 : –46° (c 2.2, CDCl3). 
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(+)-(5R,7S,9S,10R)-7-(2-Hydroxyethyl)-1,6-dioxaspiro[4.5]decane-9,10-diol (7d). 
Clear oil (16 mg, 47%). [α ]D
25 : +80° (c 1.6, CHCl3). IR: (NaCl, film): 3368, 2946, 
2883, 1441, 1391, 1192, 1163, 1086, 1006, 979, 921, 731. 1H-NMR (500 MHz): 
δ 4.00 (m, 3H), 3.81 (m, 1H), 3.75 (m, 2H), 3.36 (m, 1H), 2.70 (bs, 1H), 2.43 (bs, 1H), 
2.34 (m, 1H), 2.05–1.96 (m, 3H), 1.94–1.85 (m, 2H), 1.82–1.70 (m, 2H), 1.49 (m, 
1H). 13C-NMR (125 MHz): δ 107.7, 75.2, 70.6, 68.8, 68.6, 61.3, 38.4, 37.1, 34.0, 
23.9. ESI-MS m/z (rel int): pos 241.1 ([M+Na]+, 100); neg 252.9 ([M+Cl]–, 100). 
(–)-Enantiomer: Solid phase, 13 mg, 64%. [α ]D
25 : –86° (c 1.3, CDCl3). 
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(+)-(2S,5S,7S,9S,10R)-7-(2-Hydroxyethyl)-2-methyl-1,6-dioxaspiro[4.5]decane-
9,10-diol (7e). White solid (14 mg, 94%). [α ]D
25 : +88° (c 1.4, CDCl3). IR: (NaCl, 
film): 3356, 2948, 2883, 1444, 1384, 1202, 1161, 1080, 1058, 1010, 925, 883. 
1
H-NMR (500 MHz): δ 4.27 (m, 1H), 4.03 (m, 1H), 3.76 (m, 3H), 3.30 (m, 1H), 2.59 
(bs, 1H), 2.42 (m, 1H), 2.30 (m, 1H), 2.12 (m, 1H), 1.96 (m, 1H), 1.88–1.68 (m, 4H), 
1.48 (m, 2H), 1.26 (d, 3H, J = 6.1). 13C-NMR (125 MHz): δ 108.3, 76.0, 75.7, 71.0, 
69.3, 61.7, 38.7, 37.5, 34.8, 31.9, 21.2. ESI-MS m/z (rel int): pos 255.0 ([M+Na]+, 
100); neg 231.1 ([M–H]–, 30), 266.9 ([M+Cl]–, 100). 
(–)-Enantiomer: Solution phase, 12 mg, 97%. [α ]D
25 : –86° (c 1.2, CDCl3). 
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(+)-(2S,5S,7S,9S,10S)-7-(2-Hydroxyethyl)-2-methyl-1,6-dioxaspiro[4.5]decane-
9,10-diol (7f). Clear oil (10 mg, 94%). [α ]D
25 : +94° (c 1.0, CDCl3). IR: (NaCl, film): 
3354, 2966, 2945, 1445, 1378, 1331, 1207, 1169, 1086, 1048, 979, 924, 881, 730. 
1
H-NMR (500 MHz): δ 4.31 (m, 1H), 4.07 (m, 1H), 3.78 (m, 3H), 3.28 (m, 1H), 2.60 
(bs, 1H), 2.45 (bs, 1H), 2.29 (m, 1H), 2.08 (m, 1H), 1.96 (m, 1H), 1.89 (m, 2H), 1.80–
1.69 (m, 3H), 1.48 (m, 1H), 1.33 (d, 3H, J = 6.2). 13C-NMR (125 MHz): δ 108.2, 
79.3, 75.6, 71.1, 68.8, 61.7, 38.9, 37.6, 35.2, 32.0, 23.4. ESI-MS m/z (rel int): pos 
254.9 ([M+Na]+, 100); neg 267.1 ([M+Cl]–, 100). 
(–)-Enantiomer: Solution phase, 12 mg, 86%. [α ]D
25 : –99° (c 1.2, CDCl3). 
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(–)-(2R,4R,5S,6R)-2-(2-Hydroxyethyl)-1,7-dioxaspiro[5.5]undecane-4,5-diol (7h). 
Clear oil (21 mg, 82%). TLC: Rf  0.22 (9:1 CH2Cl2/MeOH). [α ]D
25 : –24° (c 1.0, 
CHCl3). IR: (NaCl, film): 3388, 2940, 2882, 1441, 1381, 1221, 1078, 1050, 1001, 
920, 731. 1H-NMR (500 MHz): δ 4.12 (m, 1H), 4.05 (m, 1H), 3.89 (td, 1H, J = 11.4, 
3.5), 3.81 (m, 2H), 3.71 (m, 1H), 3.23 (t, 1H, J = 5.9), 2.63 (d, 1H, J = 6.1), 2.26 (bs, 
1H), 2.02 (m, 4H), 1.83 (m, 1H), 1.72–1.53 (m, 6H). 13C-NMR (125 MHz): δ 97.9, 
75.6, 69.0, 67.1, 61.9, 60.9, 37.7, 34.5, 30.5, 25.1, 18.1. ESI-MS m/z (rel int): pos 
255.1 ([M+Na]+, 100), 487.1 ([2M+Na]+, 80); neg 231.0 ([M–H]–, 10), 267.0 
([M+Cl]–, 100). 
(+)-Enantiomer: Solution phase, 26 mg, 99%. [α ]D
25 : +26° (c 1.3, CHCl3). 
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(+)-(2R,4R,5S,6R,8R)-2-(2-Hydroxyethyl)-8-methyl-1,7-dioxaspiro[5.5]undecane-
4,5-diol (7i). Clear oil (31 mg, 86%). TLC: Rf  0.26 (9:1 CH2Cl2/MeOH). [α ]D
25 : +48° 
(c 1.6, CHCl3). IR: (NaCl, film): 3410, 2933, 1445, 1383, 1220, 1044, 1006, 924, 731. 
1
H-NMR (500 MHz): δ 4.19 (m, 2H), 3.80 (m, 3H), 3.72 (bs, 1H), 2.85 (d, 1H, J = 
2.0), 2.56 (m, 1H), 2.44 (bs, 1H), 2.36 (bs, 1H), 1.98–1.81 (m, 3H), 1.71–1.49 (m, 
5H), 1.37 (m, 1H), 1.24 (d, 3H, J = 6.2). 13C-NMR (125 MHz): δ 99.0, 69.7, 68.1, 
67.1, 66.9, 60.4, 37.9, 33.4, 31.4, 29.8, 22.2, 19.4. ESI-MS m/z (rel int): pos 269.2 
([M+Na]+, 100), 515.3 ([2M+Na]+, 70); neg 245.0 ([M–H]–, 25), 281.0 ([M+Cl]–, 
100). 
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(–)-Enantiomer: Solution phase, 25 mg, 81%. [α ]D
25 : –47° (c 1.2, CHCl3). 
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(–)-(2R,4R,5S,6R,8S)-2-(2-Hydroxyethyl)-8-methyl-1,7-dioxaspiro[5.5]undecane-
4,5-diol (7j). White solid (17 mg, 82%). TLC: Rf  0.30 (9:1 CH2Cl2/MeOH). [α ]D
25 : –
18° (c 0.84, CHCl3). IR: (NaCl, film): 3381, 2933, 1445, 1384, 1228, 1195, 1056, 
1002, 965, 916. 1H-NMR (400 MHz): δ 4.11 (m, 2H), 3.98 (m, 1H), 3.79 (m, 2H), 
3.22 (t, 1H, J = 6.2), 2.68 (d, 1H, J = 6.2), 2.18 (d, 1H, J = 2.3), 2.02–1.95 (m, 4H), 
1.82–1.53 (m, 6H), 1.18 (m, 1H), 1.13 (d, 3H, J = 6.2). 13C-NMR (125 MHz): δ 98.4, 
75.4, 69.0, 67.4, 67.2, 61.0, 37.5, 34.4, 32.6, 29.8, 21.8, 18.4. ESI-MS m/z (rel int): 
pos 269.2 ([M+Na]+, 100), 515.3 ([2M+Na]+, 90); neg 245.1 ([M–H]–, 40), 491.1 
([2M–H]–, 100). 
(+)-Enantiomer: Solution phase, 27 mg, 95%. [α ]D
25 : +19° (c 0.53, CHCl3). 
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(–)-(5R,7R,9R,10S)-7-(2-Hydroxyethyl)-1,6-dioxaspiro[4.5]decane-9,10-diol (7k). 
Clear oil (22 mg, 64%). TLC: Rf  0.17 (9:1 CH2Cl2/MeOH). [α ]D
25 : –27° (c 1.1, 
CHCl3). IR: (NaCl, film): 3371, 2932, 2883, 1439, 1379, 1188, 1161, 1067, 1002, 
922, 861, 776, 729. 1H-NMR (500 MHz): δ 4.13 (m, 1H), 4.03 (m, 2H), 3.90 (m, 1H), 
3.76 (m, 2H), 3.42 (t, 1H, J = 7.0), 2.54 (bs, 1H), 2.33 (d, 1H, J = 7.5), 2.14–1.98 (m, 
6H), 1.91 (m, 1H), 1.78 (m, 1H), 1.68 (m, 1H). 13C-NMR (125 MHz): δ 108.4,74.8, 
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70.2, 68.8, 67.5, 60.8, 37.6, 35.1, 34.5, 24.5. ESI-MS m/z (rel int): pos 219.2 
([M+H]+, 10), 241.1 ([M+Na]+, 100); neg 217.0 ([M–H]–, 100), 253.0 ([M+Cl]–, 100). 
(+)-Enantiomer: Solution phase, 18 mg, 73%. [α ]D
25 : +28° (c 0.88, CHCl3). 
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(–)-(2R,5R,7R,9R,10S)-7-(2-Hydroxyethyl)-2-methyl-1,6-dioxaspiro[4.5]decane-
9,10-diol (7l). Clear oil (17 mg, 75%). TLC: Rf  0.23 (9:1 CH2Cl2/MeOH). [α ]D
25 :       
–22° (c 0.83, CHCl3). IR: (NaCl, film): 3381, 2967, 2930, 1446, 1380, 1208, 1176, 
1097, 1063, 1001, 927, 879, 819, 731. 1H-NMR (500 MHz): δ 4.14 (m, 2H), 4.04 (m, 
1H), 3.79 (m, 2H), 3.39 (d, 1H, J = 6.5), 2.19 (m, 3H), 2.13–1.96 (m, 5H), 1.75–1.66 
(m, 3H), 1.33 (d, 3H, J = 6.2). 13C-NMR (125 MHz): δ 107.9, 78.3, 74.5, 69.9, 67.8, 
61.0, 37.6, 34.8, 34.5, 32.3, 22.0. ESI-MS m/z (rel int): pos 255.0 ([M+Na]+, 100); 
neg 230.9 ([M–H]–, 40), 266.9 ([M+Cl]–, 100). 
(+)-Enantiomer: Solution phase, 17 mg, 87%. [α ]D
25 : +21° (c 0.84, CHCl3). 
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(–)-(2S,5R,7R,9R,10S)-7-(2-Hydroxyethyl)-2-methyl-1,6-dioxaspiro[4.5]decane-
9,10-diol (7m). Clear oil (12 mg, 76%). TLC: Rf  0.26 (9:1 CH2Cl2/MeOH). [α ]D
25 :     
–18° (c 0.59, CHCl3). IR: (NaCl, film): 3365, 2929, 2359, 1456, 1199, 1069, 1007, 
926, 879. 1H-NMR (400 MHz): δ 4.33 (m, 1H), 4.14 (m, 1H), 3.99 (m, 1H), 3.76 (m, 
2H), 3.35 (t, 1H, J = 7.9), 2.30–2.11 (m, 5H), 2.00 (m, 2H), 1.84–1.62 (m, 3H), 1.46 
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(m, 1H), 1.21 (d, 3H, J = 6.2). 13C-NMR (125 MHz): δ 108.5, 75.7, 74.9, 70.2, 67.6, 
60.9, 37.6, 35.0, 34.8, 32.0, 21.1. ESI-MS m/z (rel int): pos 255.2 ([M+Na]+, 100), 
487.3 ([2M+Na]+, 20); neg 231.0 ([M–H]–, 70), 463.2 ([2M–H]–, 100). 
(+)-Enantiomer: Solution phase, 9.8 mg, 82%. [α ]D
25 : +18° (c 0.45, CHCl3). 
 
Cytotoxicity assays: 
Stock solutions (10, 5, 1, or 0.25 mM) of 52 spiroketals (6a–f,h–m and 7a–n plus 
enantiomers) were prepared in DMSO then used in the following assays.  
 
Assay for cytotoxicity in yeast: 
Yeast (Y384 strain) was grown at 30 °C in rich media to an OD value of 0.05 then 
transferred to 384 well plates (40 µL culture per well). Aliquots (100 nL) of spiroketal 
stock solutions or DMSO were transferred to individual wells using an automated pin-
transfer system. Cycloheximide (500 nL, 0.35 M in DMSO) was added manually to 
control wells. The plates were agitated at ambient temperature for 24 h prior to OD 
measurement in a plate reader set to 590 nm. 
 
Assay for cytotoxicity in HeLa cells: 
HeLa cells were grown to confluence in DMEM media then transferred to 384 well 
plates (15 µL culture per well). Aliquots (100 nL) of spiroketal stock solutions or 
DMSO were transferred to individual wells using an automated pin-transfer system. 
Staurosporine (500 nL, 0.5 mM in DMSO) was added manually to control wells. The 
plates were incubated at 37 °C for 24 h then treated with Alamar Blue (5 µL per well 
of a 1:1 solution of Alamar Blue in media). The plates were incubated at 37 °C for an 
additional 24 h prior to fluorescence measurement. 
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CHAPTER 5 
FURTHER DIVERSIFICATION OF THE SPIROKETAL LIBRARY 
 
5.1. Introduction 
Following the synthesis of our primary library (1), methods to expand upon the 
diversity and utility of the library were explored. We envisioned further diversification 
through modification of the C2-hydroxyl (2). Increased diversity and utility could also 
be achieved by incorporating an azide functionality on either ring of the spiroketals (3 
or 5). The azide would provide a handle enabling simple and versatile coupling of 
other small molecules, including reporter tags or biasing elements. 
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Figure 5.1. Expansion of the diversity and utility of the spiroketal library 
 
5.2. Derivatization of the C2-hydroxyl 
In anticipation of future library expansion, we wanted to determine if the 
spiroketal end products can be diversified further through derivatization of the 
C2-hydroxyl (Figure 5.2). In addition to increasing the diversity of our library, 
modifications such as acylation and deoxygenation may also increase cell 
permeability. It was demonstrated that acylation (9), deoxygenation (8), and oxidation 
(11) are all possible in the erythro-series of spiroketals. Oxidation has also been 
successfully followed by hydride reduction, resulting in an equatorially-oriented 
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hydroxyl (12). This sequence provides access to the stereochemical configuration that 
would arise from a syn-epoxidation reaction, thereby increasing the stereochemical 
diversity of the library. Unfortunately, Justin Potuzak found that analogous C2-
hydroxyl acylation reactions are not possible in the threo-spiroketal series, likely due 
to syn-pentane-like interactions with the C3-substituent.  
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Figure 5.2. Derivatization of C2-hydroxyl groups of erythro-series spiroketals.                              
R = (CH2)2OTBDPS 
 
5.3. Incorporation of Azide Tags 
It may be useful to incorporate biasing elements into future libraries to target 
individual proteins for which some structural or mechanistic information is available. 
Due to the array of reactions that are available using azides, we recognized that azide 
functionalization of the spiroketals (3 or 5) would provide a handle enabling simple 
and versatile coupling of other small molecules and also provide a means for further 
diversification and addition of complexity. For example, reduction to the amine 13 
using a polymer-supported triaryl phosphine would enable coupling of various biasing 
elements (e.g. 16) or complex small molecules (e.g. 17 or 18) using standard amide 
bond forming conditions. Direct coupling of the azide with a thioacid to form an 
amide bond1 (e.g. 20) is another possibility. Azide labels would also permit the 
coupling of a variety of reporter tags to the library compounds either before or after 
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biological screening2-4 in aqueous media. Potential methods for generating tagged 
compounds via an azide include Staudinger ligation with an intramolecular 
phosphine3,5 (19), Cu(I)-catalyzed Huisgen cycloaddition with an alkyne6 (14), or 
strain-promoted [3+2] cycloaddition with a cyclooctyne7 (15).   
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Figure 5.3. Diversification and tagging of azide-labeled library members (*site of 
stereochemical diversity). SK = boxed portion of spiroketal 3 or 5 
 
One potential location for an azide tag is on the second ring of the spiroketals 
(5). The optimized B-alkyl Suzuki conditions that Justin Potuzak developed allow 
coupling of chloromethyl-substituted sidechains to the glycals (Figure 2.12). After 
displacement of the chloride by azide, Justin found that the substrate can be 
deacetylated (22o–r) and epoxidized using the same conditions as our other substrates 
(Figure 5.4). We then evaluated our kinetic spirocyclization reactions in the 
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production of azidomethyl-functionalized spiroketals with inversion (23o–r) or 
retention (24o–r) of configuration. 
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Figure 5.4. Synthesis of azidomethyl-functionalized spiroketals 23 and 24 
 
While our Ti(Oi-Pr)4-promoted spirocyclization with retention of configuration 
was effective with these substrates, achieving inversion of configuration was more 
problematic (Figure 5.5).  
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Figure 5.5. MeOH- or Ti(Oi-Pr)4-induced spirocyclization with inversion or retention 
of configuration at C1. Isolated yields of the major products are shown in parentheses.  
a Inseparable mixture of spiroketals 23 and 24; b Remainder is the corresponding 
methyl glycoside. R = (CH2)2OTBDPS 
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MeOH-promoted spirocyclization was complicated by competing formation of 
the retention products (24o–r) for all substrates. In addition, epoxidation of substrates 
22o and 22p followed by treatment with MeOH resulted in the formation of significant 
amounts of methyl glycoside. Since separation of the spiroketal mixtures is not always 
possible, alternate conditions that selectively form these azidomethyl-substituted 
inversion spiroketals would be useful. 
We also expected that the desilylated spiroketals could be derivatized at the 
C7-position through selective modification of the primary alcohol (1 3, R1=R2=H; 
Figure 5.1). The possibility of incorporating an azide functionality at this position was 
explored. Since these tags would be added after synthesis and purification of the 
library members, an efficient and simple route leading to highly pure final compounds 
was required. Therefore, initial attempts were focused on one-step approaches to 
synthesize the azide (26) from the primary alcohol in spiroketal 25. Although several 
methods have been developed to directly replace primary hydroxyl groups by azide, 
none of the conditions tested were effective for the spiroketal substrate 25. Conditions 
for Mitsunobu-type azide substitution using PPh3/DIAD/DPPA
8 resulted in low 
conversion, while only starting material was recovered after treatment with 
PPh3/CBr4/NaN3
9 or PPh3/DDQ/n-Bu4NN3.
10 Another related method using 
p-NO2DPPA in the presence of DBU
11 produced the phosphate intermediate 
regioselectively, but the majority of this intermediate did not undergo displacement by 
the azide anion and was isolated after workup.  
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Figure 5.6. Selective conversion of primary alcohol in spiroketal 25 to azide in 26  
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Standard protocols involving sulfonylation followed by displacement with 
azide anion were also evaluated. A range of sulfonating agents was tested, including 
tosyl chloride, N-methyltosylimidazolium triflate,12 mesitylenesulfonyl chloride, and 
2,4,6-triisopropylbenzenesulfonyl chloride. Although the more hindered reagents did 
provide satisfactory regioselectivity, these reactions were difficult to drive to 
completion, requiring extended reaction times and large excesses of reagent. 
Interestingly, treatment of bis-tosylated products with Bu4NN3 provided only primary 
azide product, while the secondary tosylate did not react. This tendency could 
potentially be exploited through use of a sulfonyl chloride resin13 to form a polymer-
bound sulfonate. Treatment with azide ion may then cause selective release of the 
primary azide product from the resin. However, this possibility was not explored. 
Activation of the C7 position with halides was also investigated. It has been 
shown that primary alcohols can be selectively replaced by chloride in the presence of 
PPh3 and CCl4,
14 however, treatment of the spiroketal substrate with these conditions 
resulted in no reaction. Conversely, similar conditions involving nucleophilic 
displacement of a phosphonium by iodide anion (PPh3/I2/imidazole)
15,16 were very 
effective, resulting in complete and regioselective conversion to the C7-iodide (28). 
Since removal of the triphenylphosphine oxide byproduct was difficult, the possibility 
of using polymer-supported or fluorous triphenylphosphine was explored. Reactions 
run in the presence of polymer-supported triphenylphosphine17 were regioselective, 
but large excesses of all reagents were required to drive the reaction to completion. 
Fortunately, replacement of triphenylphosphine with the analogous fluorous reagent18 
27 did not compromise the regioselectivity or efficiency of the reaction, and all of the 
byproducts and excess reagents were readily removed by filtration through fluorous 
silica.19  
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Figure 5.7. Incorporation of azide handle via alkyl iodide 
 
Although treatment of the iodide 28 with a large excess of NaN3 at high 
temperature resulted in successful conversion to the azide (26), efficient and complete 
removal of the excess reagent and NaI byproduct was not feasible without an aqueous 
workup. Azide formation using tetrabutylammonium azide also proceeded smoothly, 
but complete removal of the tetrabutylammonium iodide byproduct was difficult 
without chromatography. Fortunately, the azide also formed readily when the iodide 
was exposed to polymer-supported tetraalkylammonium azide20 29, and the product 
was easily purified through filtration of the reaction mixture.  
Once these reaction conditions were developed, sequential execution of the 
two steps was attempted in one pot. Initial efforts using THF as the solvent resulted in 
efficient formation of the iodide, but no conversion to the azide. Interestingly, when 
the THF was evaporated after the iodination and the crude iodide was redissolved in 
CH3CN, the azidation proceeded as usual. Fortunately, the iodination conditions were 
also effective in CH3CN, allowing the two-step sequence to be completed in one pot. 
After azidation, direct filtration of the reaction mixture through fluorous silica resulted 
in reasonable yield of a highly pure azide product. Preliminary results suggest that this 
reaction sequence may also be effective for converting primary hydroxyl groups to 
azides in other small molecule libraries.  
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5.4. Experimental Section 
Materials and Methods: 
See Section 2.6. Compounds not cited in the previous sections of this chapter 
are numbered herein E1o–r. 
 
Derivatization of the C2-hydroxyl: 
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(2R,4R,5S,6S)-2-[2-(tert-Butyldiphenylsilyloxy)-ethyl]-4-(triisopropylsilyloxy)-1,7-
dioxaspiro[5.5]undecan-5-yl benzoate (9). DMAP (4.7 mg, 0.038 mmol, 2.5 equiv) 
then benzoyl chloride (4.0 µL, 0.031 mmol, 2.0 equiv) was added to a solution of 
spiroketal 6 (9.6 mg, 0.015 mmol, 1.0 equiv) in CH2Cl2 (0.3 mL). The reaction was 
stirred at rt 45 min then quenched with sat’d aq NaHCO3. The aqueous layer was 
extracted 3x with Et2O then the combined organic layers were washed with H2O then 
brine, dried (MgSO4), filtered and concentrated. The crude material was purified by 
flash chromatography (elution with 95:5 hexanes/EtOAc) to yield 9 as a clear oil (9.7 
mg, 87%). TLC: Rf  0.60 (4:1 hexanes/EtOAc).  IR (NaCl, film): 2941, 2865, 1724, 
1270, 1112, 709.  1H-NMR (400 MHz): δ 8.06 (d, 2H, J = 8.2), 7.69 (t, 4H, J = 7.9), 
7.56 (m, 1H), 7.40 (m, 8H), 4.89 (d, 1H, J = 2.7), 4.49 (m, 1H), 4.11 (m, 1H), 4.02 (m, 
1H), 3.82–3.69 (m, 2H), 3.51 (m, 1H), 1.80–1.69 (m, 5H), 1.63–1.49 (m, 3H), 1.35 
(m, 2H), 1.15–1.00 (m, 30H). 13C-NMR (125 MHz): δ 165.2, 135.6, 134.1, 134.0, 
133.1, 130.0, 129.8, 129.5, 128.4, 127.6, 96.6, 72.5, 67.7, 60.1, 60.0, 38.8, 35.8, 31.8, 
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26.8, 25.0, 19.2, 18.4, 18.1, 18.0, 12.3. ESI-MS m/z: pos 753.5 [M+Na]+; neg 765.3 
[M+Cl]–. 
 
O
O
O
O
O
Si
Si
S
N
N
 
(2R,4R,5S,6S)-Imidazole-1-carbothioic acid O-[2-[2-(tert-butyldiphenylsilyloxy)-
ethyl]-4-(triisopropylsilyloxy)-1,7-dioxaspiro[5.5]undec-5-yl] ester (7). Im2CS (51 
mg, 0.29 mmol, 3.0 equiv) was added to a solution of spiroketal 6 (60 mg, 0.096 
mmol, 1.0 equiv) in 1,2-dichloroethane (1.0 mL). The reaction was heated to 80 °C for 
6.5 h then the solvent was evaporated. The crude material was purified by flash 
chromatography (elution with 4:1 hexanes/EtOAc) to provide 7 as a clear oil (63 mg, 
90%). TLC: Rf  0.21 (4:1 hexanes/EtOAc).  IR (NaCl, film): 2943, 2861, 1461, 1385, 
1232, 1103, 1079, 997.  1H-NMR (400 MHz): δ 8.34 (s, 1H), 7.68 (t, 4H, J = 8.4), 
7.62 (s, 1H), 7.40 (m, 6H), 7.02 (s, 1H), 5.34 (d, 1H, J = 2.7), 4.50 (m, 1H), 4.19 (m, 
1H), 3.99 (m, 1H), 3.80-3.69 (m, 2H), 3.52 (dd, 1H, J = 11.9, 1.6), 1.77-1.48 (m, 8H), 
1.40 (dd, 2H, J = 12.9, 3.9), 1.12-0.99 (m, 30H). 13C-NMR (125 MHz): δ 183.1, 
137.0, 135.6, 135.5, 134.0, 133.9, 131.0, 129.6, 127.6, 117.9, 96.2, 80.1, 66.6, 60.3, 
60.1, 59.8, 38.7, 35.9, 31.8, 26.8, 24.8, 19.2, 18.2, 18.1, 12.3. ESI-MS m/z: 737.6 
[M+H]+, 759.6 [M+Na]+; neg 771.5 [M+Cl]–. 
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(2R,4R,6S)-2-[2-(tert-Butyldiphenylsilyloxy)-ethyl]-4-(triisopropylsilyloxy)-1,7-
dioxaspiro[5.5]undecane (8). AIBN (2.1 mg, 0.013 mmol, 0.3 equiv) then Bu3SnH 
(15 µL, 0.057 mmol, 2.2 equiv) was added to a solution of spiroketal 7 (19 mg, 0.026 
mmol, 1.0 equiv) in anhyd, degassed toluene (0.4 mL). The reaction was heated to 
reflux and stirred for 1h. The solvent was evaporated and the crude material was 
purified by flash chromatography (elution with 98:2 hexanes/EtOAc) to yield C2-
deoxy spiroketal 8 as a clear oil (13 mg, 82%). TLC: Rf  0.65 (4:1 hexanes/EtOAc).  
IR (NaCl, film): 2941, 2864, 1428, 1113, 1082, 994.  1H-NMR (400 MHz): δ 7.58 (m, 
4H), 7.39 (m, 6H), 4.34 (m, 1H), 4.19 (m, 1H), 3.95 (m, 1H), 3.77 (m, 1H), 3.68 (m, 
1H), 3.45 (dd, 1H, J = 11.6, 4.3), 1.81–1.58 (m, 5H), 1.57–1.41 (m, 5H), 1.33 (m, 2H), 
1.11–1.00 (m, 30H). 13C-NMR (125 MHz): δ 135.6, 135.5, 134.2, 134.1, 129.5, 127.5, 
95.7, 64.9, 60.3, 60.1, 42.4, 39.6, 39.1, 36.2, 26.8, 25.1, 19.2, 18.8, 18.1, 18.0, 12.3. 
ESI-MS m/z: pos 633.3 [M+Na]+; neg 645.5 [M+Cl]–. 
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(2R,4R,6R)-2-[2-(tert-Butyldiphenylsilyloxy)-ethyl]-4-(triisopropylsilyloxy)-1,7-
dioxaspiro[5.5]undecan-5-one (11). DMSO (110 µL, 1.6 mmol, 25 equiv) was added 
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dropwise to a cooled (–78 °C) solution of oxalyl chloride (28 µL, 0.32 mmol, 5.0 
equiv) in anhyd CH2Cl2 (0.3 mL). After 30 min, a solution of spiroketal 10 (40 mg, 
0.064 mmol, 1.0 equiv) in anhyd CH2Cl2 (0.3 mL) was added dropwise and the 
reaction was stirred at –78 °C for 15 min. Freshly distilled Et3N (220 µL, 1.6 mmol, 
25 equiv) was then added. The reaction was stirred at –78 °C for 1h then 0 °C for 30 
min then quenched with sat’d aq NaHCO3. The aqueous layer was extracted 3x with 
Et2O then the combined organic layers were washed with brine, dried (MgSO4), 
filtered and concentrated. The crude material was purified by flash chromatography 
(elution with 95:5 hexanes/EtOAc) to yield 11 as a clear oil (35 mg, 88%). TLC: Rf  
0.67 (4:1 hexanes/EtOAc).  IR (NaCl, film): 2942, 2865, 1753, 1464, 1111, 1004.  
1
H-NMR (500 MHz): δ 7.66 (m, 4H), 7.45–7.32 (m, 6H), 4.68 (m, 1H), 4.34 (m, 1H), 
3.92 (m, 1H), 3.85 (td, 1H, J = 11.4, 2.5), 3.77 (m, 1H), 3.67 (m, 1H), 2.32 (m, 1H), 
2.11 (m, 1H), 2.01 (m, 1H), 1.90–1.80 (m, 1H), 1.73–1.57 (m, 3H), 1.44 (m, 1H), 
1.11–1.00 (m, 30H). 13C-NMR (125 MHz): δ 203.3, 135.6, 135.5, 133.7, 129.6, 127.6, 
98.7, 70.1, 67.1, 62.2, 60.6, 41.1, 38.3, 28.6, 26.8, 24.8, 19.2, 18.0, 17.9, 12.2. 
ESI-MS m/z: pos 647.4 [M+Na]+; neg 623.5 [M-H]–, 659.3 [M+Cl]–. 
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(2R,4R,5R,6R)-2-[2-(tert-Butyldiphenylsilyloxy)-ethyl]-4-(triisopropylsilyloxy)-
1,7-dioxaspiro[5.5]undecan-5-ol (12). NaBH4 (2.4 mg, 0.064 mmol, 5.0 equiv) was 
added in one portion to a cooled (0 °C) solution of spiroketal 11 (8.0 mg, 0.013 mmol, 
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1.0 equiv) in anhyd MeOH (0.2 mL). After 2 h at 0 °C, the reaction was quenched 
with sat’d aq NaOAc. The aqueous layer was extracted 3x with Et2O, dried (MgSO4), 
filtered and concentrated. The crude material was purified by flash chromatography 
(elution with 4:1 hexanes/EtOAc) to yield 12 as a clear oil (7.7 mg, 96%). TLC: Rf  
0.35 (4:1 hexanes/EtOAc).  IR (NaCl, film): 3459, 2942, 2868, 1463, 1111, 999.  
1
H-NMR (500 MHz): δ 7.66 (m,4H), 7.38 (m, 6H), 4.32 (m, 1H), 4.18 (m, 1H), 3.93 
(m, 2H), 3.76 (m, 1H), 3.62 (m, 1H), 3.37 (dd, 1H, J = 6.9, 3.7), 2.36 (d, 1H, J = 6.9), 
2.19 (m, 1H), 1.82 (m, 2H), 1.72 (m, 2H), 1.62 (m, 3H), 1.53 (m, 1H), 1.39 (m, 1H), 
1.10–1.00 (m, 30H). 13C-NMR (125 MHz): δ 135.6, 133.9, 129.6, 127.6, 99.1, 74.5, 
68.5, 64.9, 61.5, 60.5, 38.5, 37.2, 26.8, 25.2, 19.2, 18.1, 18.0, 12.4. ESI-MS m/z: pos 
649.4 [M+Na]+; neg 625.4 [M-H]–, 661.4 [M+Cl]–. 
 
Incorporation of azide tags: 
General procedure for conversion of chloro-functionalized glycals to azido-
functionalized glycals: 
NaN3 (20 equiv) was added to a solution of chloro-functionalized glycals 21o–r (1.0 
equiv) in anhyd DMF (0.020 M final concentration) then the reaction was heated to 
90 °C. After 20 h, the reaction was diluted with Et2O. The organic Et2O solution was 
washed 3x with H2O then the combined aqueous washes were extracted 2x with Et2O. 
The combined organic extracts were washed with brine, dried (MgSO4), filtered and 
concentrated. If conversion to the azide was not complete (NMR), the above 
procedure was repeated. The crude material was purified by flash chromatography 
(elution with 95:5 pentane/Et2O) to provide azide-functionalized glycals E1o–r. 
Glycals E1o–r were characterized by Justin Potuzak. 
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(–)-(2R,4S,4′R)-2-[2-(tert-Butyldiphenylsilyloxy)ethyl]-6-(4′-acetoxy-5-
azidopentyl)-4-(triisopropylsilyloxy)-3,4-dihydro-2H-pyran (E1o). Clear oil (130 
mg, 79%) TLC: Rf  0.56 (4:1 hexanes/EtOAc). ][
25
Dα = –2.7° (c 1.0, CDCl3). IR (NaCl, 
film): 2941, 2864, 2100 (N3), 1744, 1689, 1463, 1428, 1372, 1232, 1110, 1087, 1013, 
882, 822, 738, 702. 1H-NMR (400 MHz): δ 7.66 (m, 4H), 7.44–7.35 (m, 6H), 4.97 (m, 
1H), 4.49 (m, 2H), 4.15 (m, 1H), 3.85–3.73 (m, 2H), 3.34 (dd, 1H, J = 13.1, 3.7), 3.25 
(dd, 1H, J = 13.1, 6.2), 2.09–1.92 (m, 7H), 1.80 (m, 1H), 1.65 (m, 3H), 1.46 (m, 2H), 
1.05 (m, 30H). 13C-NMR (125 MHz): δ 170.5, 154.1, 135.5, 133.9, 129.6, 127.6, 
101.4, 72.5, 71.5, 63.9, 60.3, 53.4, 37.7, 33.6, 30.8, 26.9, 22.2, 21.0, 19.2, 18.1, 12.3. 
ESI-MS m/z (rel int): pos 730.5 ([M+Na]+, 100); neg 742.4 ([M+Cl]–, 100). 
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(–)-(2R,4S,4′S)-2-[2-(tert-Butyldiphenylsilyloxy)ethyl]-6-(4′-acetoxy-5-
azidopentyl)-4-(triisopropylsilyloxy)-3,4-dihydro-2H-pyran (E1p). Clear oil (140 
mg, 68%) TLC: Rf 0.56 (4:1 hexanes/EtOAc). ][
25
Dα = –9.3° (c 1.0, CDCl3). IR (NaCl, 
film): 2941, 2864, 2099 (N3), 1744, 1668, 1462, 1428, 1372, 1283, 1232, 1110, 1088, 
1012, 882, 822, 738, 702. 1H-NMR (400 MHz): δ 7.66 (m, 4H), 7.44–7.35 (m, 6H), 
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4.97 (m, 1H), 4.49 (m, 2H), 4.15 (m, 1H), 3.85–3.73 (m, 2H), 3.36–3.23 (m, 2H), 
2.09–1.92 (m, 7H), 1.80 (m, 1H), 1.65 (m, 3H), 1.44 (m, 2H), 1.05 (m, 30H). 
13
C-NMR (125 MHz): δ 170.5, 154.1, 135.5, 133.9, 129.6, 127.6, 101.4, 72.5, 71.5, 
63.9, 60.3, 53.4, 37.7, 33.6, 30.9, 26.9, 22.3, 21.0, 19.2, 18.1, 12.3. ESI-MS m/z (rel 
int): pos 730.5 ([M+Na]+, 100); neg 742.4 ([M+Cl]–, 100). 
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(–)-(2R,4S,3′R)-2-[2-(tert-Butyldiphenylsilyloxy)ethyl]-6-(3′-acetoxy-4-
azidobutyl)-4-(triisopropylsilyloxy)-3,4-dihydro-2H-pyran (E1q). Yellow oil (35 
mg, 83%).      ][ 25Dα = –7.4° (c 3.5, CDCl3). IR (NaCl, film): 2941, 2864, 2099 (N3), 
1744, 1670, 1463, 1428, 1373, 1230, 1107, 1087, 1064, 882, 823, 738, 702. 1H-NMR 
(500 MHz): δ 7.66 (m, 4H), 7.44–7.35 (m, 6H), 4.97 (m, 1H), 4.50 (m, 2H), 4.15 (m, 
1H), 3.82–3.75 (m, 2H), 3.37 (m, 1H), 3.26 (m, 1H), 2.07–1.92 (m, 7H), 1.82–1.62 
(m, 4H), 1.05 (m, 30H). 13C-NMR (125 MHz): δ 170.3, 153.6, 135.5, 133.9, 129.6, 
127.6, 101.6, 72.3, 71.7, 63.9, 60.2, 53.3, 37.8, 37.7, 29.8, 28.7, 26.9, 21.0, 19.2, 18.1, 
12.3. ESI-MS m/z (rel int): pos 716.4 ([M+Na]+, 100); neg 728.7 ([M+Cl]–, 100). 
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(–)-(2R,4S,3′S)-2-[2-(tert-Butyldiphenylsilyloxy)ethyl]-6-(3′-acetoxy-4-azidobutyl)-
4-(triisopropylsilyloxy)-3,4-dihydro-2H-pyran (E1r). Yellow oil (32 mg, 66%).      
][ 25Dα = –7.5° (c 3.2, CDCl3). IR (NaCl, film): 2942, 2864, 2099 (N3), 1745, 1670, 
1463, 1428, 1373, 1230, 1107, 1086, 1064, 882, 823, 738, 702. 1H-NMR (500 MHz): 
δ 7.66 (m, 4H), 7.44–7.35 (m, 6H), 4.97 (m, 1H), 4.49 (m, 2H), 4.15 (m, 1H), 3.82–
3.74 (m, 2H), 3.36 (m, 1H), 3.25 (m, 1H), 2.07–1.92 (m, 7H), 1.82–1.62 (m, 4H), 1.05 
(m, 30H). 13C-NMR (125 MHz): δ 170.4, 153.4, 135.5, 133.9, 129.6, 127.6, 101.8, 
72.1, 71.7, 63.9, 60.2, 53.4, 37.8, 37.7, 29.8, 28.6, 26.9, 21.0, 19.2, 18.1, 12.3. ESI-
MS m/z (rel int): pos 716.4 ([M+Na]+, 100); neg 728.7 ([M+Cl]–, 100). 
 
The glycals E1o–r were deacetylated as described in the general procedure (Section 
2.6). Glycals 22o–r were characterized by Justin Potuzak: 
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(–)-(2R,2′R,4S)-1-Azido-5-[6-[2-(tert-butyldiphenylsilyloxy)ethyl]-4-
(triisopropylsilyloxy)-5,6-dihydro-4H-pyran-2-yl]pentan-2′-ol (22o). Clear oil (100 
mg, 100%) TLC: Rf 0.43 (4:1 hexanes/EtOAc). ][
25
Dα = –6.0° (c 1.0, CDCl3). IR 
(NaCl, film): 3442, 2941, 2864, 2100 (N3), 1668, 1462, 1428, 1274, 1106, 1087, 1011, 
882, 822, 737, 702. 1H-NMR (400 MHz): δ 7.66 (m, 4H), 7.44–7.35 (m, 6H), 4.49 (m, 
2H), 4.15 (m, 1H), 3.83–3.73 (m, 3H), 3.31 (dd, 1H, J = 12.4, 3.4), 3.21 (dd, 1H, J = 
12.4, 7.4), 2.09–1.75 (m, 7H), 1.64 (m, 1H), 1.46 (m, 3H), 1.05 (m, 30H). 13C-NMR 
(125 MHz): δ 154.1, 135.6, 133.9, 129.6, 127.6, 101.4, 71.5, 70.6, 63.9, 60.3, 57.1, 
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37.8, 37.7, 33.7, 26.9, 22.6, 19.2, 18.1, 12.3. ESI-MS m/z (rel int): pos 688.5 
([M+Na]+, 100); neg 700.4 ([M+Cl]–, 100). 
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(–)-(2R,2′S,4S)-1-Azido-5-[6-[2-(tert-butyldiphenylsilyloxy)ethyl]-4-
(triisopropylsilyloxy)-5,6-dihydro-4H-pyran-2-yl]pentan-2′-ol (22p). Clear oil (120 
mg, 100%) ][ 25Dα = –5.6° (c 1.0, CDCl3). IR (NaCl, film): 3435, 2941, 2863, 2100 (N3), 
1668, 1462, 1427, 1273, 1105, 1087, 1011, 882, 822, 737, 701. 1H-NMR (400 MHz): 
δ 7.66 (m, 4H), 7.44–7.35 (m, 6H), 4.49 (m, 2H), 4.15 (m, 1H), 3.85–3.70 (m, 3H), 
3.31 (dd, 1H, J = 12.4, 3.4), 3.21 (dd, 1H, J = 12.4, 7.4), 2.09–1.75 (m, 6H), 1.65–1.43 
(m, 5H), 1.05 (m, 30H). 13C-NMR (125 MHz): δ 154.1, 135.5, 133.9, 129.6, 127.6, 
101.4, 71.5, 70.6, 63.9, 60.3, 57.0, 37.8, 37.7, 33.7, 26.6, 22.6, 19.2, 18.1, 12.3. ESI-
MS m/z (rel int): pos 688.4 ([M+Na]+, 100); neg 700.4 ([M+Cl]–, 100). 
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(–)-(2R,2′R,4S)-1-Azido-5-[6-[2-(tert-butyldiphenylsilyloxy)ethyl]-4-
(triisopropylsilyloxy)-5,6-dihydro-4H-pyran-2-yl]butan-2′-ol (22q). Clear oil (33 
mg, 100%). ][ 25Dα = –3.5° (c 2.9, CDCl3). IR (NaCl, film): 3428, 2942, 2865, 2101 
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(N3), 1670, 1463, 1428, 1277, 1088, 1011, 882, 823, 738, 702. 
1
H-NMR (500 MHz): δ 
7.66 (m, 4H), 7.44–7.35 (m, 6H), 4.58 (s, 1H), 4.49 (m, 1H), 4.17 (m, 1H), 3.82–3.73 
(m, 2H), 3.28 (m, 1H), 3.21 (m, 1H), 2.13–2.03 (m, 4H), 1.95 (m, 1H), 1.82 (m, 1H), 
1.62 (m, 4H), 1.05 (m, 30H). 13C-NMR (125 MHz): δ 154.0, 135.5, 133.8, 129.6, 
127.6, 102.0, 71.8, 70.4, 63.9, 60.2, 56.9, 37.7, 37.6, 31.7, 30.2, 26.9, 19.2, 18.1, 12.3. 
ESI-MS m/z (rel int): pos 674.4 ([M+Na]+, 100); neg 686.4 ([M+Cl]–, 100). 
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(–)-(2R,2′S,4S)-1-Azido-5-[6-[2-(tert-butyldiphenylsilyloxy)ethyl]-4-
(triisopropylsilyloxy)-5,6-dihydro-4H-pyran-2-yl]butan-2′-ol (22r). Clear oil (29 
mg, 97%). ][ 25Dα = –9.1° (c 2.9, CDCl3). IR (NaCl, film): 3460, 2942, 2865, 2101 (N3), 
1670, 1463, 1428, 1274, 1088, 1011, 882, 823, 738, 702. 1H-NMR (500 MHz): δ 7.66 
(m, 4H), 7.44–7.35 (m, 6H), 4.57 (s, 1H), 4.49 (m, 1H), 4.17 (m, 1H), 3.82–3.73 (m, 
2H), 3.28 (m, 1H), 3.21 (m, 1H), 2.13–2.03 (m, 4H), 1.95 (m, 1H), 1.82 (m, 1H), 1.62 
(m, 4H), 1.05 (m, 30H). 13C-NMR (125 MHz): δ 154.0, 135.5, 133.8, 129.6, 127.6, 
101.9, 71.7, 70.3, 63.8, 60.2, 56.9, 37.7, 37.6, 31.6, 30.1, 26.9, 19.2, 18.1, 12.3. ESI-
MS m/z (rel int): pos 674.4 ([M+Na]+, 100); neg 686.6 ([M+Cl]–, 100). 
 
The “inversion” spiroketals 23o–r were synthesized according to the general 
procedure for epoxidation and methanol-induced spirocyclization (Section 3.5). 
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(+)-(2R,4S,5R,6S,8R)-8-Azidomethyl-2-[2-(tert-butyldiphenylsilyloxy)ethyl]-4-
(triisopropylsilyloxy)-1,7-dioxaspiro[5.5]undecan-5-ol (23o). Clear oil (5.3 mg, 
52%). TLC: Rf 0.51 (4:1 hexanes/EtOAc). ][
25
Dα = +15º (c 0.51, CHCl3). IR (NaCl, 
film): 2940, 2862, 2096 (N3), 1462, 1261, 1104. 
1
H-NMR (500 MHz): δ 7.62 (m, 4H), 
7.39 (m, 6H), 4.07 (m, 1H), 3.86 (m, 2H), 3.76 (m, 1H), 3.68 (m, 1H), 3.27 (m, 2H), 
3.19 (dd, 1H, J = 12.7, 5.4), 2.32 (d, 1H, J = 2.1), 1.90 (m, 1H), 1.83-1.54 (m, 6H), 
1.52-1.35 (m, 3H), 1.08 (m, 30H). 13C-NMR (125 MHz): δ 135.8, 134.1, 129.9, 127.9, 
100.2, 79.4, 70.8, 70.6, 66.2, 60.5, 55.4, 40.9, 38.8, 28.0, 27.1, 22.3, 19.4, 18.3, 17.4, 
12.8. ESI-MS m/z: pos 704.1 [M+Na]+; neg 680.1 [M-H]–, 716.2 [M+Cl]–. 
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(2R,4S,5R,6S,8S)-8-Azidomethyl-2-[2-(tert-butyldiphenylsilyloxy)ethyl]-4-
(triisopropylsilyloxy)-1,7-dioxaspiro[5.5]undecan-5-ol (23p). Clear oil (6.8 mg, 
47%, 81:19 23p:24p). TLC: Rf 0.43 (4:1 hexanes/EtOAc). IR (NaCl, film): 2943, 
2866, 2095 (N3), 1465, 1261, 1106. 
1
H-NMR (500 MHz): δ 7.64 (m, 4H), 7.43 (m, 
6H), 4.06 (m, 1H), 3.79 (m, 3H), 3.69 (m, 1H), 3.63 (m, 1H), 3.32 (dd, 1H, J = 9.3, 
1.9), 2.80 (dd, 1H, J = 12.5, 5.4), 2.37 (d, 1H, J = 2.0), 1.88 (m, 2H), 1.77 (m, 4H), 
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1.62 (m, 1H), 1.48 (m, 3H), 1.07 (m, 30H). 13C-NMR (125 MHz): δ 135.6, 135.5, 
129.7, 127.7, 100.8, 79.4, 72.6, 70.7, 66.5, 60.5, 54.6, 40.5, 38.6, 26.9, 25.5, 22.3, 
19.2, 18.1, 13.7, 12.6. ESI-MS m/z: pos 704.2 [M+Na]+; neg 680.2 [M–H]–, 716.3 
[M+Cl]–. 
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(+)-(2R,4S,5R,6S,8R)-8-Azidomethyl-2-[2-(tert-butyldiphenylsilyloxy)ethyl]-4-
(triisopropylsilyloxy)-1,7-dioxaspiro[4.5]decan-5-ol (23q). Clear oil (7.3 mg, 72%). 
TLC: Rf 0.47 (4:1 hexanes/EtOAc). ][
25
Dα = +1.6º (c 1.2, CDCl3).  IR (NaCl, film): 
2942, 2864, 2100 (N3), 1463, 1110.
  1
H-NMR (500 MHz): δ 7.62 (m, 4H), 7.44–7.36 
(m, 6H), 4.31 (m, 1H), 3.83 (m, 1H), 3.75–3.67 (m, 3H), 3.48 (dd, 1H, J = 9.3, 2.3), 
3.39 (dd, 1H, J = 12.7, 4.4), 3.33 (dd, 1H, J = 12.7, 5.3), 2.41 (d, 1H, J = 2.3), 2.20 (m, 
1H), 2.02 (m, 1H), 1.90 (m, 1H), 1.85–1.66 (m, 4H), 1.45 (m, 1H), 1.13–1.05 (m, 
30H). 13C-NMR (125 MHz): δ 135.5, 133.8, 129.7, 127.7, 110.0, 77.4, 76.5, 72.1, 
66.7, 60.0, 54.0, 40.4, 38.3, 27.8, 27.1, 26.9, 19.2, 18.1, 12.5. ESI-MS m/z: pos 690.4 
[M+Na]+; neg 702.6 [M+Cl]–. 
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(+)-(2R,4S,5R,6S,8S)-8-Azidomethyl-2-[2-(tert-butyldiphenylsilyloxy)ethyl]-4-
(triisopropylsilyloxy)-1,7-dioxaspiro[4.5]decan-5-ol (23r). Clear oil (7.7 mg, 75%, 
84:16 23r:24r). TLC: Rf 0.47 (4:1 hexanes/EtOAc). IR (NaCl, film): 2942, 2865, 
2100 (N3), 1463, 1091. 
1
H-NMR (500 MHz): δ 7.62 (m, 4H), 7.41–7.36 (m, 6H), 4.22 
(m, 1H), 3.79 (m, 1H), 3.74–3.66 (m, 3H), 3.51 (dd, 1H, J = 9.4, 2.1), 3.31 (m, 1H), 
3.18 (dd, 1H, J = 12.5, 5.0), 2.37 (d, 1H, J = 2.1), 2.11 (m, 1H), 2.02 (m, 1H), 1.90 (m, 
2H), 1.78–1.62 (m, 3H), 1.49 (m, 1H), 1.08 (m, 30H).  13C-NMR (125 MHz): δ 135.5, 
133.9, 129.7, 127.7, 109.7, 78.7, 76.4, 72.2, 67.1, 60.2, 56.9, 40.3, 38.2, 27.7, 26.9, 
26.0, 19.2, 18.1, 12.5. ESI-MS m/z: pos 690.5 [M+Na]+; neg 702.6 [M+Cl]–. 
 
The “retention” spiroketals 24o–r were synthesized according to the general procedure 
for epoxidation and Ti(Oi-Pr)4-induced spirocyclization (Section 3.5). 
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(+)-(2R,4S,5R,6R,8R)-8-Azidomethyl-2-[2-(tert-butyldiphenylsilyloxy)ethyl]-4-
(triisopropylsilyloxy)-1,7-dioxaspiro[5.5]undecan-5-ol (24o). Clear oil (8.2 mg, 
80%). TLC: Rf 0.43 (4:1 hexanes/EtOAc). ][
25
Dα = +19º (c 0.80, CHCl3). IR (NaCl, 
film): 2941, 2863, 2095 (N3), 1427, 1259, 1106. 
1
H-NMR (500 MHz): δ 7.68 (m, 4H), 
7.39 (m, 6H), 4.16 (m, 1H), 4.10–4.01 (m, 2H), 3.74 (m, 2H), 3.38 (dd, 1H, J = 12.4, 
7.1), 3.17 (dd, 1H, J = 12.5, 5.9), 3.10 (m, 1H), 2.18 (d, 1H, J = 6.3), 2.10 (m, 1H), 
1.98 (m, 1H), 1.79–1.53 (m, 7H), 1.37 (q, 1H, J = 11.9) 1.08 (m, 30H). 13C-NMR (125 
MHz): δ 135.5, 133.8, 129.6, 127.6, 98.9, 79.6, 72.5, 70.5, 65.5, 60.5, 54.6, 40.4, 38.4, 
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30.8, 26.9, 25.2, 19.2, 18.1, 14.7, 12.5. ESI-MS m/z: pos 704.5 [M+Na]+; neg 716.4 
[M+Cl]–. 
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(2R,4S,5R,6R,8S)-8-Azidomethyl-2-[2-(tert-butyldiphenylsilyloxy)ethyl]-4-
(triisopropylsilyloxy)-1,7-dioxaspiro[5.5]undecan-5-ol (24p). Clear oil (8.8 mg, 
86%). TLC: Rf 0.50 (4:1 hexanes/EtOAc). IR (NaCl, film): 2941, 2864, 2095 (N3), 
1463, 1428, 1388, 1262, 1106. 1H-NMR (400 MHz): δ 7.66 (m, 4H), 7.44–7.35 (m, 
6H), 4.09 (m, 1H), 3.95–3.81 (m, 3H), 3.75 (m, 1H), 3.22 (dd, 1H, J = 13.0, 7.5), 3.10 
(m, 1H), 2.98 (dd, 1H, J = 13.0, 2.7), 2.07–1.96 (m, 3H), 1.78–1.62 (m, 4H), 1.47–
1.25 (m, 4H), 1.06 (m, 30H). 13C-NMR (125 MHz): δ 135.5, 133.8, 129.6, 127.6, 
98.8, 78.3, 70.6, 70.3, 64.2, 60.3, 55.1, 40.8, 38.5, 30.2, 27.4, 26.8, 19.1, 18.1, 17.9, 
12.5. ESI-MS m/z: pos 682.9 [M+H]+, 704.8 [M+Na]+; neg 680.8 [M–H]–, 716.8 
[M+Cl]–. 
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(+)-(2R,4S,5R,6R,8R)-8-Azidomethyl-2-[2-(tert-butyldiphenylsilyloxy)ethyl]-4-
(triisopropylsilyloxy)-1,7-dioxaspiro[4.5]decan-5-ol (24q). Clear oil (8.9 mg, 87%). 
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TLC: Rf 0.42 (4:1 hexanes/EtOAc). ][
25
Dα = +41º (c 0.93, CDCl3).  IR (NaCl, film): 
2944, 2867, 2096 (N3), 1465, 1092.
  1
H-NMR (500 MHz): δ 7.68 (m, 4H), 7.40 (m, 
6H), 4.34 (m, 1H), 3.95 (m, 2H), 3.72 (m, 2H), 3.35–3.25 (m, 2H), 3.0 (m, 1H), 2.28 
(m, 1H), 2.02–1.92 (m, 3H), 1.84 (m, 1H), 1.75–1.63 (m, 3H), 1.40 (m, 1H), 1.08 (m, 
30H).  13C-NMR (125 MHz): δ 135.6, 133.9, 129.6, 127.6, 108.5, 80.9, 75.4, 71.6, 
65.5, 60.7, 56.3, 40.6, 38.4, 34.0, 27.7, 26.9, 19.1, 18.1, 12.6. ESI-MS m/z: pos 690.4 
[M+Na]+; neg 702.6 [M+Cl]–. 
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(+)-(2R,4S,5R,6R,8S)-8-Azidomethyl-2-[2-(tert-butyldiphenylsilyloxy)ethyl]-4-
(triisopropylsilyloxy)-1,7-dioxaspiro[4.5]decan-5-ol (24r). Clear oil (8.3 mg, 81%). 
TLC: Rf 0.50 (4:1 hexanes/EtOAc). ][
25
Dα = +38º (c 0.93, CDCl3). IR (NaCl, film): 
2943, 2865, 2097 (N3), 1463, 1090. 
1
H-NMR (500 MHz): δ 7.64 (m, 4H), 7.44–7.36 
(m, 6H), 4.22 (m, 1H), 4.04–3.94 (m, 2H), 3.79–3.70 (m, 2H), 3.36–3.24 (m, 3H), 
2.32 (m, 1H), 2.01–1.92 (m, 3H), 1.81 (m, 1H), 1.71–1.63 (m, 3H), 1.42 (m, 1H), 
1.12–1.04 (m, 30H). 13C-NMR (125 MHz): δ 135.5, 134.0, 129.6, 127.6, 108.6, 78.1, 
75.9, 71.7, 65.5, 60.3, 54.2, 40.8, 38.2, 33.8, 27.1, 26.8, 19.2, 18.1, 12.6. ESI-MS m/z: 
pos 690.4 [M+Na]+; neg 702.6 [M+Cl]–. 
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(2S,4S,5R,6S)-2-(2-Iodoethyl)-1,7-dioxaspiro[5.5]undecane-4,5-diol (28). A 
solution of I2 (33 mg, 0.13 mmol, 1.5 equiv) in anhyd THF (0.8 mL) was added 
dropwise to a solution of spiroketal 25 (20 mg, 0.086 mmol, 1.0 equiv), diphenyl-[4-
(1H,1H,2H,2H-perfluorodecyl)phenyl]phosphine 27 (92 mg, 0.13 mmol, 1.5 equiv), 
and imidazole (12 mg, 0.17 mmol, 2.0 equiv) in anhyd THF (2.0 mL) at reflux. The 
reaction was refluxed 20 min, cooled to rt, then filtered through a plug of Celite. The 
filtrate was concentrated, redissolved in a minimal amount of MeCN, then purified by 
fluorous silica flash chromatography (10 mL fluorous silica, elution with MeCN) to 
yield iodide 28 as a white foam (25 mg, 83%, ~90% pure). TLC: Rf 0.38 (9:1 
EtOAc/MeOH). 1H-NMR (400 MHz): δ 3.86–3.75 (m, 3H), 3.68 (m, 1H), 3.34 (m, 
2H), 2.98 (m, 1H), 2.37 (d, 1H, J = 2.0), 2.10–1.90 (m, 5H), 1.79 (m, 1H), 1.65–1.42 
(m, 4H), 1.39 (m, 1H). ESI-MS m/z: pos 365.1 [M+Na]+; neg 377.2 [M+Cl]–. 
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25 26
i) Fluorous-PPh3 (27)
   I2, imidazole, CH3CN
ii)
 
(2R,4S,5R,6S)-2-(2-Azidoethyl)-1,7-dioxaspiro[5.5]undecane-4,5-diol (26). 
Imidazole (4.1 mg, 0.060 mmol, 1.4 equiv) was added to a solution of diphenyl-[4-
(1H,1H,2H,2H-perfluorodecyl)phenyl]phosphine 27 (34 mg, 0.047 mmol, 1.1 equiv) 
and I2 (12 mg, 0.047 mmol, 1.1 equiv) in anhyd CH3CN (0.4 mL) in a vial. Spiroketal 
25 (10 mg, 0.043 mmol, 1.0 equiv) was added and the reaction was stirred at rt 4 h. 
The reaction mixture was transferred by syringe to a separate vial containing polymer-
supported azide 2920 (200 mg). The mixture was vortexed at rt 17 h then additional 
CH3CN was added to the vial (2 mL). The solution was removed from the resin by 
syringe and transferred to a column packed with fluorous silica (20 mL). The resin 
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was washed with CH3CN (2 x 2 mL) and the washings were transferred to the silica 
column. The column was washed with 75 mL CH3CN then the filtrate was 
concentrated to provide azide 26 as a clear oil (7.0 mg, 63% from 25, >95% pure). 
TLC: Rf 0.38 (9:1 EtOAc/MeOH). 
1
H-NMR (500 MHz): δ 3.87–3.74 (m, 2H), 3.70–
3.61 (m, 2H), 3.52–3.42 (m, 2H), 3.00 (t, 1H, J = 9.5), 2.44 (bs, 1H), 2.01–1.95 (m, 
3H), 1.82–1.71 (m, 3H), 1.68–1.47 (m, 4H), 1.39 (m, 1H). ESI-MS m/z: pos 280.3 
[M+Na]+; neg 256.3 [M–H]–, 292.2 [M+Cl]–. 
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CHAPTER 6 
LEWIS ACID-TETHERED INTERMOLECULAR REACTIONS: 
CONSTRUCTION OF THE β-1,2-CIS-GLYCOSIDIC LINKAGE 
 
6.1. Introduction 
Glycoconjugates play important roles in many biological processes such as 
intercellular communication and adhesion, cell growth, fertilization, immune response, 
and viral infection.1 Since homogeneous and chemically defined oligosaccharides are 
difficult to isolate from biological sources, efficient strategies to chemically synthesize 
oligosaccharides are essential to explore and manipulate the biological functions of 
these molecules. In addition, chemical synthesis provides the means to produce non-
natural saccharide building blocks or non-natural linkages. Recognition of the 
significant biological role of oligosaccharides has generated dramatic growth in the 
field of synthetic carbohydrate chemistry, particularly in the area of glycosylation 
methods.2 However, while 1,2-trans-glycosides can usually be obtained in pure form 
by exploiting the neighboring-group effect, there is still no general and straightforward 
route to 1,2-cis-glycosides.3 The β-1,2-cis-glycoside linkage is particularly difficult to 
construct since the anomeric effect favors the α-linkage. 
 The most common classical methods to synthesize the β-1,2-cis-glycoside 
linkage are the insoluble promoter strategy4 and oxidation/reduction of the 2-position 
of a β-glucoside.5 However, the insoluble promoter strategy is not reliably 
stereoselective, and the oxidation/reduction strategy is inefficient. More recently, 
intramolecular delivery strategies that employ a temporary covalent tether between the 
β-C2-hydroxyl group and the nucleophile have been developed that allow synthesis of 
β-1,2-cis-glycosides with complete stereocontrol for some substrates.6,7 These 
tethering strategies are similar to our Ti(Oi-Pr)4-mediated spirocyclization reaction, 
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and were in fact the inspiration for its development. Therefore, the possibility of using 
a noncovalent Lewis acid tether to direct intermolecular β-glycosylation of glycal 
epoxides was explored. While there is some precedent for effective syntheses of 
C-1,2-cis-glycosides using Lewis acid tethers,8-10 the potential of this strategy for 
O-glycosylation11 has not been thoroughly assessed.  
6.2. Studies Toward β-1,2-cis-Glycosidation 
In an initial study, the effect of Ti(Oi-Pr)4 on the stereoselectivity of 
methanolysis of glycal epoxide 1 was investigated. In the absence of catalyst, 
methanolysis provides the α-methyl glycoside as a single stereoisomer (Table 6.1, 
entry 1). Although β-selectivity as high as 10:1 (entry 2) can be achieved in this model 
system, the reaction is complicated by competing formation of the isopropyl 
glycosides 4 and 5. The quantity of isopropyl glycoside formed can be minimized by 
reducing the amount of Ti(Oi-Pr)4 used, but the selectivity is then compromised (entry 
3).  
 
 
Table 6.1. Methanolysis of glycal epoxide 1 in the presence of Ti(Oi-Pr)4.  
R = (CH2)2OTBDPS 
OR
OTIPS
O
OR
OTIPS
OH
OMe OR
OTIPS
OH
OMe OR
OTIPS
OH
Oi-PrMeOH
Ti(Oi-Pr)4
CH2Cl2
0 °C
+ +
2 (β) 3 (α) 4 (β)
5 (α)
1
 
entry 
Ti(Oi-Pr)4 
(equiv) 
MeOH 
(equiv) 
2 (β) 
(%) 
3 (α) 
(%) 
4 + 5 
(%) 
1 0 1000 0 100 n/a 
2 5 2 50 5 45 
3 2 5 63 30 7 
4 2 2 52 22 26 
 
Interestingly, the isopropyl glycoside that was formed in these experiments 
was found to be a mixture of the α and β anomers. Similarly, when glycal epoxide 1 
was treated with Ti(Oi-Pr)4 alone (Table 6.2, entry 1), selectivity for β- over 
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α-isopropyl glycoside formation was low. This suggests that “intramolecular” transfer 
of isopropoxide directly from Ti to the activated oxonium is not necessarily favored 
over intermolecular addition of free isopropanol to the activated species.  
Attempts to suppress unwanted glycoside formation by increasing the steric 
bulk of the ligands on titanium or reducing their capacity for exchange were 
unsuccessful. For example, although only a small amount of t-butyl glycoside was 
formed when the Ti(Oi-Pr)4 catalyst was replaced with Ti(Ot-Bu)4, the maximum β:α 
methyl glycoside ratio obtained was 70:30. This poor selectivity may be a result of 
slow coordination of MeOH to the bulky Ti species. Surprisingly, use of a Ti-BINOL 
catalyst provided the aryl glycoside as the major product, with only trace amounts of 
the desired methyl glycosides. 
 An interesting phenomenon was revealed when a Ti(Oi-Pr)4-catalyzed 
glycosylation of 1 with phenol as the nucleophile was carried out, which resulted in 
complete selectivity for the β-phenyl glycoside (6, R2 = Ph, Table 6.2). This result was 
not surprising in light of a later experiment showing that even uncatalyzed phenyl 
glycosylation of the same epoxide 1 occurs exclusively at the β-face. However, there 
was also a small amount of β-isopropyl glycoside (4) produced in the Ti(Oi-Pr)4-
catalyzed version, with no evidence of α-isopropyl glycoside formation (Table 6.2, 
entry 2). Although the basis of the effect is unclear, coordination of phenol to titanium 
may facilitate “intramolecular” transfer of isopropoxide, making intermolecular 
addition of uncoordinated isopropanol to the activated species less competitive. The 
addition of benzyl alcohol (entry 4) had a similar effect, but the presence of 
cyclohexanol did not significantly affect the β:α isopropyl glycoside ratio (cf. entries 
1 and 3), suggesting the importance of the aryl functionality.  
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Table 6.2. Ti(Oi-Pr)4-promoted glycosylations of glycal epoxide 1 with alcohol 
(R2OH) additives 
OR1
OTIPS
OR1
OTIPS
OH
OR2 OR1
OTIPS
OH
Oi-Pr OR1
OTIPS
OH
Oi-Pr
O
R2OH
Ti(Oi-Pr)4
CH2Cl2, 0 °C
+ +
6 (β) 4 (β) 5 (α)1  
 
entry 
Ti(Oi-Pr)4 
(equiv) 
R2OH 
(equiv) 
6 
(%) 
4 
(%) 
5 
(%) 
1 5 none n/a 56 44 
2 5 PhOH (2) 93 7 0 
3 5 cyclohexanol (2) 5 45 42 
4 5 BnOH (2) 64 29 7 
5 5 cyclohexylmethanol (2) 8 50 42 
6 5 pentafluorophenol (2) 72 17 11 
7 5 2,6-dimethylphenol (2) 31 44 25 
8 5 2,6-diphenylphenol (2) 6 80 14 
9 2 2,6-diphenylphenol (2) 4 51 45 
10 5 2-phenylphenol (2) 73 27 0 
11 1.3 2-phenylphenol (1.3) 70 30 0 
 
 
The outcome of the Ti(Oi-Pr)4-catalyzed glycosylation reaction in the presence 
of less nucleophilic aryl alcohols was then explored, with the anticipation that the 
β-isopropyl glycoside would still be formed selectively, but production of the 
undesired aryl glycoside would be reduced. Unfortunately, addition of 
pentafluorophenol or 2,6-dimethylphenol resulted in only moderate selectivity for the 
β-isopropyl glycoside, and significant amounts of the aryl glycosides 6 were still 
produced. Encouragingly, the desired effect was achieved in the presence of 2,6-
diphenylphenol and 5 equiv Ti(Oi-Pr)4 (entry 8). However, when only 2 equiv of 
Ti(Oi-Pr)4 was used, the outcome was similar to the case where no alcohol additive 
was employed (cf. entries 1 and 9). Since this trend was not observed with the less-
hindered 2-phenylphenol (cf. entries 10 and 11), it is possible that the sterically-
encumbered Ti-diphenylphenol complex does not form efficiently unless a large 
excess of Ti(Oi-Pr)4 is present. Attempts to pre-form and isolate various 
Ti-diphenylphenol complexes were not successful. 
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The use of TiCl4 as a catalyst resulted in decomposition, however, Yamamoto 
has shown that the Lewis acidity of TiCl4 can be moderated by combination with a 
Lewis base to generate a TiCl4•XPh3 complex (X = As, Sb, Bi).
12 This type of 
complex is thought to generate TiCl4 very slowly in situ. The use of TiCl4•AsPh3 as a 
catalyst for glycosylation of 1 with i-PrOH did result in high β-selectivity (94:6 β:α), 
however, a large amount of hydrolysis product 7 was recovered after aqueous workup. 
This may be due to incomplete conversion, followed by hydrolysis of the oxonium 
intermediate. An alternative explanation could be that the chloride adduct is formed 
during the reaction, then quenched with water upon workup. 
 
OR1
OTIPS
OR1
OTIPS
OH
OHOR1
OTIPS
OH
O OR1
OH
OH
O
OR1
OR2
OH
O
O+ R
1
OH
HO
O
FnTi
OH
O
OH
R1
O
TiFn
+
TiF4
i-PrOH
4 (β)
5 (α)
7 1
10 12
OR1
OH
OH
O
O R1
OH
HO
O
OR1
OTIPS
TiF4
i-PrOH
13 14
8 (β)
O+ R
1
O
HO
11
TiFnO
O
TiCl4•AsPh3
i-PrOH
O
(47:3:50 4:5:7)
5 (R2 = TIPS)
9 (R2 = H)
 
Figure 6.1. TiCl4•AsPh3- and TiF4-catalyzed glycosylations 
 
The possibility of replacing TiCl4 in this reaction with TiF4 was then explored, 
with the expectation that fluoride ion would be less prone to nucleophilic addition. 
Indeed, use of TiF4 with or without the AsPh3 additive resulted in exclusive formation 
of the C3-desilylated β-glycoside 8 with no evidence of any hydrolysis products. Later 
investigations revealed that this reaction is under thermodynamic control. 
Interestingly, if the reaction is quenched before equilibration to the β-glycoside is 
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complete, the remaining α-glycoside is still silylated at the C3-OH position (5). A 
possible explanation for this observation is that the α-glycoside must be deprotected at 
the C3-OH position before equilibration to the β-glycoside can occur. Once the C3-
OTIPS group of the α-glycoside has been deprotected (9), TiF4 can coordinate 
simultaneously to the free C3-OH and the oxygen of the isopropyl group (10), 
promoting oxonium formation (11). The TiFn(Oi-Pr) complex can then coordinate to 
the C2-OH (12) and deliver isopropoxide to the β-face of the anomeric position (8). 
Unfortunately, this mechanism is only applicable to substrates with an axial hydroxyl 
substituent on the α-face. Indeed, exposure of the threo-glycal epoxide 13 to the same 
conditions provided a mixture of α- and β-isopropyl glycosides 14. Although the 
substrate scope of this β-glycosylation procedure is limited, these experiments 
demonstrate the possibility of using TiF4 for selective TIPS removal in the presence of 
TBDPS. 
 
6.3. Experimental Section 
Materials and Methods: 
See Section 2.6. Racemic glycal epoxide 1 was prepared from the 
corresponding glycal as described in Section 2.4. 
 
General procedure for methanolysis of glycal epoxide 1 in the presence of Ti(Oi-Pr)4: 
Ti(Oi-Pr)4 then anhyd MeOH were added via syringe to a cooled (0 °C) solution of 
glycal epoxide 1 (1.0 equiv) in CH2Cl2 (0.03 M). The reaction mixture was stirred at 
0 °C until all glycal epoxide had reacted (TLC). The cold reaction mixture was 
quenched with sat’d aq NaHCO3. The aqueous layer was separated and extracted with 
Et2O, then the combined extracts were washed with H2O and brine, dried (MgSO4), 
  174 
filtered and concentrated by rotary evaporation. Glycoside ratios were determined by 
analysis of the crude material by NMR. 
 
General procedure for Ti(Oi-Pr)4-promoted glycosylations of glycal epoxide 1 with 
alcohol (R
2
OH) additives:  
Ti(Oi-Pr)4 then the alcohol additive (R
2OH) were added to a cooled (–78 °C) solution 
of glycal epoxide 1 (1.0 equiv) in CH2Cl2 (0.03 M), then the reaction was warmed to 
0 °C. The reaction mixture was stirred at 0 °C until all glycal epoxide had reacted 
(TLC). The cold reaction mixture was quenched with sat’d aq NaHCO3. The aqueous 
layer was separated and extracted with Et2O, then the combined extracts were washed 
with H2O and brine, dried (MgSO4), filtered and concentrated by rotary evaporation. 
Glycoside ratios were determined by analysis of the crude material by NMR. 
 
Procedure for TiCl4•AsPh3-promoted glycosylation of glycal epoxide 1 with i-PrOH: 
TiCl4 (1.0 M in CH2Cl2, 46 µL, 0.046 mmol, 5.0 equiv) was added dropwise to a 
cooled (–78 °C) solution of AsPh3 (14 mg, 0.046 mmol, 5.0 equiv) in CH2Cl2 (0.2 
mL). A solution of i-PrOH (1.4 µL, 0.019 mmol, 2.0 equiv) in CH2Cl2 (0.2 mL) was 
added dropwise, followed by dropwise addition of a solution of glycal epoxide 1 
(0.028 mmol, 1.0 equiv) in CH2Cl2 (0.2 mL). After 30 min at –78 °C and 4 h at rt, the 
reaction was quenched with sat’d aq NaHCO3. The aqueous layer was separated and 
extracted with Et2O, then the combined extracts were dried (MgSO4), filtered and 
concentrated by rotary evaporation to provide a 47:3:50 mixture of β-isopropyl 
glycoside 4, α-isopropyl glycoside 5, and hydrolyzed epoxide 7. Ratios were 
determined by analysis of the crude material by NMR.  
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Procedure for TiF4-promoted glycosylation of glycal epoxide 1 with i-PrOH: 
A solution of i-PrOH (0.50 µL, 0.0060 mmol, 2.0 equiv) in CH2Cl2 (0.1 mL) was 
added to a solution of glycal epoxide 1 (0.0030 mmol, 1.0 equiv) in CH2Cl2 (0.3 mL), 
then the combined solutions were transferred to a cooled (–78 °C) solution of TiF4 (33 
µL, 0.016 mmol, 5.0 equiv) in CH2Cl2 (0.1 mL). The reaction was stirred at –78 °C for 
10 min the quenched with sat’d aq NaHCO3. The aqueous layer was separated and 
extracted with Et2O, then the combined extracts were dried (MgSO4), filtered and 
concentrated by rotary evaporation to provide β-isopropyl glycoside 8 as a single 
isomer (NMR). 
 
O
O
O
Si
OH
O
Si
 
(2R*,3R*,4R*,6R*)-6-[2-(tert-Butyldiphenylsilyloxy)ethyl]-2-methoxy-4-
(triisopropylsilyloxy)-tetrahydropyran-3-ol (2). TLC: Rf: 0.74 (2:1 
hexanes/EtOAc). 1H-NMR (400 MHz): δ 7.65 (m, 4H), 7.40 (m, 6H), 4.65 (s, 1H), 
4.19 (m, 2H), 3.91–3.70 (m, 2H), 3.59 (m, 1H), 3.44 (s, 3H), 2.28 (d, 1H, J = 3.5), 
1.80–1.60 (m, 4H), 1.12–0.98 (m, 30H). 
 
O
O
O
Si
OH
O
Si
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(2S*,3R*,4R*,6R*)-6-[2-(tert-Butyldiphenylsilyloxy)ethyl]-2-methoxy-4-
(triisopropylsilyloxy)-tetrahydropyran-3-ol (3). TLC: Rf: 0.61 (2:1 
hexanes/EtOAc). 1H-NMR (400 MHz): δ 7.67 (m, 4H), 7.40 (m, 6H), 4.50 (d, 1H, J = 
3.4), 4.39 (m, 1H), 4.00 (m, 1H), 3.82 (m, 1H), 3.71 (m, 1H), 3.50 (m, 1H),3.31 (s, 
3H),2.00 (d, 1H, J = 5.7), 1.82-1.53 (m, 4H), 1.02 (m, 30H).  
 
O
O
O
Si
OH
O
Si
 
(2R*,3R*,4R*,6R*)-6-[2-(tert-Butyldiphenylsilyloxy)ethyl]-2-isopropoxy-4-
(triisopropylsilyloxy)-tetrahydropyran-3-ol (4). TLC: Rf: 0.68 (2:1 
hexanes/EtOAc). 1H-NMR (400 MHz): δ 7.65 (m, 4H), 7.39 (m, 6H), 4.86 (s, 1H),  
4.19 (m, 2H), 3.96 (m, 1H), 3.88 (m, 1H), 3.73 (m, 1H), 3.52 (m, 1H), 2.37 (d, 1H, J = 
3.1), 1.81–1.71 (m, 3H), 1.52 (m, 1H, obs), 1.19 (d, 3H, J = 6.2), 1.15 (d, 3H, J = 6.1), 
1.11–1.01 (m, 30H). 
 
 
O
O
O
Si
OH
O
Si
 
(2S*,3R*,4R*,6R*)-6-[2-(tert-Butyldiphenylsilyloxy)ethyl]-2-isopropoxy-4-
(triisopropylsilyloxy)-tetrahydropyran-3-ol (5). TLC: Rf: 0.63 (2:1 
hexanes/EtOAc). 1H-NMR (500 MHz): δ 7.65 (m, 4H), 7.40 (m, 6H), 4.64 (d, 1H, J = 
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3.7), 4.38 (m, 1H), 3.98 (m, 1H), 3.81 (m, 2H), 3.72 (m, 1H), 3.44 (m, 1H), 1.99 (d, 
1H, J = 5.7), 1.78 (m, 2H), 1.66 (m, 2H), 1.13 (d, 3H, J = 5.7), 1.10 (d, 3H, J = 5.6), 
1.03 (m, 30H). 
 
 
OO
Si
OH
O
OH  
(2R*,3S*,4R*,6R*)-6-[2-(tert-Butyldiphenylsilyloxy)ethyl]-2-
isopropoxytetrahydropyran-3,4-diol (8). TLC: Rf: 0.16 (2:1 hexanes/EtOAc). 
1
H-NMR (500 MHz): δ 7.64 (m, 4H), 7.39 (m, 6H), 4.87 (bs, 1H), 4.28 (m, 1H), 3.96 
(m, 1H), 3.89–3.78 (m, 2H), 3.74–3.67 (m, 2H), 3.58 (m, 1H), 1.86 (d, 1H, J = 8.2), 
1.80–1.74 (m, 4H), 1.19 (d, 3H, J = 6.3), 1.14 (d, 3H, J = 6.1), 1.04 (s, 9H). 
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CHAPTER 7 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
As a result of the broader availability of small molecule libraries, the influence 
of the chemical genetic approach in improving our understanding of biological 
systems is steadily increasing. The use of small molecules is a powerful complement 
to gene-based methods for disrupting protein function. However, in order to exhibit 
the same generality as genetic mutations, small molecules capable of selectively 
modulating all proteins of interest would need to be identified. Ascertaining the full 
capabilities of chemical genetics will require the design and synthesis of new libraries 
that provide chemical structures complementary to those that are already available. In 
addition to targeting underrepresented regions of chemical structure space, there must 
be some level of confidence that these newly-designed libraries will be meaningful in 
biological systems.  
One of the standing questions in the field is whether the kinds of chemical 
structures that are likely to affect protein function can in fact be predicted. Although 
the strategy of building libraries that are reminiscent of natural products is promising, 
there are still no generally-accepted guidelines that can be followed for effective 
library design. In order to determine whether there are a set of rules that govern what 
types of molecules are likely to modulate specific biological targets, many types of 
libraries will have to be generated, and their performance assessed in a wide variety of 
biological assays. Since each protein class will likely require a different type of small 
molecule modulator, an understanding of what kinds of structures can interact with 
each class will be necessary. 
The availability of more diverse sets of libraries will also allow better 
determination of the structural features that make a good drug. Although a set of 
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properties describing “drug-like” molecules has already been established, this 
description is based on existing drugs and may be biased by the composition of the 
chemical libraries that have been available for drug identification. Screening of a 
larger variety of small molecules will also help to determine if all proteins are 
potential drug targets. Most of the current known drugs bind to proteins that contain 
receptors for small molecules, but, for example, disrupting protein–protein interactions 
may require a completely different class of molecules due to the large protein surfaces 
involved.  
The challenge of library synthesis in the context of chemical genetics is 
twofold: reactions that provide efficient access to a diverse set of molecules must be 
developed, and these molecules should be limited to structures that are likely to be 
biologically active. The project described in Chapters 2–5 was designed to address 
these issues. We have worked out a synthetic strategy that provides access to a specific 
natural product motif in an efficient and diversified manner. In the process, we have 
developed methodology that may be useful for other areas of organic chemistry, in 
addition to library synthesis. The second phase of the project will require evaluation of 
the library in multiple biological systems to determine how these molecules compare 
with those in other types of libraries. Although our first-generation library consists of 
molecules that are relatively small and structurally simple compared to most natural 
products, we have incorporated functionality that will enable efficient generation of 
additional complexity for future libraries.  
 
 
 
